University of Wollongong

Research Online
University of Wollongong Thesis Collection
1954-2016

University of Wollongong Thesis Collections

2004

Bioactive alkaloids from medicinal plants of Bhutan
Phurpa Wangchuk
University of Wollongong

Follow this and additional works at: https://ro.uow.edu.au/theses
University of Wollongong
Copyright Warning
You may print or download ONE copy of this document for the purpose of your own research or study. The University
does not authorise you to copy, communicate or otherwise make available electronically to any other person any
copyright material contained on this site.
You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act
1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised,
without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe
their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court
may impose penalties and award damages in relation to offences and infringements relating to copyright material.
Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the
conversion of material into digital or electronic form.
Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily
represent the views of the University of Wollongong.

Recommended Citation
Wangchuk, Phurpa, Bioactive alkaloids from medicinal plants of Bhutan, M.Sc. thesis, Department of
Chemistry, University of Wollongong, 2004. http://ro.uow.edu.au/theses/315

Research Online is the open access institutional repository for the University of Wollongong. For further information
contact the UOW Library: research-pubs@uow.edu.au

Bioactive Alkaloids from Medicinal Plants of
Bhutan
A Thesis Submitted in Fulfillment of the Requirements for
the Award of the Degree

Master of Science (Research)
From

The University of Wollongong
By

Phurpa Wangchuk, B.Sc.(Gen.), A.M.C.

Supervisor: Prof. John B. Bremner
Department of Chemistry
University of Wollongong, Australia
June 2004

i

Declaration
The ideas and the materials of this thesis, submitted in fulfillment of the
requirements for the award of the Master of Science by Research (Medicinal
Chemistry) from the University of Wollongong, are entirely of my own work
and creation unless otherwise referenced or acknowledged.

Phurpa Wangchuk
18 June 2004

ii

Publications
1. Bioactive alkaloids from the Bhutanese medicinal plant Aconitum orochryseum
Stapf. Three new C20 diterpenoid alkaloids (Journal of Natural Products, in
preparation).
2. Isoquinoline alkaloids, as novel antimalarial leads from the Bhutanese medicinal
plant, Corydalis gerdae Fedde (Planta Medica, in Preparation).

iii

Acknowledgements
I am highly obliged to my government for giving this M.Sc. scholarship. My unfathomable
gratitude owes to Prof. John B. Bremner for being my supervisor without whom this work
would have been a far distant dream. I am grateful to Dr. Paul Keller for initially
coordinating my studies; Dr. John Korth and Larry Hick for training me to use the mass
spectrometer and running my samples for GCMS and HRMS; Dr. Wilford Lee and Dr.
Sandra Chapman for giving me NMR training and running experiments on the 500 MHz
NMR; Dr. David Perkins for helping me with crystal growing and computer modeling of
the structures for my alkaloids; Dr. Chris Bourke, Orange Agriculture Institute, Orange,
NSW; Dr. Sumalee Kamchonwongpaisan and Ms. Roonglawan Rattanajak, Protein-Ligand
Engineering and Antimalarial Screening Laboratories, National Science and Technology
Development Agency, Bangkok, for conducting the antimalarial testing for my samples and
Amrad, Melbourne for carrying out the antibacterial testing for my samples.
My sincere thanks goes to Mr. Bill Hawkins for being a good office mate and helping a
friend in need especially in initializing my first experiment; Mrs. Siritron for providing me
her research skills and encouragement; Ms. Waya for helping on the preparation of
preparative plates; Mr. Joseph Ambrus for proofreading my thesis; Mr. James for his
productive discussion on structure elucidation; Miss Jane and Mr. Johana for their company
and to all my fantastic and helpful friends in the Bremner group. I wouldn’t have learnt so
much had these people not been there for me.
My utmost thanks also goes to the people working in the Institute for Traditional Medicines
Services, especially Dungtshos, Mr. Dorji Thinlay and the medicinal plant collection team
from the Pharmaceutical and Research Unit of Bhutan for their belief, faith and earnest

iv

support rendered during the time of my studies in the University of Wollongong. Having
said this, it won’t be justified if Mr. Samten of Pharmaceutical and Research Unit is not
brought into the limelight of this success story. He duly did the entire methanol extractions
and supplied me the necessary ethno-medical information to which I owe him my heartfelt
gratitude.
Lastly, I thank my wife Mrs. Sonam Choden for her evergreen love, care and constant
support through out the study and the Bhutanese friends in the University of Wollongong
especially Mr. Tshewang Dorji, Mr. Ugyen Dorji, Mr. Khampa Tshering and Mr. Sonam
Dukda for their genuine friendship.

v

List of Abbreviations
AMRAD

Australian Medical Research And Development

bs

Broad singlet

13

Carbon Nuclear Magnetic Resonance

C-NMR

CNS

Central Nervous System

COSY

Correlation Spectroscopy

d

Doublet

DCM

Dichloromethane

DEPT

Distortionless Enhancement by Polarization Transfer

DNA

Deoxynucleic Acid

FDA

Fluorescein Diacetate Assay

GCMS

Gas Chromatography Mass Spectrometer

1

Proton Nuclear Magnetic Resonance

H-NMR

HIV

Human Immunodeficiency Virus

HMBC

Heteronuclear Multiple Bond Correlation

HRCIMS

High Resolution Chemical Ionisation Mass Spectrometry

HREIMS

High Resolution Electron Impact Mass Spectrometry

HSQC

Heteronuclear Single Quantum Coherence

HTS

High Throughput Screening

Hz

Hertz

IC50

Inhibitory Concentration with 50% inhibition

IR

Infrared

LRCIMS

Low Resolution Chemical Ionization Mass Spectrometry

LREIMS

Low Resolution Electron Impact Mass Spectrometry

vi

M

Multiplet

MeOH

Methanol

MGIT

Mycobacteria Growth Indicator Tube

MIC

Minimum Inhibitory Concentration

MS

Mass Spectrometer

NITM

National Institute of Traditional Medicine

NMR

Nuclear Magnetic Resonance

NOESY

Nuclear Overhauser Effect Spectroscopy

ppm

parts per million

PTLC

Preparatory Thin Layer Chromatography

q

Quartet

Q

Quaternary

s

singlet

STD

Sexually Transmitted Disease

TLC

Thin Layer Chromatography

TOCSY

Total Correlation Spectroscopy

US

United States

UV

Ultraviolet

VRE

Vancomycin Resistant Enterococcus

WHO

World Health Organization

vii

Abstract
Natural products had been indispensably used by many cultures and traditions in folklore
medicines for thousands of years. These traditional medicines cater to about 85% of the
world population for their primary health care needs. Natural products have been
intensively explored also for their bioactive pharmacophores by modern pharmaceutical
companies. In fact they are the skeletal framework of about 60% of the modern drugs that
are available today. Of these, about 80% of antibacterial drugs and 90% of antimalarial
drugs are natural derivatives. One of the interesting secondary metabolite groups which
provides these potent drug leads are the alkaloids. Owing to their broad range of
bioactivities, bioprospecting for these natural products are undertaken in many countries. In
this study, on the molecular basis of traditional medicine of Bhutan, particularly those with
potential antimicrobial components, four alkaloid positive medicinal plants, i.e. Aconitum
orochryseum Stapf, Corydalis gerdae Fedde, Rununculus brotherusi Freyn and an
Australian naturalized plant Tribulus terrestris Linn, but also used in Bhutan, were selected
for phytochemical analysis.
Bhutanese traditional medicines use Aconitum orochryseum (whole parts) for the treatment
of bilious fever or high fever related to bile disorders including cold and flu, fever of bile
(liver), fever caused by malaria, snake bites and for treating blood infections. Corydalis
gerdae (whole parts) is used for the treatment of malaria and infections. Ranunculus
brotherusi (aerial parts) is used for treating wounds, pus, infections and as antipyretics.
Tribulus terrestris (fruit) is used for the treatment of arthritis, kidney diseases and as a
diuretic. Though Tribulus terrestris and Ranunculus brotherusi failed to give any alkaloids,
a number of new as well as known alkaloids were isolated from Aconitum orochryseum and
Corydalis gerdae.

viii

Three new hetisane type diterpenoid alkaloids named orochrine, 2-O-acetylorochrine, and
lingshinaline, together with two known alkaloids atisinium chloride and virescenine and six
other unidentified alkaloids, were isolated from Aconitum orochryseum. The structures of
the new alkaloids were elucidated by 1H-NMR, gCOSY, gNOESY, TOCSY,
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C-NMR,

DEPT, gHSQC and gHMBC spectral data analysis. Atisinium chloride, a major alkaloid of
the plant, was identified by single crystal X-ray crystallography.
Four known protopine type and protoberberine type isoquinoline alkaloids (protopine,
scoulerine, cheilanthifoline, and stylopine) along with one unidentified alkaloid were
isolated from Corydalis gerdae. The protopine was the major alkaloid of this plant. The
alkaloids were identified by MS and 1H-NMR spectral data comparison.
The antibacterial testing of crude methanol extracts, crude alkaloids and the major alkaloids
(atisinium chloride, orochrine and protopine) of these two plants were found inactive
against the bacterium Staphylococcus aureus (MIC = >125 µg/ml) and Vancomycin
resistant Enterococcus faecium (MIC = >125 µg/ml). But the in vitro antimalarial assay of
crude methanol extracts, crude alkaloids, atisinium chloride, protopine, and cheilanthifoline
gave very significant activity against Plasmodium falciparum, TM4 and K1 strains. Crude
methanol extract (AO-ME) of Aconitum orochryseum was not that active (IC50 of >10
µg/ml for both the strains). Increased activity was observed for its crude alkaloid (AOCEA) with IC50 values of 20.40 µg/ml against TM4 and 19.20 µg/ml against K1 strains.
The activity was further increased for atisinium chloride with IC50 values of 4.02 µM
against TM4/8.2 and 3.59 µM against K1CB1 strains.
The antimalarial activity was better for the extracts and alkaloids of Corydalis gerdae. Its
crude methanol extract (CG-ME) had the IC50 values of 1.00 µg/ml against TM4 strain and
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2.56 µg/ml against K1 strain. The activity of crude alkaloid of this plant was far better with
IC50 values of 0.33 µg/ml against TM4 strain and 0.63 µg/ml against K1 strain. Protopine
had IC50 values of 4.25 µM against TM4/8.2 and 4.29 µM against K1CB1 strains.
Cheilanthifoline had the IC50 values of 3.76 µM against K1 and 2.78 µM against TM4
strains.
These alkaloids have the potential to become candidates for antimalarial leads. Similar
activities may be expected from other alkaloids including new ones isolated from these two
plants. Therefore, the combination of these two plant extracts would make the best
antimalarial herbal mixture for Bhutanese traditional medicines. The results proved that
ethno-directed biorational approach, combined with an alkaloid focus, is an efficient
strategy for drug lead discovery. The results also proved for the first time at the molecular
level that Bhutanese traditional medicines have clinical efficacy. The medicinal plants of
Bhutan thus have potential to provide important new drug leads. Bioprospecting them
would benefit local people, pharmaceutical industries and the patients at large.
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Chapter 1
Natural Product-Based Drug Discovery and Recent Developments
1.1

General Introduction

With the advancement in science and technology, remarkable progress has been made
in the field of medicine including diagnosis, treatments and pharmaceutics. Recent drug
discovery techniques based on Structure-Activity Relationships, Computer Modelling,
Combinatorial Chemistry, High Throughput Screening and Spectroscopy (MS, NMR,
and IR) have triggered and spearheaded the discoveries of many natural and synthetic
drugs. In 1999, world sales of pharmaceuticals (excluding veterinary medicines) were
valued at ca US$ 325 billion1.
Despite these developments, of the known 30,000 human diseases or disorders, only
one-third can be treated symptomatically with drugs (either in part or fully) and that too
at a great economic and social cost. This is because of the fact that the drugs available
today are still not very effective particularly with respect to the fight against drug
resistant pathogens and newly emerging infections. This includes infectious diseases
such as AIDS, influenza, tuberculosis and malaria as well as other chronic disorders
like cancer, autoimmune disorders and central nervous system disabilities (e.g.
Alzheimer’s disease). The lead cause of death is HIV-AIDS, followed by tuberculosis
and malaria.

In 1996, the HIV virus had infected at least 21,000,000 people

worldwide2 and in 2001, UNAIDS estimated that over 14,000 new infections occurred
daily, nearly half of them in women3 and strikingly affecting Africa4. While malaria
continues to affect 1-3 million lives each year5, ca. 2 billion people (including at least
15 million Americans) are affected by tuberculosis6,7. These infectious diseases
(microbial) will continue to be the leading causes of premature death in human beings
of both developed and developing nations as their resistance to many conventional
drugs is increasing. Therefore, microbial resistance especially by bacteria and protozoa
to drugs is of special concern to communities worldwide and to researchers.

1.2

Development of Antibacterial Resistance

The discovery of bacteria in 1683 by van Leuwenhoek helped mankind to understand
the infectious pathogens and appropriately develop antiseptic and antibiotic protocol in
the following years. By the beginning of 20th century, Paul Ehrlich proposed the
principle of chemotherapy and his work including Structure-Activity Relationships
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significantly contributed to shaping synthetic protocols and helped in the later
discoveries of antibacterial drugs2. Antibiotics were designed either to kill bacteria
(bactericidal) or to nullify growth (bacteriostatic)8 and three groups of antibacterial
agents, which included bacterial cell wall inhibitors, protein synthesis inhibitors9 and
DNA inhibitors, were developed to fight the bacterial infections. The sulphonamides
were the first group of effective antibacterials to be developed following a chance
discovery in 1932 by Domagk of antibacterial activity in the synthetic azo dye,
prontosil.
Many antibacterial drugs were developed in the late 1940s following the first report of
resistance in Staphylococcus aureus (1941) and in Mycobacterium tuberculosis
(1940s)2, a mycobacterium which also developed resistance later to the drugs isoniazid
and rifamycin in the 1950s and 1960s. However, by the 1980s most major infectious
diseases in the developed world were almost eradicated and half the major
pharmaceutical companies in Japan and the USA stopped their antibacterial drug
development programs10. As a result drug-resistant pathogens were on the rise
worldwide11. Streptococci that causes nosocomial infections showed innate resistance
to drugs including cephalosporins, clindamycin and aminoglycoside2,10. The bacterium
(Staphylococcus aureus) has now developed multi-drug resistant strains and threatens
to put an end to successful chemotherapy12. Vancomycin resistance among enterococci
became noticeable in 1987 resulting in a true ‘super bug’. A summary of bacterial
resistance to chemotherapy is shown in Table 1.
Table 1. Bacteria that have acquired resistance to some drug therapy2.
Resistant type

Bacteria

Disorder

Date (approx.)

Penicillin

Pneumococci

Pneumonia, meningitis

Mid 1970s-present

resistant

Legionella

Legionnaire’s disease

Mid 1970s-present

Borrelia burgdorferi

Lyme disease

1980s-present

Salmonella

Gastrointestinal disorders

1980s-present

Staphylococci

Toxic shock syndrome

1980s

E.coli

Gastrointestinal disorders

Mid 1980s-present

M.tuberculosis

Tuberculosis

Late 1980s-present

Vancomycin

Enterococci

Wound, blood, enteric infections

Late 1980s-present

resistant

V.cholerae

Cholera

Multi-drug

“super bugs”

Multi-drug
resistant

resistant

2002
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1.2.1

Mechanism of Bacterial Resistance

The mode of bacterial resistance is either intrinsic (maintained on the bacterial
chromosome) or acquired through chromosomal mutations and plasmid transformation,
transposition, transductions and conjugation from other species2,13. The fundamental
mechanisms of resistance generally observable in bacteria include inactivation or
degradation of the antibacterial drug by enzymatic action, decreasing or changing of
membrane permeability of the bacterial cell wall to antibiotics, the alteration of the
bacterial proteins that are antimicrobial targets, and less often, auxotrophic or metabolic
by-pass2. For example, the resistance to the penicillins and cephalosporins occurs
through antibiotic hydrolysis mediated by the bacterial enzyme beta-lactamase while
the

resistance

to

trimethoprim,

the

sulphonamides,

the

aminoglycosides,

chloramphenicol and the quinoline drugs occurs by the productions of antibioticmodifying enzymes and the synthesis of antibiotic-insensitive bacterial targets14.
It was found that the degree of resistance may vary based on the level and the capacity
of the pathogenic micro-organisms to manipulate, alter and combine all of these
biochemical and genetic processes. Several factors, such as inappropriate prescription
of drugs (use of doses that are too low), over prescription in trying to meet patients’
demand, extravagant prescription due to excessive choices of available drugs, poor
infection control practices, the length of therapy (incomplete course taken by patients)
and the duration of bacterial exposure to long-acting agents compared to drugs with
short half-lives have been found to influence the rate of selection of resistance and play
a role in the worsening situation of global resistance15. Other determinants such as the
state of immunity and the phenotypes of bacterial pathogens also influence the mode of
resistance.

1.3 Development of Antimalarial Resistance
Malaria is another pandemic disease endemic to 102 countries16. It is an infectious
disease caused by four types of parasitic protozoan in the genus Plasmodium:
Plasmodium Falciparum, Plasmodium malariae, Plasmodium ovale and Plasmodium
vivax. Falciparum malaria is the most severe form of malaria and it has already
developed resistance to many of the currently available drugs. The parasites are
transmitted by the bite of female anopheles mosquitoes. Insecticides such as DDT
(dichlorodiphenyltrichloroethane) were used in many countries to control the mosquito
vector. Though it has partially helped to bring malaria under control, it has also
generated many long-term detrimental effects.
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The search for agents to combat malaria became particularly intense in the 1800s as
British soldiers in India were infected with malaria and as outbreaks of malarial
epidemics took heavy tolls in tropical, subtropical and temperate regions of the world 2.
Population growth, urbanization, refugees, conflicts and global warming17 have
contributed significantly to the outbreak of further epidemics. Quinine 1 was the first
antimalarial drug discovered in 1820 by Caventou and Pelletier from the bark of
Cinchona officinalis18. By the early and mid 20th century, its synthetic derivatives such
as quinacrine, mefloquine and chloroquine became available. In continuation of
searches for antimalarial drugs, the first major research on plant extracts was started in
1947 by the screening of 600 species of plants belonging to 126 families but it was only
in the mid 1980s that the testing of these plant extracts were completed19. The research
found several plants, particularly in two families, the Simaroubaceae and
Amaryllidaceae, active against avian malarias18.
With the discovery of many cheap antimalarial drugs, malaria was eliminated from
Europe, North America, Australia, South America and Asia and the search for new
antimalarial agents became secondary for these countries. The limited armoury of drugs
is now greatly compromised by the spread of drug resistant parasite strains20. The
chloroquine resistant strains of Plasmodium falciparum have now developed resistance
to mefloquine, halofantrine and quinine21,22. Malaria is again claiming millions of lives,
mainly affecting children under the age of five in Sub-Saharan Africa4 (Figure 1).
Currently, a combination of synthetic drugs like sulfadoxine and pyrimethamine
(Fansidar) is used in treating these resistant parasites. Other combination therapy like
pyrimethamine with dapsone, quinine/tetracyclines, and atovaquone/proguanil are also
used. Nevertheless, resistance to such combined drug therapy has also been reported in
Africa, Thailand, Burma, Laos, Vietnam, Cambodia and China.
Artemisinin 2, which was discovered in 1972 from the Chinese medicinal plant,
Artemisia annua22, is the main hope for saving millions of lives from the multi-drug
resistant parasite, Plasmodium falciparum. Artemisinin and its derivatives such as
artemether, arteether, dihydroartemisinin, artelinic acid and artesunic acid (intravenous
and intramuscular administration)22 are currently used worldwide. Recently, the potent
antimalarial agents, raphidecurperoxin 3 and polysyphorin 4, were isolated from the
Vietnamese medicinal plants, Rhaphidophora decursiva23. These natural products
showed strong activity against Plasmodium falciparum in vitro without any toxicity and
may become potential candidates for antimalarial drugs.

5

Figure 1. World map showing the occurrence of malaria and chloroquine resistant areas4.
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Voacamine (a bisindole alkaloid), isolated from Voacanga species (Apocynaceae) has
also been found to give promising in vitro activity against chloroquine-sensitive and
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resistant strains, Plasmodium falciparum24. Termilignan, thannilignan, 7-hydroxy-3′,4′(methylenedioxy) flavan, and anolignan B, all isolated from Terminilla bellerica, have
also shown anti-HIV, antimalarial and antifungal activity in vitro25.
1.3.1

Mechanism of Parasite Resistance

Malarial infections are increasing due to the development of resistance by the parasites
to traditional drugs as well as acquisition of resistance to DDT by the vector Anopheles
mosquitoes. It was suggested that resistance to the inhibitors of dihydro-folate
reductase and dihydro-pteroate synthetase enzymes, and the novel antimalarial
atovaquone, occurs through genetic point mutations26. The mechanism of resistance to
quinoline drugs like chloroquine has been attributed to mutations in two genes; pfmdrl
and pfCRT 27. These mechanisms of drug resistance in parasite are yet to be defined but
certainly the mechanism of resistance do seem to vary according to the use and type of
drugs, each of which having distinct modes of action on parasites.

1.4

Strategy for Control of Bacterial and Malarial Infections

As the microbial infections continue to plague the nations worldwide due to very few
effective drugs that are available today (antibacterial agents make up only 12-15% of
the total pharmaceutical business2), there is an urgent need to find concrete solutions
for combating such epidemics. Prevention of famines, droughts, poverty, floods, wars,
political upheaval, economic failures, environmental depletion and pollution would be
good solutions to help reduce infections and microbial resistance.
Another measure to prevent microbial resistance (bacterial and malarial) is to use the
currently available antimicrobial drugs more judiciously and optimally. In general,
resistance is observed higher in areas of high consumption of antibiotics and lower in
areas of low consumption28. A study conducted on controlling resistance in
community-acquired pathogens in Finland in the 1990s, revealed that there was a 50%
reduction in the macrolide resistant group-A Streptococci when the use of macrolides
such as erythromycin were reduced for treating the diseases29. Therefore, choosing the
correct drug, dose, dose interval and duration of therapy may more efficiently provide
clinical benefits while contributing less to resistance than choosing the drug with the
narrowest spectrum30.
Above all, the most important strategy to control, cure and to prevent reinfection is to
develop more appropriate treatment regimens including the super drugs. Super drugs
could be developed synthetically, but as experience has taught us, natural products are
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rich in structurally diverse bioactive molecules like alkaloids, which quite often
become potential candidates for the development of drugs.

1.5

Development of Drugs from Bioactive Natural Products

Bioactive natural products are mainly secondary metabolites which are used by the host
as defensive and protective mechanisms against their enemies and predators31.
Generally, screening of these secondary metabolites and development of drugs is a very
hard task requiring much effort starting from botanical identification, collection,
extraction, isolation, purification and compound identification to pharmacological and
clinical testing. However, the enormous chemical diversity and highly unusual
structures provided by natural products is greater than that provided by most available
combinatorial approaches based on heterocyclic compounds32,33.
When screening for natural products, three main types of search strategies, namely
biorational, chemo-rational and random approaches34 are followed. The bio-rational
approach includes ethno-medically directed screening (as discussed above) and random
screening. Random high throughput screening is based on field observation such as
pest-plant analysis and plant characteristics. Drugs such as artemisinin, morphine,
quinine, and ephedrine were discovered using the ethno-directed bio-biorational
approach35. Conocurvone36, an anti-HIV agent was discovered as a result of random
high throughput screening. The chemo-rational approach is based on chemotaxonomical considerations such as alkaloid surveys, and investigation of specific
families which are known to contain potential drug leads37. Employing these three
search strategies as many as 88,000 natural product compounds have been isolated
from different sources such as plants, animals, marine organisms, insects and microorganisms.
It is estimated that ca. 250,00038 to 500,000 species of plants grow on earth39,40 and
70% of all the world’s biodiversity of vertebrates, higher plants and butterflies are
harboured by 12 countries; Mexico, Colombia, Ecuador, Peru, Brazil, Zaire,
Madagascar, China, India, Malaysia, Indonesia and Australia41. The 18 global
biodiversity hotspots support nearly 50,000 endemic plant species41. A high rate of
endemism is predicted in mountainous areas like Bhutan, oceanic islands like Australia,
mutuallistic special pollinators as present in Madagascar and plant symbionts like
orchids42. These endemic species were found to contain varieties of distinctly new
chemical structures. It is reported that only 10-15% of terrestrial biodiversity especially
higher plants were explored phytochemically for medicinal applications40, and the main
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categories of plant-derived drugs are terpenes (34%), glycosides (32%), alkaloids
(16%) and others (18%)43. Around 85% to 90 % of terrestrial resources are still intact
and await exploration.
Amongst the animal kingdom, lower groups of animals especially those secreting
venoms and toxins such as insects, amphibians, reptiles, wasps, and spiders, produce
interesting and novel bioactive compounds. There are 30 million species of insects and
very few have been studied for bioactive secondary metabolites34. Out of ca 100, 000
species of spiders, only ca 30 have been studied until date44. The marine world
represents 70% of earth’s surface, but only 5% of the marine organisms have been
explored chemically and a huge diversity of marine fauna and flora are yet to be
investigated31. Marine secondary metabolites are often observed to have anticancer
activity. Approximately 300 patents on marine natural products were issued between
1969 and 199945 and a number of compounds have progressed to clinical trials.
Micro-organisms have been a frequent source of antibiotics, ever since the discovery of
penicillin from the filamentous fungus Penicillium notatum by Alexander Fleming in
1928. Cyclosporins and rapamycin (an immunosuppressive agent), ivermectin (an
anthelmintics and antiparasitic drugs), streptomycin, chloramphenicol, tetracyclines
and cephalosporin (antibiotics) were isolated from Streptomyces or Penicillium species.
Only an estimated 1% of bacterial and 5% of fungal species have been examined to
date38. Extremophiles such as alkalophiles, halophiles, barophiles, thermophiles and
psychrophiles also offer a potentially diverse source of novel bioactive agents38.

1.5.1

Application of Alkaloids in Medicine

Hesse defined alkaloids as “nitrogen containing organic substances of natural origin
with lesser or greater degree of basic character” and include both alkaloids with
nitrogen as part of a heterocyclic system as well as the extra cyclic bound nitrogen44.
However, Roberts and Wink have suggested that a basic character is no longer a prerequisite for alkaloids46.
Many workers in the field of alkaloids have attempted classifying alkaloids based on
their biogenesis from amino acid derivatives, structural relationships, biological origin,
and spectroscopic properties44. Since many alkaloids are derived from more than one of
the major precursors, there is extreme heterogeneity in alkaloid structures, which makes
their orderly classification very difficult. The classification is, thus to some extent,
arbitrary and not well established.
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Nevertheless, biogenetic groupings of alkaloids are most commonly followed.
According to this system47, four main types of alkaloid groups are distinguishable:
i)

Alkaloids of amino acid derivatives, like ornithine, histidine, tryptophan,
tyrosine, lysine, anthranilic and nicotinic acids.

ii)

Alkaloids of purines like zanthine and caffeine.

iii)

Alkaloids of aminated terpenes, like the diterpenoid alkaloid, aconitine and
the triterpenoid alkaloid solanine.

iv)

Alkaloids of polyketides like coniine and the coccinellines46.

Alkaloids derived from ornithine are categorized into: simple alkaloids, tropane
alkaloids,

pyrrolizidine

alkaloids,

phenanthroindolizidine

alkaloids,

spermine,

spermidine and related alkaloids and the miscellaneous alkaloids. Alkaloids derived
from lysine are grouped into: simple piperidines, lobelia alkaloids, lycopodium
alkaloids, lythraceae alkaloids and complex and miscellaneous alkaloids. Alkaloids
derived from anthranilic acid include the quinoline, furanoquinoline, acridine and
quinazoline groups.
Alkaloids derived from tyrosine consist of simple β-phenylethylamine derivatives,
Amaryllidaceae alkaloids, and the isoquinoline alkaloids, which are further subcategorized into many sub-types. Alkaloids derived from tryptophan constitute the
largest alkaloid group and include tryptamine derivatives, carbazoles, ergot alkaloids,
borreria alkaloids, monoterpenoid and indole alkaloids. Alkaloids derived from
aminated terpenes include, monoterpenoid pyridine alkaloids, nuphar alkaloids,
celastraceae alkaloids, erythrophleum alkaloids, diterpenoid alkaloids, steroidal
alkaloids, and the daphniphyllum alkaloids. Diterpenoid alkaloids are a major and
fascinating sub group in this category and they have been the source of many bioactive
compounds in the past. It has been found that species in a given genus or related genera
yield the same or structurally related alkaloids; for example seven different genera of
plants in the Solanaceae contain hyoscyamine48, while 164 genera of 47 families
produce both isoquinoline and indole alkaloids49.
With alkaloid nomenclature, trivial naming is commonly observed, however about four
different types of naming are followed based on44:
i)

A systematic plant name, e.g Papaverine is derived from Papaver species.

ii)

The plant discoverer, for example spegazzinine from Aspidosperma
chakensi SPEGAZZI.

iii)

Geographical settings for example tasmanine after Tasmania.

iv)

A person’s name, for example macrosalhine after the lady Salhiha.
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But such naming of alkaloids falls short when several new alkaloids are isolated from a
single plant. Judicious naming can be followed based on the chemist’s imagination,
assigning sufixes like ‘-ine’, ‘-idine’, ‘- anine’, ‘-aline’, and ‘-inine’44, since IUPAC
naming becomes complex as most of the natural products are very large molecules.
In 1988, the NAPRALERT database listed ca.16000 alkaloids with varying types of
nomenclature as described above40,46. It is estimated that 10-15% of all vascular plants
contain alkaloids, but they are observed particularly in the families: Apocyanaceae,
Papaveraceae, Papilionaceae, Ranunculaceae, Rutaceae and Solanaceae48. The
alkaloids serve plants as a feeding deterrent to protect them from predators and they are
also believed to act allelopathically in some plants44.
Alkaloid distribution in the plant can vary. In many cases higher concentrations are
observed in areas where herbivores usually attack, i.e. in the inflorescence, young
growing tips and peripheral cell layers of stems and roots46. An analysis of 3,589
varieties of plants of various origin in different growth phases and parts of the plant
revealed the fact that the maximum amount of total alkaloids is produced by young
plants and by green parts of the plant50. The alkaloid content and the types of alkaloids
also vary from species to species, season to season and region to region. The
biosynthesis and the formation of alkaloids in plants involve elaborate chemical
reactions that are performed sequentially in a way unique to each species and quite
often different from laboratory synthesis51.
Lipinski and his co-workers49,52 suggested alkaloids as suitable candidates for orally
bio-available drugs. Such drugs should have:
a) Less than five hydrogen bond donor groups (such as –OH and -NH).
b) Less than ten H-bond acceptors in the molecule (such as oxygen and nitrogen
atoms).
c) A molecular weight less than 500 Dalton.
d) A Log P value less than five units.
At present, approximately 600 alkaloids have been analysed for their bio-medicinal
properties and many of them have become important drug leads or actual drugs in the
pharmaceutical industry46. For example, the taxol, isolated from Taxus brevifolia and
the vincristine and vinblastine isolated from Catharanthus roseus (Madagascar) are the
important anti-cancer drugs derived from plant alkaloids. Very recently, provir, an oral
product for the treatment of respiratory viral infections, and virend, a topical antiviral
product for the treatment of herpes (both in clinical trials) were developed from plant
alkaloids53. Hadi et al54 isolated the antimicrobial alkaloids: lombine, cononaridine, and
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mataranine A and B from the plant Vocanga foetida Rolfe. These alkaloids were
reported to have strong activity against Staphylococcus aureus. A mixture of
mataranine-A and B was found active in vitro against Plasmodium falciparum. While
25 to 50% of the current pharmaceuticals, including antimalarial drugs, were derived
from plants, no ideal antibacterial drugs (antibiotics) have yet been developed from
plants55.
Captopril, an antihypertensive agent31 was derived from an alkaloid, teprotide (isolated
from Snake venom). Epibatidine, which was isolated from the frog Epipedobates
tricolor56 was shown to be a novel non-opioid analgesic agent with two hundred times
the analgesic potency of morphine. In the mid 1980s, bryostatin-1 was isolated from
Bugula neritina, a marine bryozoan, and was found to be effective against ovarian
carcinoma

and

non-Hodgkin’s’

lymphoma38.

Halobacilin,

bisucaberin

and

homocereulide await clinical applications57. Studies on the egg masses of Dicathais
orbita (a marine mollusc) by Benkendorf et al. using an ecologically-directed approach
resulted in the isolation of the broad spectrum antibacterial alkaloid derivative,
tyriverdin58.

1.6

Natural Products in Traditional Medicines

Because Homo sapiens are herbivores to some degree, they first encountered bioactive
agents in vegetal food items59. Having lived harmoniously in close association with the
environment, they learned to utilise the toxic and medicinal properties of plants and
other natural products. Some of those toxic plants were used as poisons for causing
death and as arrow poisons for hunting food, warfare, depredating wild animals and for
gaining mastery over a hostile environment46,60. The most remarkable of all the ancient
inventions was the art of utilising these toxic and medicinal natural products for
treating various ailments but the ethno-medical knowledge was restricted to a few elites
such as priests, medicine men, shamans, magicians and witch doctors59. Although some
cultures used individual herbs or plants as medicines, many traditions propounded
powerful combinations with different ingredients known as poultices, tinctures and
mixtures.
It was the Mesopotamians who first used the herbs like oils of cypress, cedar, liquorice
and poppy juice for treating different ailments in 2600 B.C38 followed by the Indian
Buddhist system of medicine that dates to 2500 BC61. Then came the Egyptian’s Ebers
Papyrus (1500 BC) that documented some of the 700 drugs including formulas such as
gargles, snuffs, poultices, infusions, pills and ointments38, the Chinese materia medica
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Wu-Shi Er-Bing Fang which contains 52 prescriptions dating to 1100 BC38,62 and the
Indian Ayurvedic Medicine that dates to 1000 BC (Susruta and Charaka) documenting
the medicinal use of plants like Datura, Aconitum, Canabis and Sarcostemma59.
From these ancient cultures, some of the knowledge reached Mediterranean countries
through traders and migrations and it was in Hippocrates’s (460-377 BC) time that
pharmacognosy reached a summit in Greece59. Theophrastus (ca 300 to 322 BC), who
was a philosopher and naturalist, was the first to deal with the history of plants, which
later on helped in the classification of plants including herbs. Pedanius Dioscorides, a
Greek physician (ca 40-90 AD) produced De materia medica in 78 AD, which
described more than 500 medicinal plants and their uses in detail.
Galen (ca 129-199 AD) founded “Galenics” and taught pharmacy and medicine in
Rome63. Avicenna (980-1037 AD), a Persian pharmacist, physician, philosopher and a
poet described 1400 drugs and medicinal plants which greatly contributed to the
formation of a codified Graeco-Roman Medicine in the 5th century38,59. Paracelsus
(1493-1541) administered dosage formulations separating “Arkanum” from non-active
ingredients of drugs. Western medicine and pharmacy originated from this medical
system.
Tibetan medicine, also called gSo-ba Rig-pa, took shape in the 7th-8th century with the
advent of Mahayana Buddhism in the country61,64. Bhutanese traditional medicine
known as gSo-ba Rig-pa was conceived subsequent to Tibetan medicines in the 8th
century and contain more than three hundred herbal formularies and recipes65,66. In the
USA, homeopathy, that includes hydrotherapy, nutritional therapy, herbal therapy,
manual manipulation and midwifery, was founded by German physician Hahnemann
(1755-1843) became popular in 1830s.
The discovery of antibiotics and vaccines in the 20th century dramatically changed
medical practice worldwide and as a result a separate field of ethno-medicine emerged
as an academic specialization focusing on traditional healing systems67. The
investigation of the principles of drug action of Japanese traditional Sino-medicine at
the molecular level have resulted in obtaining many novel compounds and the
uncovering of new mechanisms of drug action68. Clinical trials of Tibetan medicine, the
PADMA Products, also proved successful in the treatment of irritable bowel
syndrome69 and fibrinolysis with stable intermittent claudication70,71. This products also
furnished new anti-oxidative mechanisms at the molecular level72.
Thus, traditional medicines were found to be effectively addressing the health needs of
millions of people including developed nations by completely different strategies and
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well defined approaches, and generally with minimal side effects67. Current WHO
estimates show that 75% of the French population, 30% of the Vietnamese population,
and 40% of Indonesia’s population uses traditional medicines73. In Germany, 77% of
pain clinics provide acupuncture, in Japan 72% of registered western style doctors uses
kampo medicine73 and in Bhutan, traditional medicine caters to 80% of the population.
Overall, traditional medicines provide primary health care needs to almost 65-85% of
the world’s population including developed nations39,40. In terms of economic value,
traditional therapies contribute to US $ 60 billion a year and the USA alone spends US
$ 2.7 billion per year followed by China with US $ 1.8 billion and Australia with Aus $
1 billion a year73.
Since almost every traditional medicine regimen uses medicinal plants as the bulk
ingredients, they also play significant roles in natural product based drug discoveries.
More than 13,000 species of plants are used in traditional medicines and herbal
cosmetics43. About 8000 of these medicinal plant species are known in South Asia
alone74. Many pharmaceutical companies have successfully explored these medicinal
plants by applying an ethno-directed biorational approach75. In fact, among the search
strategies, the ethno-directed bio-rational approach has proved to be the shortest and the
most effective search strategy for discovering drugs from Nature. For example, the
National Cancer Institute, USA, has noted that extracts from medicinal plants in in vitro
bioassays gave greater rates of bioactivity than those from other plants75. In another
survey, out of 800 medicinal plant extracts collected from Vietnam and Laos, at least
25 biologically active compounds were isolated; of these 13 were new anti-HIV agents
and 3 were antimalarial agents76. Similarly, in the USA, out of 119 plant drugs
available from 1959 to 1980, 74% of these were discovered as a result of chemical
studies directed at isolating the active substances from the plants used in traditional
medicines38.
However, in using this ethno directed search strategy, it is crucial to have intimate
understanding of the disease concepts of the culture whose pharmacopeia is under
examination. The products used as medicines by local people are usually not those that
are tested in the laboratory. Most of the effective brews or formularies are multiingredient compounds. Chemical reactions occur within these mixtures or poultices and
are most often associated with synergism making them more effective than the single
isolated lead compound. When the medicinal plants are subjected to phytochemical
screening, researchers often target only one compound, or a few limited compounds,
which quite often turn out to be biologically inactive owing to the loss of other active

14
components during this screening process. Therefore, the ethno-medical indication may
not necessarily be productive when screening is directed towards only specific
phytochemical isolations.

1.7

Natural Products and Bhutanese Traditional Medicine

Bhutanese Traditional Medicine is locally known as gSo-ba Rig-pa, which means “The
Art of Healing Sciences”65. It is one of the world’s oldest surviving medical traditions,
preserved intact, and practised in Bhutan in conjunction with western medicine.
Currently it provides primary health care to 80% of the country’s population. The
history of gSo-ba Rig-pa dates back to the era of Buddha Kashyapa, the predecessor of
the historical Sakyamuni Buddha. It was Buddha Kashyapa who transmitted the
medical teachings to Brahma and then ultimately propagated them to the human realm
as a weapon to fight suffering66,77. Buddha Sakyamuni, also sometimes called the
Supreme Physician, was then said to have taught a healing system ‘Vimalagotra’
(Immaculate Lineage) simultaneously with the first turning of the Wheel of Dharma at
Sarnath on Four Noble Truths in India, followed by the text gSo-dPyad hBum-pa (One
Hundred Thousands Verses of Healing) at Jagoe Phungpoi Ri (Vulture’s Peak) and
gSer-′od Dampai mdo (Supreme Golden Rays Sutra) that contained a separate chapter
on “Nad-thams Cad Zhi-bar bYed-pai rGyud” (The Ways of Completely Curing
Diseases) during the third turning of the wheel78. Dul-ba rLung (Vinaya Sastra)
teaching on moral discipline also contained medical teachings.
He taught his disciples and followers, mostly using disease and healing as metaphors to
illustrate his philosophy of the human condition79. Though Buddha’s teachings spread
to many Asian countries, gSo-ba Rig-pa became prominent only in Tibet and Bhutan. It
was in 718-785 A.D. that Tibet saw the peak development of astrology, medicine and
astronomical science80. During that time, Tibet hosted several medical conferences at
Samye inviting the great healers from Tibet, China, India, Persia, Byzantium and
Himalayan countries like Bhutan and Nepal79. It was reported that all the different
medical systems were analysed at this conference and the best practices were
incorporated into gSo-ba Rig-pa. Pre-Buddhist Shamanistic views and the Bon tradition
also influenced the way Tibetan Medicine evolved81,82.
With the advent of Mahayana (Tantric) Buddhism from Tibet in the 8th century, the
gSo-ba Rig-pa (Art of Healing) also took shape in Bhutan as well65. The Buddhist
philosophy remained as the mainstream of this medical tradition. However, Tibetan
Medicine, Indian Ayurvedic Medicine, Unani Medicine, Chinese Traditional Medicine,
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Shaman Medicine, Local Ethno-Medicine, Exorcism and the Bon Tradition had a
definite influence on the way Bhutanese Traditional Medicine evolved.
Philosophically, gSo-ba Rig-pa is based on the fact that all suffering is caused by
ignorance of the nature of reality and the craving, attachment, and grasping that arise
from such ignorance and that the path to overcome such suffering is to follow the
Noble Eightfold Path of Lord Buddha, which consists of right views, right intention,
right speech, right action, right livelihood, right effort, right-mindedness, and right
contemplation. Fundamentally, gSo-ba Rigpa states that human beings are composed of
three main elements called “Three Humours”; rLung inadequately translates as air,
mKhris-pa translates as bile and Bae-dkan, translates as phlegm64-66. They are
interrelated in all the vital systems and functions of the body such as the nervous
system, circulatory system, digestive system, excretory system, reproductive system,
respiratory system and musculo-skeletal system. Each of the three humours has
different functions in the body (Table 2).
Table 2.

The Three Humours and Body Function 65,78,79.

Three Humours
RLung (air)

Characteristics

Function

Has the nature of air,

Controls movement and bodily functions such as

rough,

cold,

respiration, excretion, circulation, speech, intellect,

subtle, hard and mobile

impulses, gives clarity to sense organs and sustains

light,

life by means of acting as a medium between mind
and body.
It has the nature of fire,

Controls

oily,

hot,

metabolism generating heat and energy. Stimulate

sharp, light, fetid and

feelings of hunger and thirst, gives lustre to body

purgative

complexion and provides courage and determination

Bae-dKan

Cold in nature, oily,

Firmness of body, stability of mind, induces sleep,

(Phlegm)

cool,

connects body joints, generates tolerance, lubricates

mKhris-pa (bile)

fluidity,

heavy,

blunt,

smooth, firm, sticky

digestion,

assimilation,

and

basic

the body and regulates the balance of energies.

Based on this, body meridians are drawn to help diagnose diseases related to the energy
system of the body. Explicit knowledge of body meridians is important in acupressure
therapy of gSo-ba Rig-pa, so the Buddhist medical system is more than a study of
anatomy, physiopathology and the pharmacopoeia. Physiopathology, as per gSo-ba
Rig-pa, is based on the close relationship between the human microcosm and the
universal macrocosm65. Each of the three humours of the human body is considered a
combination of the five basic constituents (proto-elements) of the Universe: Sa (earth),
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Chu (water), Mei (fire), rLung (wind/air) and Nam-mKha (space)78. They are essential
elements for the existence of all life on earth and they coexist in equilibrium. As long
as these proto-elements are in their natural state and maintain a proper balance,
suffering does not erupt from the environment nor do they affect the three humours.
When these three humours are well balanced in an individual, then the person is said to
be healthy65.
Any sign of imbalance or modifications in the three humours are clearly apparent in the
pulse, urine and on the surface of the body. Based on this theory, physicians perform
pulse readings, physical urinalyses and observe the eyes, tongue and earlobes (in
babies) to detect disorders. In modern allopathic medicine, pulse reading is only used to
detect anomalies of the heart and the circulatory system, but in gSo-ba Rig-pa, the
pulse reading links the network of body meridians and can detect any diseases affecting
different parts, organs and systems of the body66.
The treatment regimen in gSo-ba Rig-pa is holistic in nature and it mainly includes five
kinds of healing methods like behavioural modification, herbal physiotherapy, minor
surgery and prescription of herbal medicine. Bhutanese traditional medicine texts report
the use of as many as 2200 traditional prescription drugs and each of these drugs are
multi-ingredient drugs77,81. However, in 1969, only 167 formulations, which used 300
different types of ingredients, were selected for the essential drugs list83. The essential
drugs list was further streamlined based on disease patterns and prevalence in Bhutan
and was reduced to 103 after thorough examination and standardization processes84.
The manufacturing unit in Bhutan produces 8-9 tonnes of traditional medicines
annually and these are formulated into different dosage forms which includes pills
(39.81%), tablets (30.10%), ointments (3.88%), syrups (1.94%), capsules (12.62%),
powders (3.88%), crude extracts (0.97%) and unestablished dosage forms (6.80%)85.
Some pills like Rinchen Rilbu also uses precious metals such as gold, silver, turquoise,
pearls, gems and other rare minerals as ingredients.
There are 46 alkaloid-containing drugs on the Bhutanese essential drugs list. Toxic raw
materials are pre-processed and detoxified before formulation following traditional
methods. Since 1998, the standardization of traditional drugs has been done using the
Total Quality Profiling Method86,87. These standardized drugs have the potential to go
forward for regulatory approval. Bioprospecting the medicinal plants used in gSo-ba
Rig-pa medicine also has an international market value and should play an important
role in any new drug discovery programme.
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1.8

Research Aims and Objectives

As discussed earlier, microbial (bacteria, fungi, viruses) and parasite (protozoan)
resistance to traditional antimicrobial and antimalarial drugs has emerged continuously
and has become a great health concern for the communities worldwide. A new arsenal
of antiinfective drugs is required for combating these resistant pathogens. Bhutan is
rich in its ethno-medical heritage including treatments for infectious diseases (bacterial,
fungal and viral infections and also for malaria) and uses more than 300 medicinal
plants in different preparations. However, till date, active components of herbal
mixtures have not been identified at the molecular level. Based on this ethno-botanical
knowledge, analysing Bhutanese medicinal plants for anti-infective agents, with a focus
on alkaloidal compounds, were the twin themes of the research described in this thesis.
Therefore, the main objectives of this research project were:
a) To investigate the alkaloidal components of selected medicinal plants of Bhutan
where their use suggested antibacterial and antimalarial activities.
b) To determine structures of the new alkaloids isolated from the selected
medicinal plants.
c) To assess their antibacterial and antimalarial properties and identify potential
new lead compounds.
d) To provide validation for gSo-ba Rig-pa, in an effort to help preserve the gSoba Rigpa and to help to develop it as a sustainable traditional medicine.
The medicinal plants of Bhutan selected for the study are discussed in Chapter 2.
Chapter 3 presents the isolation of alkaloids from the medicinal plant, Aconitum
orochryseum Stapf. In Chapter 4, the isolation of alkaloids from the plant Corydalis
gerdae Fedde is discussed. Chapter 5 and Chapter 6 present an investigation of the
alkaloids from Tribulus terrestris Linn and Ranunculus brotherusi Freyn respectively.
Chapter 7 discusses the antimicrobial testing conducted on some isolated pure
compounds and the crude extracts of the plants. Conclusions and future directions are
presented in Chapter 8, while Chapter 9 covers the experimental section of the study.
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Chapter 2
Selection and Collection of Bhutanese Medicinal Plants
2.1

General Introduction

Bhutan is known to the outside world for its youthful inaccessible mountains, rich
biodiversity and unique culture and tradition. It is sandwiched between the two
historically, culturally, and politically contrasting giant nations of the world, India and
China88 (Figure 2). It has an area of 47000 square kilometres and a population of
600,000.
Geographically, Bhutan is laterally divisible into four zones with a continuous SouthNorth gradation of vegetation. The foothills region ranging from 95 to 2000 metres
above sea level receive the heat of the Sahara desert and an annual rainfall of 80-90
inches per annum, and thus supports tropical vegetation such as riverine species, sal
evergreen forests and dense savannah grasses.
The interior valleys (ranging from 2000 to 3000 meters) have cool pleasant winters and
mild hot summers, which supports temperate vegetation. The annual rainfall ranges
between 30-35 inches per annum and most of the flowering plants grow in this region.
The alpine zone (starting from 3000 to 6000 metres) experiences intense cold winters
and cool summers with scanty rainfall. This region has Tundra vegetation and supports
meadows, scrub and shrubs. Most of the rare herbs grow in this zone. The
mountaintops are permanently snow clad and don’t support any form of vegetation but
they are a permanent source of rivers and spring waters in Bhutan. The highest point
measures 7800 meters above sea level on the peaks of the major inaccessible
mountains88.
Due to this unique topographical and climatic position89, the country is blessed with
great biological diversity. About 5603 to 7000 species of plants including 60 species of
Rhododendron and 600 species of orchids are reported to grow in Bhutan90,91. Out of
50,000 endemic plant species reported to thrive in global hotspots of the world92, about
82 endemic plant species have been discovered in Bhutan90. Bhutan has also abundant
fungal and parasitic flora. As a result, Bhutan is often described as a “Botanist’s
Paradise”93 and, recently, Bhutan was identified as one of the ten global hotspots of
biodiversity in the world94,95. The conservation and preservation of this rich
biodiversity (environment) including the medicinal plants is one of the country’s top
development strategic priorities. Bhutanese view the environment as an essential
component not only for material life but also for medical and spiritual life and thus
about 72.5% of the forest is still preserved in its original form89.
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Figure 2. Map showing the strategic location of Bhutan.

The rich Bhutanese biodiversity supports many medicinal plants. In fact, owing to the
plentiful medicinal plants thriving in the country, Bhutan was known as “sMan-jong”,
the land of medicinal plants77. Taking advantage of the availability of such rich
medicinal plants and other bioactive natural products applications, the Bhutanese
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developed their own medical tradition called gSo-ba Rig-pa. Around 600 species of
medicinal plants have been identified to date and 300 of them are in routine use in the
day-to-day formulation of gSo-ba Rig-pa medicines.

2.2

Medicinal plants of Bhutan

According to gSo-ba Rig-pa, there are seven categories of medicinal sources: three are
of vegetable origin, which comprising of Sgo-sman (High Altitude Medicinal Plants
and Herbs above 3000 metres), Khrog-sman (Low Altitude Medicinal Plants below
3000 metres) and Rtsi-sman (resins and extracts); two are of mineral origin comprising
of Rin-po-che-sman (precious stones/gems), rdo-sman (base minerals/stone) and Sasman (medicinal soils) while one is of animal origin or srog-chags-sman (includes
marine organisms). About 2990 species of medicinal plants73, 35 types of animal
parts96, 18 types of minerals including precious stones and precious metals such as
gold, silver, copper and iron are used in traditional medicine in Bhutan97. Marine
products like crabs, pearls, seashells and other marine products are also used.
Almost 70% of these raw materials, almost all of which are collected in the wild, are
available within the country73. Only 30% are imported from India. Some rare and
expensive animal parts such as rhino’s horn, tiger bone, elephant tusk and musk or
gLar-tsee (used in 30% of the formulations) are banned from use in the herbal
formulations96. Low Altitude Medicinal Plants (Khrog-sman) are collected from the
temperate and tropical zone (Figure 3, Collection site-II) and the High Altitude
Medicinal Plants (Ngo-sman) are collected from the alpine region (Figure 3, Collection
site-I). About 60% of the species are harvested from high altitudes-between 3000 to
6000 metres above sea level and only 40% are collected from low altitudes. The herbs
are harvested and collected by the Pharmaceutical and Research Unit in Bhutan once a
year employing good harvesting practices and with strict quality control monitoring.
The time of collection is based on gSo-ba Rig-pa guidelines. According to these
guidelines, therapeutic properties of the plants are directly affected by the collection
season, picking time (morning, afternoon and evening) and the nature of drying
conditions that has to be carefully monitored. For example, some medicinal plants need
to be picked only in the presence of moonlight. If such plants are picked at other times,
it is believed that they lose their efficacy. Plants are collected as whole plants (40
species), fruits (26 species), seeds (20), roots/bulbs (31 species), stems (12), flowers (9
species), leaves (7 species), extracts/resins (7 species) and bark/cambium (3 species)97.
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Figure 3. Map of Bhutan showing the collection sites of medicinal plants.

Some medicinal plants that are not used by the Institute have recently been explored by
the Aromatic and Phytochemical Section of the Tashi Commercial Corporation of
Bhutan and the Japan Himalayan Company which was established in 199098.

2.2.1

Sustainability of Medicinal Plants

Bhutanese Traditional Medicine is gaining popularity among people within the country
as well as internationally. Many medicinal plants such as Aquilaria agallocha,
Rauwolfia serpentine, Ephedra gerardina, Taxus bacccata, Rheum nobile, Rheum
accuminata, Picrorhiza kurroa, Nardostachys jatamansi, Aconitum species, Artemisia
species, Panax pseudo-ginseng sub species himalaicus and Cordyceps sinensis are in
high demand for pharmaceuticals and have potential international market value99. As a
result, the pressures on the alpine medicinal plants have increased undermining their
sustainability. In fact, because of the legalisation of the regional trade of highly prized
perennial herbs like Picrorhiza kurrooa, Nardostachys grandiflora and Cordyceps
sinensis in Asia100 and highly executed operational networks of illegal traders in the
region, these medicinal plants are already at high risk of overexploitation 100,101.
Since Bhutan is an agricultural country, removal of forests for farming has had an
adverse impact on the environment, particularly resulting in the loss of the medicinal
plant species. Cattle, yak and sheep rearing is another significant economic activity of
Bhutan. Overgrazing of the forest by such animals has a detrimental effect on the
survival of the grazed plant species. For example, intense browsing by yaks checks the
growth of seedlings of the Himalayan yew, Taxus baccata102. Some plant species like
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Senecio and the Ligularia, which contain pyrrolizidine alkaloids, were found to be
toxic to yaks and cattle44,103. Such poisonous plants are cleared by cattle herders in
order to protect the cattle. This act significantly contributes to the extinction of many
alkaloid-containing plant species.
The threats to medicinal plants also stem from logging activity carried out in Bhutan.
This has led to deforestation and the loss of a number of medicinal plants. The natural
phenomenon of decaying and dying of Himalayan mountains also contributes to the
loss of some plant species104. Industrialization poses another significant threat to the
medicinal plants of Bhutan.
Although, some medicinal plants may be cultivated, the content of phytochemicals in
these plants may not be same as that in the wild species but cultivation is the only
proper solution to meet this ever increasing demand. Before all wild plants become
extinct or fully domesticated, it is essential to assess them for their chemical content in
their original state. In this context, the author has selected some potential medicinal
plants used in the traditional medicine of Bhutan for thousands of years and has
analysed them for potential antimicrobial and antimalarial lead drug molecules.

2.3

Selection of Medicinal Plants

Based on an ethno-directed biorational approach, the databases of Traditional Medicine
of Bhutan97,105 as well as the inventory carried out by the ethno-botanist77 and the
Forestry Department99 were analysed and a list of medicinal plants was generated
consisting of 156 plant species (Table 3). Every effort has been made to assign
individual therapeutic uses based on the text, “Medicinal Flora of Bhutan”105. The
medicinal plants list was then further analysed and those plants which met all the
selection criteria were short listed for collection and phytochemical analysis.

2.3.1

Criteria for Selecting the Medicinal Plants

Because of the large number of possible species for analysis, criteria were established
for plant selection as follows:
a)

Only those medicinal plants that were used for treating malaria or infectious
diseases were to be selected.

b)

Further selection of medicinal plants was then based on those that were
endemic to Bhutan and the Himalayas (high altitude plants, above 3500
metres above sea level).

c)

Finally, only alkaloid-containing medicinal plants were to be selected.
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Many plants listed in Table 3 have been used for treating fever arising from different
disorders including malaria but only Corydalis gerdae was specifically used against
malaria. Aconitum orochryseum was used for treating infections, snake bite, and bilous
fever or fever arising from bile disorders. There were also many medicinal plants used
for treating infections including blood infections, skin infections, and infections of
internal organs. About fifty five medicinal plants were selected based on the first
criterion. The selection was then streamlined by focusing on endemic species growing
at high altitudes (ca 4000m), since these species were the least studied phytochemically
and could contain new molecules that would potentially be new drug leads. About 26
medicinal plants were short listed based on this criterion. Introduced medicinal plant
species were not considered here except for Tribulus terrestris.
Only those medicinal plants that contained alkaloids were then selected from these 26
species. This is because alkaloids have interesting structural types with a wide range of
biological activities and have quite often become potential drug leads. An effort was
also made to select medicinal plants representing different families since different
families usually contain different classes of alkaloids. So preliminary tests for the
presence of alkaloids were conducted on the selected medicinal plants of Bhutan
(Table 4) at the Pharmaceutical and Research Unit Laboratory in Bhutan using the
Culvenor and Fitzgerald106 test procedure. Only fifteen plants were found to contain
alkaloids. The result was reported only as alkaloid positive or alkaloid negative and the
degree of alkaloid content was not estimated. Finally, only five alkaloid-containing
medicinal plants were selected for chemical analysis (Table 5) based on their
availability for larger scale collection. The selection methodology is summarised in
Scheme 1.

Free listing of medicinal plants (160 species)
Medicinal plants used for treating malaria and infectious diseases ( 55 species)
Medicinal plants that are endemic to the Himalayas and Bhutan (26 species)
Alkaloid-containing medicinal plants (15 species)
Final selection (5 species)
Scheme 1. Flow chart for the selection of the medicinal plants based on the four selection criteria.
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Table 3.

Medicinal plants considered with ethno-medical information.

Botanical name

Family

Altitude
HA

Distribution
Himalaya

Part
used
R/L

HA

Endemic

A

HA

Himalaya

R

Polygonaceae
Araceae
Liliaceae

gSo-ba rigpa
name
Bong-nga-nagpo
Bong-nga-dkarpo
Bong-ngadmar-po
Sna-lo
Shu-dag-nag-po
Dam-bu-ka-ra

Aconitum lacinatum

Ranunculaceae

Aconitum orochryseum

Ranunculaceae

Aconitum violaceum

Ranunculaceae

Aconogonon tortuosum
Acorus calamus
Aletris pauciflora

HA
LA
LA

Himalaya
Cosmopolitan
Himalaya

R
R
W

Allium sativum
Allium wallichi

Liliaceae
Liliaceae

Sgog-skya
Re-sgog

LA
HA

Cosmopolitan
Himalaya

B
W

Amomum subulatum
Androsace strigillosa
Anemone rivularis

Zingiberaceae
Primulaceae
Ranunculaceae

Ka-ko-la
Sga-tig-nag-po
Srub-ka

LA
HA
HA

Himalaya
Himalaya
Himalaya

F
W
S

Aquilaria agallocha

Thymelaceae

A-ga-ru

LA

W

Areca catechu
Arenaria kansuensis

Palmae
Caryophyllaceae

Go-yu
Rtsva-a-krong

LA
HA

Aristolochia griffithii
Asparagus racemosus

Aristolochiaceae
Asparagaceae

Ba-le-ka
Nye-shing

LA
LA

Bhutan, India
and Indonesia
Asia
Tibet
and
Bhutan
Himalaya
Cosmopolitan

Aster flaccidus

Conpositae

Lug-mig

HA

Himalaya

F

Aster stracheyi
Astragalus floridus
Beaumontia grandiflora

Compositae
Leguminosae
Apocynaceae

Chu-de-ba
Srad-ser
Dug-mo-nyung

HA
HA
LA

A

Berberis aristata

Berberidaceae

HA

Bistorta macrophylla
Bombax ceiba
Brassica juncea

Polygonaceae
Bombacaceae
Brassicaceae

Skyer-pa-dkarpo
Spang-ram
Pad-ma-ge-ser
Spong-thogs-pa

Himalaya
Himalaya
Bhutan
and
Nepal
Himalaya.

HA
LA
HA

Himalaya.
Tropics
Cosmopolitan

R
Fl
A

Butea buteiformis

Leguminosae

Ma-ru-rtse

LA

S

Capsella bursapastoris
Caragana jubata

Cruciferae
Leguminosae

So-ka-pa
Mdzo-mo-shing

HA
HA

Carum carvi

Umbelliferae

Go-snyod

HA

Bhutan
and
India
Cosmopolitan
Bhutan
and
India
Cosmopolitan

Cassia fistula

Leguminosae

Dong-ga

LA

Cassia tora

Leguminosae

Thal-ka-rdor-rje

LA

Cavea tanguensis

Compositae

HA

Cedrilla toona

Meliaceae

Ming-chen-nagpo
Snying-sho-sha

Choenomeles lagenaria
Chrysosplenium
forrestii
Cinnamomum tamala

Rosaceae
Saxifragaceae

Bse-yab
gYaa-kyi-ma

LA
HA

America
Bhutan
Bhutan
Himalaya

Lauraceae

Shing-tsa

LA

Himalaya

Clematis connata

Ranunculaceae

HA

Himalaya.

Codonopsis bhutanica

Campanulaceae

Bbyi-mongdkar-po
Klu-bdud-rdorrje

R
Bk
St.

HA

Endemic

W

Codonopsis
convulvulaceae
Cordyceps sinensis

Campanulaceae

Snyi-ba

HA

Himalaya

B

Fungus

HA

Himalaya

W

Coriandrum sativum

Umbelliferae

Dbyar-rtsvadgun-bu
hu-su

Cosmopolitan

S

Corydalis flabellata

Fumariaceae

Re-rdzun

HA/
LA
HA

Himalaya

A

LA

Himalaya and
Burma
South America
and Bhutan
Himalaya
and

S
Fl

Ethno-medical use
Tinging of muscles,
poisoning and bones
Flu-fever,
infections
antidote for snake bite

meat
and

Lung and liver disorders,
pneumonia, cuts and wounds
Gastritis,
inflammation,
disorders

tuberculosis,
and
rlung

Oedema, fever and infections
Antipyretics,
blisters,
antiseptics, antidote, and to
increase body temperature

Lund disorders and abscess
above chest including head

St
R
Bronchitis, cramps, common
cold and to relieves pain

S
Bk
Diarrhoea and blood dysentery
Meat-poisoning,
spasmolytic,
lung, heart and blood disorders

A
St.
S/A

Detoxifiers, headache, migraine,
nausea and eyes disorders

S
A
F
F
A

Bile diseases

Sexually transmitted diseases
and digestion
Evil
affliction,
tinging,
nephrosis, numbness, gout,
leprosy and blood regulator
Cough and cold, sore throat,
chest pain and decongestant

Bay-kan disorders including
digestive system disorders
Anti-hypertension,
blood
purifier and nerve pain
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Corydalis gerdae

Fumariaceae

Stong-ri-zil-pa

HA

W

Antimalarial and infections

HA

Bhutan
and
Chumbi valley
Himalaya

Corydalis stracheyi

Fumariaceae

Cotoneaster
microphyllus
Curcuma longa

Rosaceae

Bya-rgod-sugpa
Bya-pho-tsi-tsi

A

Blood disorders, liver disorders
and analgesic

Ha

Himalaya.

F

Zingiberaceae

Yung-ba

LA

Rh

Boraginaceae

Nad-ma-gyu-lo

HA

Orchidaceae

Dbang-lag

HA

Bhutan
and
India
Afghanistan to
Bhutan
Himalaya

Cynoglossum
glochidiatum
Dactylorhiza hatagirea
Delphinium
brunonianum

Ranunculaceae

Bya-rgod-spos

HA

Himalaya

A

Delphinium
drepanocentrum

Ranunculaceae

Bya-rkang

HA

Diospyros spp.

Ebenaceae

LA

Dracocephalum
tanguiticum
Dryopteris fragrans
Elettaria cardamomum
Ephedra gerardiana

Labiatae

Rgun-bdrumnag-po
Pri-yang-ku

Endemic
Nepal
Sikkim
Himalaya

HA

Tibet

A

Polypodiaceae
Zingiberaceae
Ephedraceae

Re-rel
Sug-smel
Mtshe-ldum

LA
LA
HA

Cosmopolitan
Sub-tropics
Afghanistan to
Bhutan

Rh.
F
A

Elshoutia eriostachya
Eriophyton wallichiana

Labiatae
Labiatae

HA
HA

Erythrina arborescens

Leguminosae

Bje-rug
Spang-mtshanspu-ru
Mkhal-ma-shosha

Eugenia fruticosa
Euphorbia griffithi
Euphorbia spp.
Euphrasia himalaica

Myrtaceae
Euphorbiaceae
Euphorbiaceae
Scrophulariaceae

LA
HA
HA
HA

Fragaria indica.

Saxifragaceae

Sa-bras
Dur-byid
Thar-nu
Zhim-thig-ledkar-po
Bri-rta-sa-dzin

HA

W.Nepal
to
S.W China
India, Bhutan,
China
and
Burma
Himalaya
Tropics
Tropics
Afghanistan to
Bhutan
Worldwide

Fritillaria delavayi

Liliaceae

HA

Himalaya

B

Fritillaria gardneri
Galium aparine

Liliaceae
Rubiaceae

HA
HA

Himalaya
Himalaya

A
W

Gentiana algida

Gentianaceae

HA

Gentianaceae

HA

Kashmir
and
S.W China
Himalaya

Fl

Gentiana spp.
Gentiana urnula

Gentianaceae

Dkar-po-chigthub
A-bhi-kha
Zings-rtsi-dkarpo
Spang-rgyansngon-po
Spang-rgyandkar-po
Gang-ga-chung

HA

Himalaya

A

Geranium spp.

Geraniaceae

Gla-sgang

HA

Himalaya

A

Geranium tuberaria

Geraniaceae

li-ga-dur

HA

R

Glycyrrhiza glabra
Hemiphragma
heterophylla Wall

Leguminosae

Shing-mgar
A-bi-ra

LA
HA

Pakistan, India
and
Central
Asia
Cultivated
Himalaya

Heracleum candicans

Umbelliferae

Spru-nag

HA

Himalaya

R

Herpetospermum
caudigerum
Hippophae rhamnoides

Cucurbitaceae

Gser-gyi-metog
Star-bu

HA

Semi-cultivated

S

HA

F

Hypecoum leptocarpum
Impatiens laxiflora
Inula grandiflora

Fumariaceae
Balsaminaceae
Compositae

HA
HA
HA

Inula racemosa
Iris kemaonensis

Compositae
Iridaceae

Par-pa-ta
Byiu-star-ga
Ming-can-serpo
Manu
Dres-ma

Central Asia,
India
and
Pakistan
Himalaya
Tibet
Pakistan
and
Central Nepal
Cultivated
India
and
Pakistan

Elaegnaceae

LA

HA
HA

to
and

R

A

Suppleness of the body tonics
and builds body
Fevers,
trembling,
bile
malfunctioning
and
as
detoxifiers
Dermatitis
and
dysentery,
wounds and abscess

F

A
W

Stomach, lung and the liver
disorders and heals wound

Fever,
wounds,
injuries,
bleeding and heals every fever
including malaria
Boils, wounds and tuberculosis

F

F
R
R
A
W

Fl

R
W

A
W
Fl
R
F

Anthelmintics,
neurological
infection, chest infections, and
lung inflammation
Detoxifier, blood purifier and as
antipyretic
Detoxicant and joining bone
Bile disorders like jaundice,
migraine, and sinusitis
Anti-dote, inflammation of
throat and lung, and pain reliever
Bile related disorders, leprosy
and blood disorders
Diarrhoea and as
Detoxicant
Sore throat and bronchitis,
intestinal disorders, fevers,
tuberculosis and diarrhoea
Common cough and cold and
swelling of limbs

Body tonic, for roper blood and
menstruation regulation, UTI
infection and backache
Leprosy, bleeding, headache and
neurology
Bile disorders and intestinal
disorders
Tuberculosis, anticoagulant and
Liver diseases
Common cold and detoxifier
Abscess/boils, numbness
fever, evil affliction
Anthelmintic and antipyretic

and
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Jaeschkea oligosperma
Juniperus squamata

Gentianaceae
Cupressaceae

HA
HA

Scrophulariaceae

Lcags-tig
Shug-pa-tshercan
Pa-yag

A
L/F

HA

Kashmir
Afghanistan,
and S.W.China
Himalaya

Lancea tibetaca
Lepisorus spp.

Polypodaceae

Brag-spos-pa

HA

Himalaya

W

Luffa aegyptiaca
Malva sylvestris

Cucurbitaceae
Malvaceae

Ka-bed
Lcam-pa

LA
HA

Tropics
Himalaya

S
A

Malva verticillate

Malvaceae

So-ma-ra-dza

LA

S

Meconopsis horridula

Papaveraceae

Tsher-ngon

HA

Pakistan, India,
Euro-Asia and
Africa
Himalaya

Meconopsis paniculate

Papaveraceae

Ud-pal-ser-po

HA

Fl

Meconopsis primulina

Papaveraceae

HA

Meconopsis
simplicifolia

Papaveraceae

Yi-mo-mdeubyin
Ud-pel-sngonpo

Utter Pradesh to
S.E. Tibet
Himalaya

HA

C. Nepal to S.E
Tibet

A

Morina nepalensis

Dipsacaceae

HA

Tamaricaceae

Myristica fragrans
Nardostachys
grandiflora
Onosma hookeri

Myristicaceae
Valerianaceae
Boraginaceae

Bri-mog

HA

W. Nepal to
S.W. China
C.Nepal
to
S.W China
South East Asia
Utter Pradesh to
S.W China
Himalaya

A

Myricarea rosea

Spyang-tsherlo-ma-phra-ba
Chu-shing-ombu
Dza-ti
Spang-spos

Oreosolen wattii

Scrophulariaceae

Khron-bu

HA

R

Oxytropis lapponica

Leguminosae

Srad-dkar

HA

Oxytropis reniformis
Parnassia ovata

Leguminosae
Saxifragaceae

Sngo--stag-sha
Dngul-tig

HA
HA

West Nepal to
Bhutan
Pakistan
and
India
Himalaya
Himalaya

Pedicularis flagellaris
Pedicularis longiflora

Scrophulariaceae
Scrophulariaceae

Glang-sna
Lug-ro-ser-po

HA
HA

A
A

Pedicularis megalantha

Scrophulariaceae

HA

Pedicularis siphonantha

Scrophulariaceae

Lug-ru-smugpo
Lug-ru-dmar-po

Phlomis rotate

Labiatae

Rta-lpags

HA

Pholidota recurva
Phyllanthus emblica

Orchidaceae
Euphorbiaceae

Pu-shel-rtse
Skyu-ru

LA
LA

Phytolacca esculanta

Phytolaccaceae

HA

Picrorhiza kurroa

Scrophulariaceae

Dpah-bo-dkarpo
Hong-len

Himalaya
Pakistan to S.W
China
Utter Pradesh to
S.E Tibet
Utter Pradesh to
S.E Tibet
W. Nepal to
S.W China
Himalaya
India
and
Nepal
Cultivated

R

Blood purifiers

Piper nepalense
Plantago erosa
Pleurospermum amabile
Pleurospermum hookeri

Piperaceae
Plantaginaceae
Umbelliferae
Umbelliferae

LA
HA
HA
HA

F
S
W
R

Diarrhoea
Antidote, fever and indigestion
Heart disorders

Podophyllum
hexandrum(emodi)

Podophyllaceae

Pi-pi-ling
Tha-ram
Rtsad
Tang-kun-dkarpo
Hol-mo-se

Pakistan
to
Utter Pradesh
Himalaya
Cosmopolitan
Himalaya
Pakistan to S.W
China
Afghanistan to
S.W China

Polygonatum
singalilense
Polygonatum
verticillatum

Liliaceae

Lug-mnye

HA

Himalaya

Rh.

Liliaceae

Ra-mnye

HA

Pakistan
S.E.Tibet

Potentilla peduncularis
Pterocephalus hookeri

Rosaceae
Dipsacaceae

HA
HA

Punica granatum
Rununculus
brotherusi (nuichillus)

Punicaceae
Ranunculaceae

Gro-ma
Spang-rtsi-dobo
Se-bru
lChe-tsha

Nepal
W.Nepal
S.W.China
Tropics
Himalaya

Ranunculus tricuspis

Ranunculaceae

Chu-rug-pa

HA

HA
LA
HA

HA

HA

HA

LA
HA

Kashmir
S.E.Tibet

W

A

Revitalising kidney,
wounds and diarrhoea

diuretic,

Broken bones (skull) and make
joints strong

A
Antipyretics, antimalarial, lungs
disorders, liver cirrhosis and
blood disorders.

A
S
R
R

Chronic fever, detoxicant, and
heart disorders
Asthma, hypertension
and
pneumonia

Fl
W
A

A

Antiseptic, wounds and antidote
Bile disorders and ganglion
blockage.
Anti-diuretic and wounds
Dehydration of mouth and
tongue
Antidote, meat poisoning and
intestinal disorders

A
A
St.
F
R

F

to

Rh.

to

R
W
F
A

to

Wounds, lung and heart
disorders
Bone fracture, burns, wounds
and kidney disorders

W

Female
gynaecological
problems,
paralysis,
blood
disorders and kidney disorders

Fluid accumulation in joints,
anthelmintics,
tranquilliser,
appetiser and longevity
Dysentery
Gout, dysentery, fever and
hypertension
Antiseptic, wounds and pus and
as antipyretic
Relieves nerve pain, hbam-grum
and fevers
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Rheum australe
Rhodiola himalenses
Rhododendron
anthopogon
Rhododendron
lepidotum
Rhus semi-alata

Polygonaceae
Crassulaceae
Ericaceae

Chu-rtsa
Sro-lo-dmar-pa
Dvali-dkar-po

HA
HA
HA

India and Nepal
Kashmir
Pakistan to S.E
Tibet
Pakistan to S.W
China
Kashmir, S.W
China, Japan,
and Burma
Tropics
Himalaya

R
R
Fl

Ericaceae

Dva-li-nag-po

HA

Anacardiaceae

Da-trig

LA

Ricinus communis
Rosa macrophylla

Euphorbiaceae
Rosaceae

Dan-rog
Se-rgod

LA
HA

Rosa sericea
Roscoea capitata
Rubia cordifolia

Rosaceae
Zingeberaceae
Rubiaceae

Se-bai-me-tog
Sga-skya
Brtsod

HA
LA
LA

Fl.
Rh.
St.

HA

Himalaya
Nepal
Pakistan
to
S.E.Tibet
Himalaya
W. Nepal to
S.W. China
Kashmir to S.W
China
Himalaya
Pakistan to S.W
China
Utter .Pradesh
to Bhutan
Himalaya

Salvia castanea
Sambacus adnata

Labiatae
Caprifoliaceae

Jib-rtsi-chen-po
Yu-gu-shing

HA
HA

Saussurea gossypiphora

Compositae

HA

Saussurea spp.
Saxifraga
moorcroftiana
Saxifraga parnassiflora

Compositae
Saxifragaceae

Bya-rgod-sugpa
Ru=rta
Zang-tig

Saxifragaceae

Gser-tig

HA

Saxifraga umbellulata

Saxifragaceae

Tig-ta

Scopolia lurida

Solanaceae

Thang-phromnag-po
Chu-srin-sdermo
Spos-kar
Ra-sug

HA

Cosmopolitan

S

Selaginella pulvinate

Selaginellaceae

LA

Himalaya

A

Shorea robusta
Silene satisperma

Dipterocarpaceae
Caryophyllaceae

LA
HA

Re.
W

Srol-gong-serpo
Rgya-tig
Rgu-drue
Kyi-lce-dkar-po
Byi-tang-ka

HA

Khan-pa-dkarpo
Khur-mong

HA

Himalaya
Pakistan to E.
Nepal
India to S.E
Nepal
Himalaya
Himalaya
Himalaya
India to S.W
China
India to Bhutan

Soroseris hookeri

Compositae

Swertia chirata
Swertia wolfangiana
Swertia kingii
Symplocos ramosissima

Gentianaceae
Gentianaceae
Gentianaceae
Symplocaceae

Tanacetum nubigenum

Compositae

Taraxacum officinalis

Compositae

W

LA
LA
LA

Ranunculaceae

Ba-ru
A-ru
Gze-ma-ra-goma
Sngo-sprin

Europe,
Asia
and
North
America
Tropics
Tropics
Tropics

Terminalia bellerica
Terminalia chebula
Tribulus terrestris

Combretaceae
Combretaceae
Zygophyllaceae

Thalictrum reniforme

A

Thermopsis barbata

Leguminosae

Gla-ba-sran-ma

HA

Thlaspi arvense
Tinospora cordifolia
Verbascum thapsus

Cruciferae
Menispermaceae
Scrophulariaceae

HA
LA
HA

Veronica himalensis

Scrophulariaceae

HA

Himalaya

Unidentified
Unidentified
Unidentified

Liliaceae

Bre-ga
Sle-tres
Shing-gi-gserbye
Ldom-nagldom-mkhri
Byiu-lp-hug
Stab-seng
Seng-ldeng

Nepal
to
Bhutan
Kashmir to S.W
China
Cosmopolitan
Himalaya.
Euroasia

HA
LA
LA

Himalaya
Himalaya
Himalaya

Moraceae

HA
HA

LA
HA
HA
LA

HA

HA

L
F

S
F

Constipation, liver and bile
disorders, cough and cold,
antidote and abscess

R
A
A
R
W
W
A

Antipyretic and bile disorders
Wounds, cough cold, and bile
disorders including jaundice
Liver and bile disorders,
wounds, and fever

W
W
A
Fl.
F
W

F
F
F

W
C
S

Wounds and joins nerves

Abscess, kidney disorders and
haemorrhage
Stomach disorders, all fevers
and detoxifiers

Arthritis, diuretics and kidney
disorders
Antidote, anti-bacterial, antimalarial and painkiller

Pneumonia and kidney disorders

Ulcers, heals
haemorrhage

wounds,

W
C
Wd

Note: A: aerial, Bk: bark, B: Bulb, C: Cambium, Fl: flower, F: fruit, R: root, Rh: Rhizome, S: seed, St:
stem, W: Whole, Wd: Wood, LA: Low altitude, HA: High altitude.
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Table 4. Medicinal plants investigated for alkaloids at ITMS using the Culvenor and Fitzgerald
procedure106.
Botanical name

Gso-ba Rig-pa name

Alkaloid Test

Aconitum lacinatum

Btsan-dug

Positive

Aconitum orochryseum

Bong-dkar

Positive

Aletris pauciflora

Dam-bu-kara

Positive

Bistorta macrophylla

Spang-ram

Negative

Chrysosplenium forrestii

gYa-kyi-ma

Positive

Codonopsis bhutanica

Klu-bdud-dorji

Positive

Corydalis flabellata

Re-skon

Positive

Corydalis gerdae

Tong-ri-zil-pa

Positive

Corydalis megacalyx

sTong-zil

Positive

Corydalis stracheyi

Bya-rgod-sug-pa

Positive

Delphinium brunonianum

Bya-rgod-spos

Positive

Fritillaria devalayi

Dkar-po-chig-thub

Negative

Parnassia ovata

Dngul-tig

Positive

Pleurospermum amabile

Rtsad

Positive

Polygonatum verticillatum

Ra-mne

Negative

Ranunculus brotherusi

Che-rtsa

Positive

Rhododendron anthopogon

Da-li

Positive

Rosa macrophylla

Se-rgod

Negative

Thalictrum reniforme

Sgno-sprin

Positive

Thlapsi arvense

Bre-ga

Negative

Table 5.

Selected medicinal plants with their indications.

Botanical name

Family

Distribution

Ethno -medical use

Aletris pauciflora

Liliaceae

Himalayas

Pneumonia, liver and lung diseases

4100 metres
Ranunculus brotherusi

Ranunculaceae

Himalayas

Antipyretic, wounds & pus

4100 metres
Codonopsis bhutanica

Campanulaceae

Endemic

Gout, leprosy and infections

4500 metres
Corydalis gerdae

Fumariaceae

Bhutan

and

Malaria and infections

Chumbi
4100 metres
Aconitum Orochryseum

Tribulus terrestris

Ranunculaceae

Zygophyllaceae

Endemic

Fever, antidote (snake bite) and

4720 metres

infections

Australia and

Arthritis,

Coastal areas

diseases

diuretics

and

kidney
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Extracts of two of the selected medicinal plants, Aletris pauciflora and Codonopsis
bhutanica, were damaged on transportation to Wollongong, so as an alternative, the
locally available plant, Tribulus terrestris L107 was selected for the study. This plant
was known to have caused hepatopathy108, staggers109 and locomotor effects110 in
Australian sheep but the specific compound (suspected to be an alkaloid) responsible
for neurotoxicity whose symptoms are related to the symptoms of Parkinson’s disease
in humans, was not known. The plant is also used in the traditional medicine of Bhutan.
It should be noted that the medicinal plants used in Bhutanese traditional medicine
were never used as single plant components, but rather as a mixture of two or more
active ingredients.
The theory behind using multi-ingredient compounds is that those mixtures of
ingredients are believed to act synergistically by neutralising the toxicity of individual
ingredient and enhancing the therapeutic values of the mixture. So, quite often the
individual therapeutic indication is lost when it is formulated as multi-ingredient
products. For example, Tribulus terrestris is used for formulating four different multiingredient products in combination with other ingredients (Table 6). Although the
therapeutic properties of Tribulus terrestris are retained while formulated, the
individual therapeutic properties of other ingredients used in the formulation of 4
products (Table 6) could have lost.

Table 6. Traditional medicine products which use Tribulus terrestris in their formulation.
Sl. No.

Name of Product

Traditional use

1

Go-yu-28

Diuretic & kidney disorders

2

Seng-lden-25

Paralysis, arthritis, *CNS disorders

3

Ba-sam-lha-rlung

Kidney and renal disorders

4

Bdud-rtsi-nga-lum

Paralysis, gout and arthritis

*CNS: Central Nervous System

Similarly, Aconitum orochryseum is used for formulating eighteen different multiingredient products (Table 7). Only three of these products (Products 8, 9 and 10) have
similar therapeutic indications as those of the individual plant and Products 8 and 9
could be possibly good antimalarial compounds since they are used against high fever.
The other products (Products 1, 2, 3, 4, 5, 6, 7, 11, 12, 13, 14, 15, 16, 17 and 18) have
entirely different therapeutic indications to that of the individual therapeutic properties.
Two products (Products 5 and 12) are used against poisoning and infections, and to
treat liver diseases.
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Table 7. Aconitum orochryseum Stapf. used in formulating 18 types of multi-ingredient drugs.
Sl. No.

Name of Product

Traditional use

1

Tig-ta-8

Jaundice and Headache

2

Tig-ta-16

Jaundice and yellowing of eyes

3

Gser-mdog-11

Gallstone

4

Hong-len-9

Hypertension and joint pain

5

Thang-chen-25

Poisoning and Infections

6

Gyu-rgyal

Rheumatism

7

Bol-sman-7

Stomach upset

8

Rta-ze-dmar-po

High fever related to cold and flu

9

Spang-rtsi-12

High fever

10

Gtso-bo-8

Cough and Cold

11

Dbang-po-kuen-sel

Sinusitis

12

Gur-gum-13

Liver diseases

13

Man-sil

Poisoning and Bile disorders

14

Ko-la-19

Spleen diseases

15

Dvag-sman-15

Indigestion

16

Brag-zhun-9

Stomach ulcer

17

Mkhris-phyi-7

Dysentery

18

Ded-pon-10

Constipation

Corydalis gerdae and Codonopsis bhutanica are used for the formulation of a product
called kLu-bdd-8 which is used for treating dermatitis and leprosy.

2.4

Collection of medicinal plants

The collection was done from July to August 2002 by the medicinal plant collection
team from the Pharmaceutical and Research Unit of the Institute for Traditional
Medicine Services. Corydalis gerdae Fedde is endemic to Bhutan and the Chumbi
valley in Tibet111 and was collected from the upper Mochu (Yha-le-La near Lingshi),
Chomolhari (4400-4900 m) bases and from nearby mountain screes77 (Figure-3,
Collection site-I). Codonopsis bhutanica, Ranunculus brotherusi, Aletris pauciflora
were also collected from the Lingshi region (Figure 3, Collection site-I). Aconitum
orochryseum Stapf. has been collected from alpine regions (3950-4720 m)111 including
Thampe la, Zaradingthang and Tolegang77 in Bhutan. However, for this study,
Aconitum orochryseum was collected from Chukhalung, Lingshi (Figure 3, Collection
site-I). Herbarium specimens for each of the plants collected for this study are housed
at the Pharmaceutical and Research Unit of the Institute for Traditional Medicine
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Services, Thimphu, Bhutan. The herbarium voucher number and the collection codes
are noted in Table 8.
Tribulus terrestris was collected from near Wellington (Central West, NSW) in
February 2002 by Dr. Chris Bourke, Orange Agriculture Institute, Orange, NSW. The
air-dried (room temperature) plant material (stems, leaves, flowers and fruits, approx. 8
kg) has been coarse chopped using a petrol driven plant-mulching machine.

Table 8. Site of collection of the selected medicinal plants.
Collection season
Medicinal Plants

Collection sites

Parts

Herbarium

(Bhutan)

collected

No.

Aletris pauciflora

July/August

Zangpothang

Whole

47

Codonopsis bhutanica

July/August

Chewla

Whole

71

Ranunculus brotherusi

July/August

Zangpothang

Whole

18

Corydalis gerdae

July/September

Chukhalung

Whole

07

Tribulus terrestris

February

Wellington,

Aerial

NA

Aerial

83

NSW, Australia
Aconitum orochryseum

July/August

Jaradingthang

Except for Aletris pauciflora and Codonopsis bhutanica, all the plants collected here
are rare species77, and care was taken with respect to the environmental impact. The
collected plants were then analysed for their alkaloidal components and the results of
the investigations are discussed in the ensuing chapters.
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Chapter 3
Alkaloids from Aconitum orochryseum Stapf.

3.1

Family:

Ranunculaceae

Genus:

Aconitum

Species:

orochryseum

Common name:

Aconites

gSo-ba Rig-pa name:

Bong-nga-dkar-karpo

Distribution:

Endemic to Himalayas

Botanical Description and Ethno-medical Use

Aconitum orochryseum is a herbaceous perennial plant and is a close relative of
Delphinium species77. The plant grows to a height of 40-100 cm with pubescent slender
stems77, palmately divided or cleft leaves (3-9 cm diameter) and hairy petalled, 2-10
racemes flowers. There are more than 100 species of Aconitum and they are native to
temperate regions of the northern hemisphere.
Aconitum and Delphinium species both contain biologically active diterpenoid
alkaloids. Crude preparations from plants in these two genera have long had a broad
range of applications in Asia, Alaska, and Europe59, ranging from covert human
poisons (e.g. Aconitum napellus is used in arrowhead dips and reputedly as an agent for
euthanasia) to traditional medical uses in neuralgia, gout, hypertension and rheumatism
and they have also been included as ingredients in intoxicating liquors112. The
powdered root of Aconitum heterophyllum Wall has been used by Indians (Asia) as a
febrifuge and bitter tonic, especially in combating debility after malaria and other
fevers113. It is also considered efficacious in the treatment of diarrhoea, dysentery,
cough, dyspepsia and chronic enteritis114.
Aconitum leucostomum Vorosch is used in China for the treatment of traumatic
injury115, while Aconitum hemsleyanum Pritz has been used as a folk remedy for the
treatment of arthritic pain116. In Bhutan, three species of aconites: Aconitum lacinatum,
Aconitum violatum and Aconitum orochryseum are used in the formulation of more
than 25 traditional medicines85. Aconitum orochryseum, which is endemic to Bhutan
and her bordering areas, has been used for bilious fever, as an antidote against snake
bite and also for the treatment of malaria105.
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3.2

Diterpenoid Alkaloids: Biosynthesis and Classification

Diterpenoid alkaloids occur mainly in the families Ranunculaceae (Aconitum,
Delphinium, Thalictrum and Consolida genera), Cornaceae (Garrya species), Rosaceae
(Spirea japonica) and Compositae (Inula royleana) and possess widely recognised
pharmacological and biological activities

117-122

. The majority of the phytochemical

studies of these three genera have been carried out with species from Asia, Europe, and
North America123,124. A series of new and known alkaloids have been isolated and
identified from them.
Over two hundred diterpenoid alkaloids are reported to date from 92 different species
of Aconitum alone47. These diterpenoid alkaloids occur commonly either as amino
alcohols or as esters of amino alcohols and these permutations and combinations thus
give rise to many interesting bases121. A number of common biosynthetic pathways
have been proposed for the diterpenoid alkaloids which are skeletally closely related.
Some authors have suggested, based on the structural similarities, that the diterpenoid
alkaloids are derivatives of mevalonate 5.

CH3

HO

O

O

5 Mevalonate

However, the classification of these alkaloids by some authors in this field indicated
that the alkaloids arise from cyclization and rearrangement processes. Pelletier and
Keith125, Dalton121, and Southon and Buckingham47 have classified these alkaloids
mainly into two major structural types, the C19 and C20 diterpenoid alkaloids. The C19
diterpenoid alkaloids have three types of basic skeletal ring systems: the aconitum-type
6, the lycoctonine-type 7, and the lactone-type or heteratisane-type 8.
The aconitane group accounts for the majority of the alkaloids of this diterpenoid class
and they differ only in the substitution by hydroxy, methoxy, acetyloxy, benzoyloxy
and acyloxy47 groups. Recently, tuberaconitine and tubermesaconitine, along with the
known alkaloids flaconitine, mesconitine, tuberanine and aconitine that belong to the
aconitane group have been isolated126. Hemsleyatine 9 was the first aconitane-type C19
diterpenoid alkaloid bearing an amino group at the C-8 position and it was isolated
from the plant Aconitum hemsleyanum Pritz127.
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The un-substituted C-14 aconitane ring system with C-7 substitution occurs in the
lycoctonine-type alkaloids. Its sub-type, the pyrodelphinine-type 10 of the C19
diterpenoid alkaloids, originates as a result of C-8-C-15 double bond formation in the
aconitane ring system. The oxidative fission of the C-13-C-14 bond of the aconitane
framework forms lactone or heteratisane-type alkaloids as represented by heteratisine47.
Two new C19 diterpenoid alkaloids, jiufengdine and jiufengtine, were also isolated
recently from Delphinium potainii W.T.Wang varieties jiufengshanense W.J.Zhang et
G.H.Chen128.
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The second major group are the C20 diterpenoid alkaloids based on the atidane ring
system 11. Atidine was first isolated from the Himalayan plant Aconitum
heterophyllum Wall along with the known alkaloids atisine, hetisine, heteratisine, and
benzoylheteratisine129. The atisane-type alkaloid 12 represents a smaller group with
interesting chemical features and complex structures which has been the subject of
extensive chemical study130. Atisine, the first representative of this type, was isolated
as the major alkaloid from the Himalayan plant Aconitum heterophylloides Stapf., but it
has also been reported from Aconitum gigas, Aconitum anthara and Aconitum
heterophyllum131. It was suggested132 that the aconitanes were derived from compounds
with the atisine skeleton, through the rearrangement of the C-8-C-9 bond to the C-8-C15 position and the loss of the C-17 substituent133. Hetisane and delnudine together
represent the biggest sub-types of atidane-based C20 diterpenoid alkaloids and they are
discussed separately in section 3.2.1.
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The third major group is represented by the veatchine skeletal type 13 of the C20
diterpenoid alkaloids. Delphinium species (Ranunculaceae) generally contain veatchine
or atisine-type diterpenoid alkaloids134-136. A striking similarity is present in the
chemistry of atisine 14 isolated from Aconitum heterophyllum Wall (Ranunculaceae)
and veatchine 15 isolated from Garrya veatchii Kellogg (Garryaceae)137,138 although
they belong to different families139. A study of the NMR spectra of 44 alkaloids from
these two plants confirmed that atisine-type alkaloids which contain an oxazolidine
ring, have a boat conformation in ring E 14138.
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Varieties of bases, that don’t fit into any of the above structural types, could also be
formed by either modifications of these skeletal rings or by introduction of a new ring
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system (as a result of bond formation) into the main structural skeleton as is the case
with the icacine 16 and they are grouped under miscellaneous diterpenoid alkaloids140.
A new C20 diterpenoid alkaloid, arcutinine 17, that has a C-5-C-20 bond instead of the
normal C-11-C-17 and C-10-C-20 bridging bonds, was isolated recently from Aconitum
arcutum Maxim and is still the only one of its kind141. Secokaraconitine 18, another
new diterpenoid alkaloid that has no C-7-C-17 bond, was isolated from the Kyrgystan
plant Aconitum karacolicum Rapaics142.
OH
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3.2.1
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Hetisane-type Diterpenoid Alkaloids

The strong interest in hetisane-type alkaloids is due to their complicated structures,
unique chemistry, valuable pharmacological properties and the widespread popularity
of plants containing these compounds in folk medicine122. The first representatives of
this type, paniculatine, hetisine and kobusine, were isolated in the 1930s and 1940’s122.
As of 1998, more than 100 hetisane-type representatives were known122.
While some sources have suggested that the introduction of additional rings into the
atidane ring system by formation of C-14-C-20 and N-C-6 bonds forms the hetisanetype 19 C20 diterpenoid alkaloids, a recent review more accurately pointed out that the
formation of the bridge bonds C-14-C-20 and N-C-6 bridges in atisine produces the
hetisane carbon framework122,143. The contraction of ring C in the hetisane forms
complex derivatives belonging to the delnudine type of alkaloid as exemplified by
delnudine 20. The 13-O-acetyl derivative of hetisine was isolated from a related plant,
Delphinium nutallianum Pritz144.
It was proposed that the formation of the N-C-6 bond is based on the structures of the
natural alkaloids miyaconitine and miyaconitinone, an analogue of the intermediate 21
122,143

. Other alternatives for forming the N-C-6 were also studied, proposed and

reviewed recently.118
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As illustrated in structure 19, the skeletal system of the hetisane-type alkaloids is made
up of six membered (chair shaped ring-A and ring-B, and a boat shaped ring-C, ring-D,
ring-E and ring-F) and five membered (ring-G with a twist-form, ring-H with an
envelope form and the ring-I with an equal mixture of the twist and an envelope
conformations) rings145. For all the hetisane alkaloids the fusion of rings A, B and C is
identical. This structural framework and ring conformations of the hetisane type
alkaloids significantly helped the author in structural elucidation and the
conformational analysis of the compounds isolated from Aconitum orochryseum Stapf..

3.3

Pharmacological Investigation of the Diterpenoid Alkaloids from Aconitum

species.
Aconitum alkaloids have been the subject of extensive chemical and pharmacological
investigation owing to their toxicity as well as their potential medicinal values. An
aconitane-type diterpenoid alkaloid, such as aconitine, which was isolated as the major
component from the poisonous plant, Aconitum napellus, was probably the first
diterpenoid alkaloid to have been studied pharmacologically146. Aconitine-containing
liniments like AconitysatTM, BrinpaxTM, EtermolTM and PectovoxTM have been used in
modern medicine for the treatment of rheumatism, neuralgia and sciatica146. Another
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derivative, deacetylranaconitine, which was isolated from the roots of Aconitum
finetianum, showed good analgesic activity47.
Hetisane and atisane type alkaloids are closely related and have been reported to have
the lowest cytotoxicity among the different categories of aconitum-diterpenoid
alkaloids114. About 12 diterpenoid alkaloids were isolated from Aconitum coreanum
Rapaics collected from the Korean Peninsula and China and have been assessed for
structure-biological activity relationships147. This study found that atisine chloride,
isoatisine and coryphine had the highest toxicity as well as the highest myorelaxant
activity among the 12 alkaloids, and hetisine-type alkaloids were found to be less toxic
with less myorelaxant activity. This indicated that the therapeutic value is proportional
to the toxicological index.
The veatchine-type diterpenoid alkaloids, napelline and its acyl derivatives (isolated
from the most toxic plants Aconitum napellus, Aconitum karakolicum and Aconitum
yesoense), were studied for their antiarrhythmic activity148 and it was found that one of
the derivatives, 1-O-benzoylnapelline, had maximum activity, even markedly
exceeding that of napelline itself and the reference Class I antiarrhythmic drugs
novocainamide, quinidine and lidocaine.
Although studies on diterpenoid alkaloids from Aconitum species have been extensive
and they are still vigorously continued in pursuit of potential new alkaloids, little has
been reported on the antimicrobial activity of these diterpenoid alkaloids. In this
context, a Bhutanese medicinal plant, Aconitum orochryseum Stapf. was analysed for
alkaloids and antimicrobial activity of the alkaloids.

3.4

Isolation, Structural Elucidation and Identification of Diterpenoid Alkaloids

from Aconitum orochryseum Stapf.
The methanol extract of whole parts of air-dried plant material was subjected to a series
of extraction, fractionation, separation, purification and crystallization processes
(Chapter 9). This resulted in the isolation of eleven alkaloids from Aconitum
orochryseum Stapf.. Comparative literature analysis of data revealed that two of the
alkaloids were the known compounds virescenine and atisinium chloride. The structure
of virescenine was established by NMR spectral analysis and that of atisinium chloride
was confirmed by single crystal X-ray crystallography. Three other alkaloids were
identified as new alkaloids and they were named as orochrine, 2-O-acetylorochrine and
lingshinaline.

Orochrine

was

named

after

the

species

orochryseum,

2-O-

acetylorochrine was based on the acetate substituent at the C2 position of orochrine,

39
while lingshinaline was named after the place of collection called Lingshi in Bhutan. In
the presence of base Na2CO3, some of the alkaloids existed in an amino keto form
(apply to all the three new alkaloids that were isolated as salts), which would be soluble
in chloroform. However, there may have been some left in the aqueous phase.
Among the compounds isolated, atisinium chloride was found to be the major alkaloid
from the plant followed by lesser amounts of lingshinaline, orochrine, virescenine, and
2-O-acetylorochrine. To identify and establish their structures, physico-chemical and
spectral analysis were conducted for each of these three alkaloids and the results are
discussed sequentially in the following section. Six other alkaloids were isolated as
minor components.

3.4.1 Orochrine
a. Physico-chemical properties
The alkaloid named orochrine 22 was obtained as needle-like crystals (14.9 mg/1 kg
dried plant weight) on recrystallization from acetone/diethyl ether. This alkaloid
formed a translucent solid in the presence of chloroform. The alkaloid was optically
active and had a high melting point.

b. Spectral Analysis of Orochrine.
Low Resolution Chemical Ionisation Mass Spectrometry (LRCIMS) indicated a
molecular ion peak at m/z 342 (MH+), which was 18 amu less than that of the alkaloid
vakhmadine. High Resolution Chemical Ionisation Mass Spectrometry (HRCIMS) and
High Resolution Electron Impact Mass Spectrometry (HREIMS) supported the
molecular formula C21H27NO3 for this alkaloid, and hence an index of hydrogen
deficiency of 15. In the LREIMS (Appendix 1), the molecular ion fragments were
observed at m/z 341 (M+), together with major fragment ions at m/z 326, 313, 282, 254,
192, 136, 122, 84, 55, and 44 (100%). The number of protons (from integration in the
1

H-NMR spectrum) and carbons (from the

13

C-NMR) matched with the number of

protons and carbons presented by the molecular formula (HRCIMS).
The structure of orochrine 22 was established by the analysis of 1H-NMR (Appendix
2),

13

C-NMR (Appendix 3), DEPT (Appendix 4), gCOSY (Appendix 5), TOCSY

(Appendix 6), gNOESY (Appendix 7), gHSQC (Appendix 8) and gHMBC
(Appendix 9) spectral data. No signals for aromatic protons were evident in the 1HNMR spectrum so the index of hydrogen deficiency was structurally indicative of
saturated rings or double bonds. Two broad singlets (5.04 ppm, 1H and 4.94 ppm, 1H)
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indicated the presence of the H-17 exocyclic methylene group. A strong singlet
resonating at 1.48 ppm (3H) was ascribed to the H-18 methyl group. Signals ascribed to
the H-20 and H-12 (1H each, bs) protons were observed at 4.27 ppm and 2.98 ppm
respectively. The H-19 protons resonated at 3.35 ppm (d, 1H, J=11.5 Hz) and 4.30 ppm
(d, 1H, J=11.5 Hz). Since almost all hetisane type alkaloids contain these four
characteristic proton signals122, it was concluded that the alkaloid (orochrine) belonged
to the hetisane type diterpenoid alkaloids (Section 4.2.1).
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Figure 4. 3D-Model of orochrine (N-blue, O-red, C-black, H-white).

From the gCOSY spectrum, a distinct geminal coupling was observed between the
proton signals at 2.69 ppm (d, 1H, J = 17 Hz, H-15) and 2.52 ppm (d, 1H, J=17.5 Hz,
H-15). These geminal protons (2.69 ppm, d, 1H, J=17 Hz and 2.52 ppm, d, 1H,
J=17.5Hz) were coupled to the H-17 exocyclic methylene protons (5.04 ppm, bs,1H
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and 4.94 ppm, bs, 1H), clearly indicating that they were close to each other. The
gCOSY spectrum also showed strong coupling between the H-19 protons at 4.30 ppm
(d, 1H, J = 11.5 Hz), and 3.35 ppm (d, J = 11.5 Hz).
From the

13

C-NMR spectrum, the peaks at 142.3 ppm and 112.3 ppm indicated the

presence of an alkene group in the structure. A ketone carbonyl group was assigned to
the resonance signal at 208.7 ppm. Generally, for the hetisane type C20 diterpenoid
alkaloids, a doublet for C-2 with chemical shifts of 66.1-67.2 ppm, and its respective
protons resonating between 4.02-4.31 ppm a broad singlet, has been assigned to the C-2
α-hydroxyl moiety149,150. In the

13

C-NMR spectrum of the alkaloid isolated here, the

chemical shift ascribed to the C-2 carbon resonated at 65.5 ppm and its associated
proton resonated at 4.14 ppm (H-2β) as a broad singlet in the 1H-NMR spectrum. Thus,
based on this evidence, a hydroxyl group (C-2αOH) was assigned to the C-2 position of
orochrine.
The DEPT spectral analysis showed that there were fifteen protonated carbons. Seven
of them were methylene carbon atoms (-CH2 × 7 including the exocyclic methylene
group), six were methine carbon atoms (-CH × 6) and two were methyl carbon atoms (CH3 × 2). Based on DEPT, gHSQC, gCOSY and TOCSY spectral analysis, complete
carbon-proton connectivity, proton-proton correlations and group assignments were
achieved (Table 9). The gHSQC correlations found that C-17 had a chemical shift of
112.3 ppm and that of C-18 (methyl carbon) corresponded to the signal resonating at
30.3 ppm.
The structure was then drawn by cross peak analysis of the gHMBC (proton-carbon
correlations. of a maximum of 4 bonds away) and gNOESY spectra (Table 10). Using
the scaffold of the hetisane-type diterpenoid alkaloid 19, the appropriate carbon peaks
of the ring were assigned and a complete structure for orochrine was established as 22.
From the gHMBC correlation (Table 10), C-4, C-6, C-8, C-10, C-13 and C-16 were
found to be the quaternary carbons. The chemical shifts of C-4 (36.6 ppm) and C-10
(47.4 ppm) matched the range of chemical shifts reported in the literature on hetisane
type alkaloids122.
The gNOESY correlation is also represented diagrammatically in Figure 5. Based on
this gNOESY correlation, the stereochemistry of orochrine was established. The
gNOESY correlation was also consistent with the spatial arrangements of protons and
functional groups observed in a computer generated 3D model (Figure 4) of orochrine
(enantiomeric form, exept at C-2), using the Spartan program. The long range
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correlation existing between the N-Me and the C-14 was clearly seen in this 3D
computer model because orochrine has a rigid spatial conformation.
Table 9. The gHSQC, gCOSY and TOCSY NMR data (500 MHz, CD3OD) of orochrine 22.
g HSQC (δC to δH)
δC (ppm)

Assignment

δH (ppm)

C-1

34.5

-CH2

1.59

C-2

65.5

-CH

C-3

41.4

-CH2

C-4

36.6

Q

Carbon

C-5

59.1

-CH

C-6

106.2

Q-OH

C-7

38.2

-CH2

C-8

43.9

Q

C-9

49.4

-CH

C-10

47.4

Q

C-11

23.3

-CH2

Multiplicity Integration

J(Hz)

d

1H

15

1.75

d

1H

15

4.14

bs

1H

1.60

d

1H

15

1.93

t

1H

15

2.15

s

1H

2.23

d

1H

12.5

2.31

d

1H

12.5

2.20

s

1H

1.86

d

1H

14

2.03

d

1H

14.5

2.97

bs

1H

53.5

-CH

208.7

Q,C=O

C-14

56.3

-CH

2.98

bs

1H

C-15

32.6

-CH2

2.52

d

1H

17.5

2.69

d

1H

17

C-16

142.6

Q

C-17

112.3

-CH2

5.04

bs

1H

4.94

bs

1H

-CH3

1.48

s

3H

C-19

70.5

-CH2

3.35

d

1H

11.5

4.30

d

1H

11.5

-CH

4.27

s

1H

-CH3

2.90

s

3H

Note: Q = Quaternary carbon

O
CH2
HO
H3C

N+

H-1, H-3

H-1, H-3

H-1

H-1

-

OH

CH3OH

Figure 5. gNOESY Correlation of orochrine.

H-11

H-9

H-11

H-17

H-15

30.3

37.3

H-2β

H-9, C-11

C-18

75.1

Correlation

H-11

C-13

C-21 (N-Me)

TOCSY

Correlation

H-9

C-12

C-20

gCOSY

H-15

H-3, H-7
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Table 10. gHMBC and gNOESY NMR correlation (500 MHz, CD3OD) of orochrine 22.
gHMBC Correlation
Carbon

δC (ppm) δH (ppm)
1.59,

δC to δH
H-20

gNOESY
δH to δC

34.5

C-2

65.5

4.14

H-1, H-3

C-20

H-1, H-3

C-3

41.4

1.60,

H-1, H-18, H-19

C-1, C-2, C-4, C-5, C-10,

H-1, H-18

1.75

36.6

C-5

59.1

C-6

106.2

C-7

38.2

C-8

43.9

C-9

49.4

H-3

C-20

1.93
C-4

C-2, C-3, C-4, C-5, C-10,

Correlation

C-1

C-18
H-3, H-18, H-19

2.15

H-1, H-3, H-7, H-15, H-20

C-9, C-18, C-19, C-20

H-1, H-18

C-5, C-6, C-8, C-9, C-11,

H-5, H-9

H-7, H-9, H-19, H-20,
H-21
2.23,
2.31

C-14, C-15, C-20
H-7, H-11, H-15, H-20

2.20

H-5, H-7, H-15, H-20

C-5, C-6, C-8, C-10, C-11,

H-1, H-5, H-11

C-12, C-14, C-20
C-10

47.4

H-11, H-12, H-14, H-20
H-1, H-3

C-11

23.3

1.86,

C-8, C-9, C-10, C-12, C-13, C-16

H-1

C-13, C-14, C-15, C-16,

H-11

2.03
C-12

53.5

C-13

208.7

C-14

56.3

2.97

H-9, H-11, H-15, H-17

C-17
H-11, H-12, H-14, H-20
2.98

H-7, H-12, H-15 (w),

C-9, C-13, C-15, C-16, C-20

H-19, H-20
C-15

32.6

2.52,

H-12, H-14, H-17

2.69
C-16

142.6

C-17

112.3

H-7, H-15,
H-21 (N-CH3)

C-7, C-8, C-9, C-12, C-14, C-16,

H-7, H-9

C-17
H-11, H-12, H-14, H-15

5.04,

H-12, H-15

C-12, C-15, C-16 (w)

H-12, H-15

4.94
C-18

30.3

1.48

H-3, H-5, H-19

C-3, C-4, C-5, C-19

C-19

70.5

3.35,

H-3, H-5, H-18, H-20,

C-3, C-4 (w), C-5 (w), C-6,

H-3, H-18,

4.30

H-21

C-14, C-18, C-20, C-21

H-21 (N-Me)

C-20

75.1

4.27

H-1, H-2, H-5, H-9, H-12,

C-1, C-4 (w), C-6, C-8, C-9, C-10

H-1, H-14,

H-14, H-19, H-21

(w), C-13, C-14, C-19

H-19, H-21

H-19

C-6, C-19, C-20

H-7, H-15

C-21 (N-Me)

37.3

2.90

From the gHMBC and gNOESY cross peak assignments, orochrine was assigned to
have N-C-6 and C-14-C-20 bonds. The presence of a quaternary nitrogen (attached to
C-19, C-20, C-6 and C-18 methyl group) and the quaternary carbon at C-6 (attached to
C-5, C-7, N-Me and hydroxyl group) indicated its relation to vakhmadine 23 which was
isolated as a quaternary base (i.e. nitrogen bonded to CH3, C-19, C-20 and C-6) from
Aconitum palmatum151.
In order to check consistency in the chemical shift assignments of functional groups,
the NMR data for orochrine was compared with those for vakhmadine and also with the
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range of chemical shifts reported in the literature on C20 hetisane type diterpenoid
alkaloids122 (Table 11).
Table 11. Comparison of NMR data (500 MHz, CD3OD) of the orochrine with vakhmadine (300 MHz, D2O)151 and the
range of chemical shift generally observed for hetisane type alkaloids.
General range of δ C (ppm) and δH
Compounds
Carbon

Vakhmadine
δC

(ppm) for hetisane-type alkaloids*
Orochrine

δH (J=Hz)

δC

δH (J=Hz)

δC

δH (J=Hz)

C-1

30.0

34.5

1.59, 1.75

26.4-39.3

C-2

69.3

3.97 (bs, 1H, H-2β,)

65.5

4.14 (bs, 1H , H-2β)

66.1-67.2 (d,) with OH

C-3

73.5

3.33 (d, 1H, J= 4.3)

41.4

1.60 (d, 1H,

36.5-43.3 (-OH attached

1.93 (t, 1H)

in C-2)

C-4

40.6

36.6

35.9-38.7

4.02-4.31 (bs)

1.29-1.68
(-OH in C-6)

C-5

58.9

59.1

C-6

105.0

106.2

C-7

40.1

38.2

C-8

41.5

43.9

C-9

45.3

49.4

C-10

45.2

47.4

C-11

21.4

23.3

2.15

58.0-62.3
96.8-107.2

2.23

42.5-46.7 (β-effect of

2.31

-OH at C-6)
40.5-44.2 (s)

2.20

48.6-48.9 (due to C=O
group on C-13)
46.0-52.0

1.86

22.7-23.4 (with C=O on

2.03

C-13)
53.2-54.0

C-12

41.5

53.5

2.97

C-13

67.8

208.7

Ketone group

(with

C=O

group on C-13)
3.93

(d,

1H,13β,

2.14-2.94
( bs)

J=11.0)
C-14

48.1

56.3

2.98

C-15

31.8

32.6

2.52 (d, 1H, J=17.5 )

C-16

148.1

142.6

C-17

107.2

58.8-61.9 (d, with C=O on
C-13)
32.3-36.1 (t)

2.69 (d, 1H, J=17)

4.59 (s, 1H)

112.3

4.73 (s, 1H)

138.0-147.0 (s)
4.94 (s, 1H)

104.3-114.4 (t)

5.04 (s, 1H)

4.8-5.52
(bs, 1H each)

C-18

25.3

1.40 (s, 3H)

30.3

1.48 (s, 3H)

28.5-32.0 (q)

C-19

66.7

4.05 (d, 1H, J=11.7)

70.5

3.35 (d, 1H, J = 11.5)

62.7-65.0

4.30 (d, 1H, J =11.5)

2.21-3.02
2.61-3.85
(J =11.5-14)

C-20

73.2

4.22 (s, 1H)

75.1

4.27 (bs, 1H)

C-21

36.3

2.58 (s, 3H)

37.3

2.90 (s, 3H)

65.0-75.0 (d)

2.04-4.30
(1H, bs)

(N-Me)

Note: The range of chemical shifts were adapted from the literature review by Bessonova et al122.

From this comparative analysis, the chemical shifts of the carbon and proton signals of
orochrine were found to be consistent with those reported for vakhmadine122,151. In both
cases, the presence of a quaternary nitrogen atom caused a weak deshielding effect on
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nearby protons of N-Me (2.90 ppm), H-19 (3.35 ppm, d, 1H, J= 11.5 Hz and 4.30 ppm,
d, 1H, J=11.5 Hz) and H-20 (4.27 ppm, bs). Similarly, the hydroxyl group at C-6
caused the protons of C-18 to shift slightly downfield to 1.48 ppm and the N-methyl
carbon and protons to shift upfield to 37.3 ppm (γ effect)122 and 2.907 ppm152
respectively. This C-6 hydroxyl group also affected the chemical shift of C-5 (1H)
which resonated at 59.1 ppm.
However, unlike vakhmadine, which has a hydroxyl group at C-13 and an extra
hydroxyl group attached at C-3, orochrine 22 does not have a C-3 hydroxyl either.
Because of the C-13 carbonyl group, the chemical shifts of C-9 (49.4 ppm), C-11 (23.3
ppm) and C-12 (53.5 ppm) were shifted downfield compared to the same carbon
position assignments in vakhmadine 23.
When orochrine was compared with the structure of panicudine 24 that has a C-13
carbonyl group and no C-3 hydroxyl group, the chemical shifts of C-13 and its
neighbouring carbons (C-9, C-12, and C-11) in orochrine were found to be consistent
with the corresponding chemical shifts for the carbon and proton signals of panicudine.
Panicudine was isolated from Aconitum paniculatum Lam122. Therefore, the above
analysis supported 22 as the structure of orochrine.
The counter ion for the structure of orochrine 22, 2-O-acetylorochrine 25 and
lingshinaline 26 was assigned as a hydroxide ion (OH-) because only methanol and
water had been used for the extraction, separation and purification. Vakhmadine 23
was also isolated as its hydroxide salt.

3.4.2

2-O-acetylorochrine

a. Physico-chemical properties
The optically active alkaloid named 2-O-acetylorochrine 25 was obtained as a creamy
white solid. It dissolved readily in chloroform and methanol.
b. Spectral Analysis of 2-acetylorochrine
LRCIMS gave a peak at m/z 384 (MH+) which was 42 amu more than that of orochrine.
HRCIMS and HREIMS supported the molecular formula C23H29NO4 for this alkaloid,
and thus an index of hydrogen deficiency of 10. The LREIMS spectra (Appendix 10)
showed a molecular ion at m/z 383 (M+), plus fragment ions at m/z 368, 355, 340, 324,
296, 282, 254, 226, 176, 174, 134, 122, 105, 91, 84, 70, 58, 55, and 43.
Its structure was established by 1H-NMR (Appendix 11),
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C-NMR (Appendix 12),

DEPT (Appendix 13), gCOSY (Appendix 14), gNOESY (Appendix 15), TOCSY
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(Appendix 16), gHSQC (Appendix 17) and gHMBC (Appendix 18) spectral data
obtained in deuterated methanol (CD3OD). The structure of this compound differed
from orochrine only in the C-2 functional group. This compound had an acetate group
rather than a hydroxyl at C-2 position. Such biosynthetically reasonable acetylations
are not unusual in these types of alkaloids.

O
13
17
23

22

O

12

11

CH3

20

CH2
16

14
15

O

9

1
2

CH3
21

N+

5

3
4

19

8

10

7
6

CH3 OH
18

25 2-O-acetylorochrine

Figure 6. 3D-Model of 2-O-acetylorochrine (N-Blue, O-Red, C-Black, H-White).

Like orochrine, no signals for aromatic protons were evident in the 1H-NMR spectrum
of 25 and so the index of hydrogen deficiency was structurally indicative of saturated
rings or double bonds. However, the presence of an exocyclic methylene group was
indicated by two broad singlets (1H each) observed at 4.86 ppm and 4.95 ppm. These
protons were attached to the carbon signal resonating at 112.4 ppm in the

13

C-NMR

spectrum from the gHSQC correlation. The proton signals in this case shifted upfield
(+ 0.087 ppm) but the signal for the carbon shifted downfield (+ 0.15 ppm) in
comparison to the equivalent signals in orochrine. The signal at 30.1 ppm in the

13

C-

47
NMR was assigned to C-18, while the associated methyl protons resonated at 1.43 ppm
(s, 3H).
The N-CH3 carbon was assigned to the signal at 37.3 ppm, with the methyl protons
resonating at 2.90 ppm (s). In addition, another singlet for the acetyl protons was
present at 2.06 ppm (s, 3H), which in turn correlated with a carbon signal at 23.3 ppm.
A new carbon peak at 171.3 ppm was assigned to the ester carbonyl group. The C-13
carbonyl group resonated at 208.7 ppm. The signal at 106.6 ppm was ascribed to C-6
which was substituted by a hydroxyl group, the assignment being based on the gHMBC
spectrum.
From the 1H-NMR and gCOSY spectra, the H-15 geminal protons (2.47 ppm, d, 1H, J
= 17 Hz, and 2.62 ppm, d, 1H, J=17.5 Hz) were coupled to each other and to the H-17
exomethylene protons. The H-19 geminal methylene protons at 3.37 ppm (d, 1H, J = 12
Hz), and 3.79 ppm (d, J = 12 Hz) were also coupled. Like all hetisane type alkaloids122,
the singlet (1H) at 3.37 ppm for H-20 and the doublet at 2.98 ppm (1H, J = 3.5Hz) for
H-12 were present. The signals for H-5 (1H) and H-9 (1H) appeared as a partially
resolved broad singlet. Unlike orochrine, the signal for H-11 (2H) was a multiplet (half
width = 3.5 Hz) and the signal for H-14 was a doublet at 2.97 ppm (1H, J = 2Hz). A
doublet signal for H-2β was observed slightly downfield at 5.11 ppm (1H, J = 3Hz) due
to the presence of the adjacent α-acetate group122. The chemical shift for the carbon (C2) to which they were attached was observed at 69.0 ppm.
The DEPT spectra revealed sixteen protonated carbons; seven methylene (-CH2 × 7
including the exomethylene group), six methine (-CH × 6), and three methyl groups (CH3 × 3). The complete carbon-proton correlations for these protons and carbons were
established by analysing the gHSQC, gCOSY and TOCSY spectra as presented in
Table 12. The gHMBC and gNOESY correlations (Table 13) provided complete
information on the carbon-proton connectivities and their arrangements. The structure
was derived by both carbon-proton correlations cross peak analysis and assignments.
The gHMBC data analysis generated a structure 25 and the gNOESY spectrum
confirmed the relative stereochemistry of this alkaloid. The gNOESY correlation is
diagrammatically represented in Figure 7.
The gHMBC correlation indicated C-4, C-6, C-8, C-10, C-13 and C-16 were quaternary
carbons. The peaks at 36.5 ppm, 47.4 ppm and 58.5 ppm were assigned to C-4, C-10
and C-5 respectively as the chemical shifts were within the normal range noted for
these carbon signals in the related alkaloids122. A 3D model (Figure 6) was generated
for 2-O-acetylorochrine (enantiomer shown, apart from C-2) using the Spartan
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computer program and the spatial arrangements of atoms and functional groups in the
structure were analysed. The gNOESY correlations were found to be consistent with
the orientations of protons and functional groups in the 3D model of the structure
giving added weight to stereochemical assignments.
Table 12. gHSQC, gCOSY and TOCSY NMR data (500 MHz, CD3OD) of 2-O-acetylorochrine 25.
gHSQC (δC to δH)

gCOSY

Carbon

δC (ppm) Assignment δH (ppm) Multiplicity Integration J (Hz)

C-1

31.6

-CH2

1.65

d

2H

17.5

C-2

69.0

-CH

5.11

d

1H

C-3

38.5

-CH2

1.66

d

1H

1.92

d

1H

16

C-4

36.5

Q

C-5

58.5

-CH

2.17

s

1H

C-6

106.6

Q, -OH

C-7

38.0

-CH2

2.23

d

1H

14.5

2.27

d

1H

14.5

2.17

s

1H

Correlation

3

H-1, H-3

H-1, H-3

15.5

H-1

C-8

44.2

Q

C-9

49.3

-CH

C-10

47.4

Q

C-11

23.3

-CH2

1.84

m

2H

3.5

C-12

53.3

-CH

2.89

d

1H

3.5

C-13

208.7

Q, C=O

C-14

56.2

-CH

2.97

d

1H

2

C-15

32.4

-CH2

2.47

d

1H

17

2.62

d

1H

17.5

4.86

bs

1H

43.5

C-16

142.3

Q

C-17

112.4

-CH2

4.95

bs

1H

C-18

30.1

-CH3

1.43

s

3H

C-19

70.5

-CH2

3.37

d

1H

12

3.79

d

1H

12

C-20

75.1

-CH

3.76

s

1H

C-21 (N-Me)

37.3

-CH3

2.90

s

3H

C-22 (CH3*COO)

171.3

C-23 (*CH3COO)

21.3

-CH3

2.06

s

3H

H-11

H-11

C-11

H-11

H1, H-7

H-15

H-3, H-7

O
CH2
O
O

H3C

N+

H-15

H-14

Note: Q = Quaternary carbon, *carbon represented in numbering

H3C

TOCSY

Correlation

OH

CH3 OH
Figure 7. gNOESY correlation of 2-O-acetylorochrine 25.
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Table 13. gHMBC and gNOESY NMR data (500 MHz, CD3OD) of 2-O-acetylorochrine 25.
gHMBC Correlation
Carbon

δC
(ppm)

C-1

31.6

δH

δC to δH

δH to δC

gNOESY
Correlation

(ppm)
1.65

H-3, H-11 (w), H-20

C-2, C-3 (w), C-4, C-5, C-10,
C-20

C-2

69.0

5.11

H-1, H-3, H-18 (w)

C-22

H-1, H-3

C-3

38.5

1.66

H-1, H-19

C-1, C-2, C-4, C-5, C-10, C-18

H-1, H-18

C-4

36.5

C-5

58.5

C-6

106.6

C-7

38.0

1.92

(w), C-19
H-1, H-3, H-18, H-19

2.17

H-1, H-3, H-7, H-9, H-18

C-7 (w), C-9 (w), C-14, C-18,

H-18

C-19, C-20
H-5, H-7, H-19, H-20, H-21
2.23

H-9 (w), H-15

2.27
C-8

44.2

C-9

49.3

C-10

47.4

C-11

23.3

C-5, C-6, C-8, C-9 (w), C-14,
C-15 (w)

H-7, H-9, H-11, H-15
2.17

H-5, H-7, H-11, H-12, H-14,

C-5 (w), C-7 (w), C-12, C-14,

H-15, H-20

C-20

H-1, H-11

H-1, H-3, H-9 (w), H-11, H-14
1.84

C-1 (w), C-8 (w), C-9, C-10,

H-1

C-12, C-13, C-16
C-12

53.3

2.89

C-13

208.7

C-14

56.2

2.97

C-15

32.4

2.47

C-16

142.3

C-17

112.4

H-9, H-11, H-15, H-17

C-9, C-13, C-14, C-15

H-11

C-9,C-10, C-13, C-20

H-7, H-15

C-7 (w), C-8, C-9, C-12, C-14,

H-7

H-11, H-12, H-14, H-20
H-7, H-9, H-15, H-19 (w),
H-20, H-21 (w)
H-7, H-12, H-17

2.62

C-16, C-17
H-11, H-15

4.86

H-12 (w), H-15

C-12, C-15

H-12, H-15

4.95
C-18

30.1

1.43

H-1, H-3, H-5, H-19

C-3, C-4, C-5, C-19

C-19

70.5

3.37

H-3, H-5, H-18, H-20, H-21

C-4, C-5, C-14 (w), C-18, C-20

3.79
C-20

75.1

C-21 (N-Me)

37.3

C-22 (COOCH3)

171.3

C-23 (CH3COO)

21.3

3.76

H-18,
H-21 (N-Me)

H-1, H-5, H-14, H-19, H-21

2.90

C-1, C-6, C-8, C-9 (w), C-13,

H-1, H-14,

C-14 (w), C-19

H-20, H-23

C-6, C-19, C-20

H-7

H-2, H-23
2.06

C-22

The chemical shifts of protons and carbons of the structure of 2-O-acetylorochrine were
then compared with the chemical shifts of protons and carbons of orochrine and also
with the general range of chemical shifts for the respective carbons and protons
reported in the literature for hetisane-type diterpenoid alkaloids. Except for the C-2
acetyl group, all the chemical shifts of protons and carbons in the respective NMR
spectra of 2-O-acetylorochrine were found to be consistent with those of orochrine and
the relevant chemical shifts reported in the literature. Thus, the structure was confirmed
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as drawn in 25. The NMR spectroscopic comparison of 2-O-acetylorochrine with the
orochrine is tabulated in Table 14.
Table 14. Comparison of NMR data of the 2-O-acetylorochrine (500 Mhz, CD3OD) with orochrine (500 Mhz, CD3OD).
Compounds
Carbon

2-O-acetylorochrine
δC (ppm)

Orochrine

δH (ppm, J=Hz)

δC (ppm)

δH (ppm, J=Hz)

C-1

31.6

1.65 (d, 2H, J=17.5)

34.5

1.59 (d, 1H, J =15)

C-2

69.0

5.11 (d, 1H-2β, J=3)

65.5

4.14 (bs, 1H-2β)

C-3

38.5

1.66 (d, 1H, J=15.5)

41.4

1.60 (d, 1H, J=15)

1.75 (d, 1H, J =15

1.92 (d,1H, J=16

1.93 (t, 1H, J=15

C-4

36.5

C-5

58.5

36.6

C-6

106.6

C-7

38.0

C-8

44.2

C-9

49.3

C-10

47.4

C-11

23.3

1.84 (m, 2H, Half width =3.5)

23.3

C-12

53.3

2.89 (d, 1H, J=3.5)

53.5

2.97 (bs, 1H)

C-13

208.7

ketone group

208.7

ketone group

C-14

56.2

2.97 (d, 1H, J=2)

56.3

2.98 (bs, 1H)

C-15

32.4

2.47 (d, 1H, J=17)

32.6

2.52, (d, 1H, J =17.5)

2.17 (s, 1H)

59.1

2.15, (s, 1H)

106.2
2.23 (d, 1H, J=14.5)

38.2

2.27 (d, 1H, J=14.5)

2.23, (d, 1H, J=12.5)
2.31, (d, 1H, J=15

43.9
2.17 (s, 1H)

49.4

2.20 (s, 1H)

47.4
1.86 (d, 1H, J=14)
2.03 (d, 1H, J=14.5

2.62 (d, 1H, J=17.5)

2.69 (d, 1H, J=17)

C-16

142.3

C-17

112.4

142.6

C-18

30.1

1.43 (s, 3H)

30.3

1.48 (s, 3H)

C-19

70.5

3.37 (d, 1H, J=12)

70.5

3.35 (d, 1H, J=11.5)

C-20

75.1

3.76 (s, 1H)

75.1

4.27 (s, 1H)

C-21 (N-Me)

37.3

2.90 (s, 3H)

37.3

2.90 (s, 3H)

C-22 (COOCH3)

171.3

C-23 (CH3COO)

21.3

2.06 (s, 3H)

Not present

4.86, (bs, 1H)

112.3

4.95 (bs, 1H)

5.04 (bs, 1H)

3.79, (d, 1H, J =12)

3.4.3

4.94 (bs, 1H)

4.30 (d, 1H, J=11.5)

Lingshinaline

a. Physico-chemical properties
Lingshinaline 26, was isolated as a pale green solid. The alkaloid was optically active
but the [α]D was smaller than for orochrine or 2-O-acetylorochrine. Its melting point
was also lower than orochrine or 2-O-acetylorochrine.
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Figure 8. 3D-computer model of lingshinaline (N-blue, O-red, C-black, H-white).

b. Spectral Analysis
HRCIMS indicated the MH+ peak at m/z 400 (calc. 400.2124) and the LREIMS gave
the M+ peak at m/z 399 that is 16 amu more than that of 2-O-acetylorochrine. HRCIMS
and HREIMS supported the molecular formula C23H29NO5 for this alkaloid, and hence
an index of hydrogen deficiency of 10. This suggested that lingshinaline had one extra
hydroxyl group compared with 2-O-acetylorochrine. The LREIMS spectrum
(Appendix 19) showed ions at m/z 399 (M+), 382, 370, 356, 340, 315, 312, 270, 176,
174, 173, 148, 134, 122, 105, 91, 84, 55, and 43.
The structure of lingshinaline was established by 1H-NMR (Appendix 20),

13

C-NMR

(Appendix 21), DEPT (Appendix 22), gCOSY (Appendix 23), gNOESY (Appendix
24), TOCSY (Appendix 25), gHSQC (Appendix 26) and gHMBC (Appendix 27)
spectral data analysis obtained in deuterated chloroform (CDCl3).
Like orochrine and 2-O-acetylorochrine, the 1H-NMR spectrum of lingshinaline had no
signals for aromatic protons and so the index of hydrogen deficiency was structurally
indicative of saturated rings or double bonds. However, the exomethylene peaks were
clearly present at 4.92 ppm (bs, 1H) and 5.00 ppm (bs, 1H). These protons were
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connected to the C-17 carbon, resonating at 112.4 ppm (t) in the 13C-NMR. The C-18
carbon had a chemical shift of 29.7 ppm, and its protons resonated at 1.52 ppm (s, 3H).
The N-methyl carbon had a chemical shift of 40.4 ppm and its protons resonated at 3.12
ppm (s). A singlet ascribed to acetate ester protons (s, 3H) was present at 2.10 ppm and
corresponded to a carbon signal at 21.4 ppm. A carbon peak assigned to the ester
carbonyl was present at 169.1 ppm. The C-13 carbonyl group resonated at 206.7 ppm.
The signal ascribed to the carbinolamine C-6 substituted by a hydroxyl group resonated
at 105.7 ppm. The N-C-6 bond was established using the HMBC spectrum (see Table
16).
The 1H-NMR and gCOSY spectra revealed that the H-15 geminal protons (2.48 ppm, d,
1H, J = 17.5 Hz, and 2.96 ppm, d, 1H, J=17.5 Hz) were coupled to the H-17
exomethylene protons. The H-19 geminal methylene protons at 3.42 ppm (d, 1H, J =
11.5 Hz), and 3.61 ppm (d, J = 11.5 Hz) were also coupled. Like all hetisane
alkaloids122, the H-20 (3.63 ppm, s, 1H) and H-12 (2.95 ppm, s, 1H) proton signals
were also present. The signal for the H-5 proton resonated at 2.12 ppm (s, 1H) and that
for the H-9 proton resonated at 2.20 ppm (d, 1H). The signal for H-14 resonated at
3.00 ppm (s, 1H) and that for H-2β (1H) was observed a little downfield as a broad
singlet at 5.21 ppm due to the presence of the adjacent α-acetyl group.
The DEPT spectra revealed sixteen protonated carbons: six methylene (-CH2 × 6,
including the exomethylene group), seven methine (-CH × 7), and three methyl groups
(CH3 × 3). In this case the structure has gained one methine and lost one methylene
carbon compared to 2-O-acetylorochrine. The complete carbon-proton correlations for
these protons and carbons were established by analysing the gHSQC, gCOSY and
TOCSY (long range couplings) spectra, as tabulated in Table-15.
From the gHMBC correlation (Table 16), proton-carbon connectivities were
established and the cross peaks observed were assigned on the scaffold of the hetisane
type alkaloids. Cross peak assignment established C-4, C-6, C-8, C-10, C-13 and C-16
as quaternary carbons. The peaks at 35.9 ppm, 47.7 ppm and 55.8 ppm in the 13C-NMR
were assigned to C-4, C-10 and C-5 respectively as the chemical shifts were within the
normal range noted for these carbon signals in the related alkaloids122.
The C-7 (71.7 ppm) carbon was substituted by a hydroxyl group and its proton H-7 was
ascribed to the 1H-NMR signal at 4.35 ppm. It was reported in the literature that, as a
rule in these alkaloids this C-7 hydroxyl group has the α-orientation and the signal for
H-7β should be within the chemical shift range of 3.87-4.50 ppm122. Although the
chemical shifts for C-7 and its proton (s, 1H, H-7) were within the range noted in the
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literature, the gNOESY correlation (Table 16) supported a β-orientation of the C-7
hydroxyl group in lingshinaline. From the 3D model (Figure 8) of lingshinaline
(enantiomeric form shown apart from C-2, C-7 configuration), the C-7 hydroxyl group
was found to be protruding to the front and the hydrogen atom going backward thereby
correlating with the H-5, H-9 and H-15 protons which also had α-orientations. The
gNOESY correlation is diagrammatically represented in Figure 9.
Table 15. gHSQC, gCOSY and TOCSY NMR data (500 MHz, CDCl3) of lingshinaline 26.
gHSQC (δC to δH)

gCOSY

Carbon

δC (ppm) Assignment δH (ppm) Multiplicity Integration J (Hz)

C-1

31.2

-CH2

C-2

66.9

-CH

C-3

37.9

-CH2

1.65

d

1H

16.5

1.74

d

1H

15.5

5.21

s

1H

1.65

d

1H

17

1.93

d

1H

16.5

2.12

s

1H

4.35

s

1H

2.20

d

1H

7.5

6.5

C-4

35.9

Q

C-5

55.8

-CH

C-6

105.7

Q

C-7

71.7

-CH

C-8

45.3

Q

C-9

46.7

-CH

C-10

47.7

Q

C-11

22.1

-CH2

1.86

d

2H

C-12

51.6

-CH

2.95

s

C-13

206.7

Q, C=O

C-14

52.5

-CH

3.00

C-15

28.2

-CH2

C-16

139.1

Q

C-17

113.1

-CH2

TOCSY

Correlation

Correlation

H-1, H-3

H-3

H-1

H-11

H-11

1H

H-11

H-9, H-11

s

1H

H-9

H-11, H-9

2.48

d

1H

17.5

2.96

d

1H

17.5

4.92

bs

1H

H-12, H-15

H-15

5.00

bs

1H

C-18

29.7

-CH3

1.52

s

3H

C-19

70.4

-CH2

3.42

d

1H

11.5

3.61

d

1H

10.0

C-20

73.5

-CH

3.63

s

1H

C-21 (N-Me)

40.4

-CH3

3.12

s

3H

C-22 (CH3*COO)

169.1

C-23 (*CH3COO)

21.4

-CH3

2.01

s

3H

Note: Q = quaternary carbon, *carbon represented in numbering.

H-14, H-21

H-14
H-14
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Table 16. gHMBC and g NOESY NMR data (500 MHz, CDCl3) of lingshinaline 26.
gHMBC Correlation
Carbon

δC (ppm) δH (ppm)

δC to δH

C-1

31.2

1.65 and 1.74

H-20, H-3

C-2

66.9

5.21

H-3, H-1, H-18 (w),

C-3

37.9

1.65 and 1.93

C-4

35.9

C-5

55.8

C-6

105.7

C-7

71.7

C-8

45.3

C-9

46.7

δH to δC
C-2, C-5, C-8 (w), C-3

gNOESY
Correlation
H-3

(w), C-4
H-1, H-3

H-23 (vw)
H-1 (w), H-18, H-19

C-2, C-5, C-4 (w), C-1

H-18

C-20, C-7, C-19, C-9, C-18

H-3, H-18

C-14, C-10

H-5, H-9

H-19, H-3, H-18
2.12

H-3, H-1, H-18
H-20, H-21

4.35

H-21 (w), H-5 (w)
H-14, H-11, H-1 (w)

2.20

H-14, H-15, H-5, H-11,

H-5, H-11

H-12
C-10

47.7

C-11

22.1

1.86

H-7, H-20

C-12

51.6

2.95

C-13

206.7

C-14

52.54

3.00

H-7, H-15

C-13, C-20, C-9, C-8

C-15

28.2

2.48 and 2.96

H-17, H-7 (w)

C-16, C-17, C-9, C-14

C-16

139.1

C-17

113.1

4.92 and 5.00

H-15, H-12

C-12, C-15

C-18

29.7

1.52

H-19, H-5

C-19, C-2, C-5, C-3, C-4

C-19

70.4

3.42 and 3.61

H-20, H-21, H-5, H-18

C-20, C-3, C-4, C-18, C-5,

C-20

73.5

3.63

H-19, H-21, H-14, H-5

C-21 (N-Me)

40.4

3.12

H-19 (w)

C-22 (CH3*COO)

169.1

C-23 (CH3COO)

21.4

C-13, C-16, C-8, C-12 (w),

H-1

C-9 (w)
H-17, H-15 (w), H-11

C-16,C-17,C-9

H-11

H-20, H-14, H-12, H-11

H-15, H-12, H-11
H-12, H-15

H18, H-21

C-21 (w)
C-13, C-6, C-10, C-1,

H-1,

H-14,

C-19 (w)

H-21, H-23

C-6, C-20, C-7, C-19

H-14

H-23
2.01

C-22, C-2 (w)

O
CH2

O
H3C

O
H3C

N+

OH
OH

CH3 OH

Figure 9. gNOESY correlation of lingshinaline 26.

To confirm the structure, the NMR data for lingshinaline was compared with that of 2O-acetylorochrine 25 (Table 17) and the general range of chemical shifts for the
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respective carbons and protons reported in the literature on hetisine type C20diterpenoid alkaloids122,140. Except for C-7 (as expected), the

13

C-NMR chemical shift

values of lingshinaline were found to match closely with those for 25, and all the
chemical shifts were found consistent with the ranges of chemical shifts provided in the
literature above.
Slight differences observed were very negligible and could have been caused by either
differences in the NMR solvents used or the variations in oxygen containing
substituents at C-2 and C-7 positions. Thus the structure of lingshinaline was
established and confirmed as 26.
Table 17. Comparison of NMR data of the 2-O-acetylorochrine (500 MHZ, CD3OD) with NMR data of lingshinaline (500
MHz, CDCL3).
Compound
2-O-acetylorochrine 25
δH (ppm, J=Hz)

Lingshinaline 26

Carbon

δC (ppm)

δC (ppm)

δH (ppm, J=Hz)

C-1

31.6

1.65 (d, 2H, J=17.5)

31.2

C-2

69.0

5.11(d, 1H-2β, J=3)

66.9

5.21 ( s, 1H)

C-3

38.5

1.66 (d, 1H, J=15.5)

37.9

1.65 (d, 1H, J=17.0)

1.65 (d, 1H, J=16.5)
1.74 (d, 1H, J=15.5)

1.92 (d,1H, J=16
C-4

36.5

C-5

58.5

C-6

106.6

C-7

38.0

1.93 (d, 1H, J=16.5)
35.9

2.17 (s, 1H)

55.8

2.12 (s, 1H)

105.7
2.23 (d, 1H, J=14.5)

71.7

4.35 (s, 1H)

2.27 (d, 1H, J=14.5)
C-8

44.2

C-9

49.3

45.3

C-10

47.4

C-11

23.3

1.84 (m, 2H, Half width = 3.5)

22.1

C-12

53.3

2.89 (d, 1H, J=3.5)

51.6

2.95 (s, 1H)

C-13

208.7

Ketone group

206.7

Ketone group

C-14

56.2

2.97 (d, 1H, J=2)

52.5

3.00 (s, 1H)

C-15

32.4

2.47 (d, 1H, J=17)

28.2

2.48 (d, 1H, J=17.5)

C-16

142.3

C-17

112.4

2.17 (s, 1H)

46.7

2.20 (d, 1H, J=7.5)

47.7
1.86 (s, 1H, J= 6.5)
1.87 (s, 1H)

2.62 (d, 1H, J=17.5)

2.96,(d, 1H, J= 17.5)
139.1

4.86, (bs, 1H)

113.1

4.95 (bs, 1H)

4.92 (bs, 1H)
5.00 (bs, 1H)

C-18

30.1

1.43 (s, 3H)

29.7

1.52 (s, 3H)

C-19

70.5

3.37 (d, 1H, J=12)

70.4

3.42 (d, 1H, J=11.5)

C-20

75.1

3.76 (s, 1H)

73.5

3.63 (s, 1H)

C-21 (N-Me)

37.3

2.90 (s, 3H)

40.4

3.12 (s, 3H)

C-22 (COOCH3)

171.3

C-23 (CH3COO)

21.3

3.79,(d, 1H, J=12)

3.61 (d, 1H, J=10.0)

169.1
2.06 (s, 3h)

21.4

2.01 (s, 3H)

56
3.4.4

Virescenine

a. Physico-chemical properties
This alkaloid was obtained as an amorphous solid from which a crystalline
hydrochloride salt was derived. The alkaloid had a low optical rotation ([α]D26 = +
14.07) and a low melting point (76.7-79.8oC) compared with the alkaloids 22, 25, 26
isolated from the same plant. Unfortunately the crystals of the hydrochloride were not
suitable for a single crystal X-ray structure determination.

b. Spectral analysis
The LRCIMS of this alkaloid showed a peak at m/z 424 (MH+ peak). The HREIMS
indicated the molecular formula as C23H37NO6 and hence an index of hydrogen
deficiency of 20. Its mass was 24 amu more than that of lingshinaline 26. The LREIMS
spectrum (Appendix 28) gave molecular and fragment ions at m/z 423 (M+), 408, 405,
406, 390, 374, 365, 352, 336, 178, 164, 148, 122, 108, 98, 85, 71, 58 and 45. The
molecular formula of this alkaloid was the same as that of senbusine A153 and
virescenine 27154. Furthermore the optical rotation, melting point, and ion
fragmentation pattern were very similar to those for virescenine ([α]D24 = +16.9 in 95%
EtOH where c =1.0; m.p. = 68-70oC, Et2O-C6H14)47.
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Virescenine 27 was previously isolated from Aconitum yesoense var. macroyesoense
Tamura155, Aconitum delphinifolium DC156, Aconitum nagarum var.lasiandrum
W.T.Wang157, Delphinium virescens Nutt154 and Aconitum napellus ssp.vulgare (DC.)
Rouy et Fouc158. So the alkaloid isolated in this study was thought to be virescenine 27.
To substantiate this deduction, the structure of the alkaloid was elucidated by 1H-NMR
(Appendix 29), 13C-NMR (Appendix 30), DEPT (Appendix 31), gCOSY (Appendix
32), gNOESY (Appendix 33), gHSQC (Appendix 34), TOCSY (Appendix 35) and
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gHMBC (Appendix 36) spectral analysis. The 1H-NMR showed that the alkaloid had
no aromatic protons as well as no H-17 exomethylene and H-18 methyl groups. Instead
this alkaloid had two methoxyl signals that resonated at 3.29 ppm (s, 3H) and 3.31 ppm
(s, 3H) and an N-ethyl signal whose methyl protons (N-CH2CH3) resonated at 1.08 ppm
(t, 3H) and the methylene protons (H-18) at 2.95 ppm (q, 1H) and 3.06 ppm (q, 1H).
This was the only alkaloid isolated from Aconitum orochryseum with an N-ethyl group.
The H-19 protons (2H) that were present in orochrine, 2-O-acetylorochrine,
lingshinaline and atisinium chloride were also present in this alkaloid and their signals
resonated at 2.50 ppm (d, 1H, J=11 Hz) and 2.76 ppm (d, 1H, J=11 Hz).
From the 13C-NMR spectrum, it was found that the alkaloid contained no ester or other
carbonyl groups. The DEPT spectrum showed the presence of 19 protonated carbons:
eight methylene, eight methine and three methyl groups. Based on the DEPT, gHSQC,
gCOSY and TOCSY spectra, the assignment of the groups and carbon-proton
connectivities was achieved (Table 18) and the complete structure was established
using the gHMBC spectrum and gNOESY correlations (Table 19).
Table 18. Proton-carbon correlation (from DEPT and gHSQC spectrum) and proton-proton correlation (from gCOSY and
long range TOCSY spectrum) of the isolated alkaloid virescenine 27.
δC (ppm)
Carbon

Assignment

δH (ppm, J=Hz)

(From DEPT)

(From gHSQC)

1

72.0

-CH

3.67 (s, H-1β)

2

28.7

-CH2

1.45 (q), 1.57 (d, J= 18.5)

3

26.6

-CH2

1.63 (dd, J=5), 1.82 (dd, J=6)

4

37.6

Q

5

41.7

-CH

1.71 (t, J=7)

6

33.3

-CH2

7

85.7

Q

8

76.0

Q

9

47.7

10

43.3

11

49.3

Q

12

28.2

-CH2

13

39.4

-CH

14

75.3

15
16

gCOSY

TOCSY

H-2, H-3, H-12

H-2, H-18

H-2

H-6

1.54 (d), 2.26 (d)

H-5, H-10

H-5, H-6

-CH

2.15 (t, J=5.5)

H-10

H-10

-CH

1.76 (q)

1.55 (t), 1.97 (t)

H-10

H-15

2.27 (m)

H-10, H-12

H-9

-CH

4.17 (t, J=4.5, H-14β)

H-9, H-13

H-9, H-13

35.8

-CH2

1.73 (dd, J=9.5), 2.89 (m)

81.5

-CH

3.37 (q, H-16α)

H-10, H-15

17

65.2

-CH

2.83 (s)

H-12

18

78.4

-CH2

3.01 (d, J=9), 3.16 (d, J=9)

19

55.7

-CH2

2.49 (d, J=11), 2.72 (d, J=11)

20

50.7

-CH2 (NCH2CH3)

2.95 (q), 3.06 (q)

21

13.4

-CH3 (NCH2CH3)

1.08 (t, J=7.5)

22

59.3

-OCH3 (C-18-OCH3)

3.28 (s)

23

56.3

-OCH3 (C-16-OCH3)

3.31 (s)

Note: Q = Quaternary carbon.

H-6
H-15

H-5

H-21

H-21

H-17
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Table 19. gHMBC spectrum and the gNOESY correlation of the isolated alkaloid virescenine 27.

Carbon
1

δC

δH

(ppm)

(ppm)

72.0

3.67

gHMBC
δC to δH
H-3, H-5

gNOESY
δH to δC
C-3, C-5

Correlation
H-2, H-10, H-12,
H-15, H-17

2

28.7

1.45, 1.57

H-3 (w)

C-4, C-5, C-11

H-9

3

26.6

1.63, 1.82

H-1, H-18, H-19

C-1, C-4, C-18, C-19

H-2

4

37.6

5

41.7

C-4, C-7, C-10, C-11, C-17,

H-2, H-12

H-3, H-5, H-6, H-18, H-19
1.71

H-6, H-10, H-17, H-18, H-19

C-18, C-19
6

33.3

7

85.7

2.26, 1.54

H-17
H-5, H-6, H-15

8

76.0

H-5, H-6, H-9, H-10, H-14,

C-4, C-5, C-7, C-11, C-17

H-5, H-9

H-10

H-15, H-17
9

47.7

2.15

H-10, H-13, H-15

C-8, C-10, C-12, C-13, C-15

10

43.3

1.76

H-1, H-2, H-5, H-9, H-13, H-

C-1 (w), C-2, C-8, C-5, C-9,

12, H-15, H-17

C-11, C-12, C-17

11

49.3

12

28.2

1.55, 1.97

H-9, H-10, H-16 (w)

13

39.4

2.27

H-9, H-12, H-15

C-9, C-10, C-15, C-16

H-12

14

75.3

4.17

H-12, H-16

C-8, C-16

H-6, H-9, H-13,

15

35.8

1.73, 2.89

H-9, H-13

C-6, C-7, C-8, C-9, C-13,

16

81.5

3.37

H-12, H-14, H-15, H-23

C-12 (w), C-14, C-23

H-2, H-3, H-6, H-12

17

65.2

2.83

H-5, H-6, H-10, H-19,

C-5, C-6, C-8, C-10 (w),

H-6, H-21

H-20 (w)

C-11, C-19, C-20

H-12, H-10, H-17
C-5, C-10, C-11, C-13, C-14,

H-15

C-16

C-16

18

78.4

3.01, 3.16

H-3, H-5, H-19, H-22

C-3, C-4, C-5, C-19, C-22

H-3, H-5, H-17

19

55.7

2.49, 2.72

H-3, H-5, H-17, H-18, H-20

C-3, C-4, C-5, C-17, C-18,

H-3, H-6, H-21

C-20
20

50.7

2.95, 3.06

H-17 (w), H-19, H-21

C-17, C-19, C-21

21

13.4

1.08

H-20

C-20

H-19, H-21

22

59.3

3.28

H-18

C-18

H-18

23

56.3

3.31

H-16

C-16

H-3, H-6, H-15

Considering the biogenetic relationship in these alkaloids, oxygenation occurs at C-1,
C-3, C-4, C-6, C-13, C-16 and C-18. In fact almost all the C19 diterpenoid alkaloids
bear a hydroxyl or methoxyl group on C-1, C-8, C-14 and C-16159,160. Using gCOSY,
gNOESY and gHMBC correlations, the three hydroxyl groups of the isolated alkaloid
were assigned to the C-1, C-8 and C-14 positions. The hydroxyl groups at C-1 and C14 had the α-orientation140,154,159. The last hydroxyl group was assigned to C-7. The C7 hydroxyl group is characteristic of the lycoctonine-type 7 C19 diterpenoid alkaloids
and this hydroxyl group, as well as the hydroxyl group at C-8, has the βorientation47,158. The C-16 methoxyl group was assigned to the β-position while the

59
adjacent C-16 proton was assigned as α in almost every report of the aconitane-type
diterpenoid alkaloids126.
The NMR spectroscopic data for the isolated alkaloid was then compared with the data
for virescenine 27 (Table 20). The NMR spectra were all obtained in CDCl3; very close
chemical shift matches were noted apart from the chemical shifts of C-10 and C-13.
The literature on virescenine140,154 has reported the chemical shift of C-10 as 39.9 ppm
and that of C-13 as 43.6 ppm. In contrast, with the alkaloid isolated in this study, the C10 signal resonated at 43.3 ppm and for C-13 at 39.4 ppm. The assignment of these C10 and C-13 signals for the alkaloid was supported by the gCOSY and the gHMBC
correlations.
From the gCOSY spectrum, the protons of C-6 (1.54 ppm, d and 2.26 ppm, d), C-9
(2.15 ppm, t), C-12 (1.55 ppm and 1.97 ppm, t), C-13 (2.27 ppm, m) and C-16 (3.37
ppm, q) were coupled to the proton (1.76 ppm, q) of the carbon that resonated at 43.3
ppm. This suggested that the carbon at 43.3 ppm was C-10. From the gHMBC
correlation, C-10 was connected to the neighbouring carbons C-11 (quaternary), C-9 (CH) and C-12 (-CH2) rendering it a quartet.
Table 20. Comparison of 1H-NMR and 13C-NMR data of the isolated alkaloid (500 MHz, CDCl3) with that of virescenine154.
Virescenine
Carbon

δC (ppm)

δH (ppm) J=Hz

Virescenine (Isolated)
δC (ppm)

δH (ppm) J=Hz

1

72.4

72.0

3.67 (s)

2

28.8

28.7

1.45 (q), 1.57 (d, J= 18.5)

3

29.3

26.6

1.63 (dd, J=5), 1.82 (dd, J=6)

4

37.7

37.6

5

42.0

41.7

1.71 (t, J=7)

6

33.6

33.3

2.26 (d), 1.54 (d)

7

86.1

85.7

8

76.3

76.0

9

47.9

47.7

2.15 (t, J=5.5)

10

39.9

43.3

1.76 (q)

11

49.5

49.3

12

26.9

28.2

1.55 (t), 1.97 (t)

13

43.6

39.4

2.27 (t)

14

75.5

75.3

4.17 (t, J=4.5, H-14β)

15

35.9

35.8

1.73 (dd, J=9.5), 2.89 (m)

16

82.2

81.5

3.37 (q)

17

64.9

65.2

2.83 (s)

18

78.7

78.4

3.01 (d, J=9), 3.16 (d, J=9)

19

55.9

55.7

2.49 (d, J=11), 2.72 (d, J=11)

-CH2 (NCH2CH3)

50.5

50.7

2.95 (q), 3.06 (q)

-CH3 (NCH2CH3)

13.9

1.10 (3H, t, J=7.0)

13.4

1.08 (3H, t, J=7.5)

-OCH3 (C-18-OCH3)

59.4

3.33 (3H, s)

59.3

3.28 (3H, s)

-OCH3 (C-16-OCH3)

56.4

3.35 (3H, s)

56.3

3.31 (3H, s)

4.23 (1H, t, J=5, H-14β)
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The long range gHMBC correlation also found that C-5, C-8, C-11, C-13 and C-17
correlated with the protons (1.76 ppm, q) attached to the carbon that resonated at 43.3
ppm (assigned as C-10, Table 20) and this carbon peak (43.3 ppm, δC to δH)
correlated with the protons H-1, H-2, H-5, H-9, H-12, H-13, H-15 and H-17. If the
carbon peak at 43.3 ppm is assigned to C-13, these correlations would not be possible.
Similarly, from the gHMBC correlation, C-13 (39.4 ppm) for the alkaloid isolated was
connected to C-12 (-CH2), C-14 (-CH) and C-16 (-CH). From the 1H-NMR spectrum,
the chemical shift of the signal ascribed to the C-13 proton resonated well downfield at
2.27 ppm compared to the C-10 protons that resonated at 1.76 ppm. This was plausible
because the C-13 protons were close to the carbons that are substituted with hydroxyl
(C-14) and methoxyl (C-16) groups.
There has been little discussion in the literature on the proton-carbon correlations in
this alkaloid. It is possible that the original spectra were incorrectly assigned. Since all
the

13

C-NMR data, other than C-10 and C-13, were in agreement with each other, it

was concluded that the alkaloid (27) isolated was virescenine.

3.4.5

Atisinium chloride

a. Physico-chemical properties
This alkaloid was the major alkaloid of the plant and had been reported before from
many Delphinium and Aconitum species47,124,161. The needle-like crystals were obtained
from methanol/diethyl ether. The alkaloid had an optical rotation of [α]D25 = + 31.27 (c,
0.94 in MeOH) and a melting point of 305.7-308.6oC (decomposition) which was
slightly different from the corresponding values noted in the literature {optical rotation
varies from [α]D23 = + 22.6 (c, 4.9 in 95% EtOH)162 to [α]D25 = + 28 (c,1.10 in H2O)47 and
the melting point from 311-312oC47 to 325-326oC162}. The alkaloid was the most polar
compound of the other alkaloids isolated from the same plant.

b. Spectral analysis
The LRCIMS indicated the MH+ peak at m/z 344. From the HRESMS, the molecular
formula was found to be C22H33NO2 (M+) for this alkaloid. The LREIMS spectrum
(Appendix 37) had ion peaks at m/z 343 (M+), 342, 328, 314, 300, 284, 257, 241, 186,
171, 159, 143, 131, 105, 91, 79, 72, 55 and 44.

61
CH2

S

Cl

HO

20

N

S

+

R
S
R

H

OH

S

H

6
R

H
CH3
28 Atisinium chloride

Figure 10. The X-ray structure of Atisinium chloride.

The crystal structure (Figure 10) was determined by single crystal X-ray
crystallography (by Professor A.H.White, University of Western Australia; Appendix
38) and was identified as atisinium chloride 28. An earlier crystal structure of atisinium
chloride (with 4S, 5S, 8R, 12S, and 15S absolute configuration) had been reported in
1976162.
The torsion angles (deg) (Appendix 38), crystal data, data collection parameters, and
refinement results (Table 21) were compared with the old data reported in the
literature162. All this data including dihedral angles, fractional atomic position
parameters, individual atom parameters, input atom coordinates, bond angles and
contact distances were found in agreement to the previous crystal data on atisinium
chloride.
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Table 21. Crystal data and refinement results of a atisinium chloride.
Description

Atisinium chloride (1976)

Atisinium chloride (2004)

a

14.340

7.670

b

18.180

14.246

c

7.709

17.919

V

2009.7

1958.1

Space group

P212121

P212121

Z

4

4

379.972

379.97

Observed

1.256

1.289

Calculated

1.256

Cell dimensions

Mol wt
-3

Density, g cm

150.20

2θmax

1.289
o

65o

Reflections
Measured

2377

3372

Observed

2007

3408

Non-observed

370

485

R

0.038

0.042

Rw

0.037

0.045

0.33

0.64

0.20

0.36

Final agreement

Average shift/estimated
Max in final difference electron
density map, eÅ-3

3.4.6

AO-358

This alkaloid was isolated as a milky white solid. It had a high melting point (122.6124.2oC) and a large optical rotation ([α]D27 = +86.6). The LRCIMS indicated a peak at
m/z 358. From the HRCIMS, the molecular formula was found out to be C22H32NO3. In
the HREIMS, ion fragments were observed at m/z 357 (M+), 344, 342, 329, 328
(100%), 327, 326, 312, 300, 286, 284, 250, 234, 148, 122, 105, 91, 77, 71, and 60.
When the mass spectral library (available on the Department of Chemistry mass
spectrometer) was searched for a match, none of the spectra matched the HREIMS
spectrum of this alkaloid isolated here.
The 1H-NMR spectrum (nanoprobe) was not clear enough to assign the structure and
the sample was insufficient to obtain the 13C-NMR spectrum and 2D spectra. However,
the presence of three methoxy groups, a C-methyl group and N-ethyl signals were clear
in the 1H-NMR spectrum. The three methoxyl protons resonated at 3.23 ppm (s, 3H),
3.38 ppm (s, 3H) and 3.43 ppm (s, 3H). The C-methyl protons (probably C-18)
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resonated at 1.10 ppm (s, 3H) and the N-CH2CH3 protons at 0.90 ppm (t, 3H) with the
methylene (-CH2) protons resonating at 3.12 ppm (q, 2H). Since the alkaloid didn’t
have signals for an exomethylene group it probably belongs to the C19-diterpenoid type
of alkaloid whose structure could be related to virescenine 27. Nevertheless, the
structure was not established due to the lack of spectroscopic data.
Interestingly, another alkaloid fraction was also isolated with the same molecular
weight but different molecular formula, and different polarity (on TLC). This
compound had a lower Rf value compared to the above compound. Its molecular
formula was determined by HRCIMS to be C15H5NO10 .

3.4.7

AO-340

This alkaloid was isolated as a milky white solid. The LRCIMS indicated the presence
of a peak at m/z 340 (MH+). The HRCIMS supported the molecular formula of
C21H26NO3. In the LREIMS, the molecular ion and ion fragments were observed at m/z
339 (M+), 322, 310, 297, 283, 245, 179, 159, 128, 124 (100%), 108, 94, 79, 65, 55, and
42.

3.4.8

AO-330

This alkaloid was isolated as a milky white solid. LRCIMS indicated the MH+ peak at
m/z 330. The HRCIMS supported the molecular formula of C20H28NO3. Due to small
quantities of sample, it was not possible to obtain adequate NMR data. The mass
spectral library was searched for compound matches and none of the spectra in the
mass spectrometer library was found to match the mass spectrum of AO-330. Judging
by the molecular formula and ion fragmentation pattern, it appears to be a new alkaloid.

3.4.9

AO-372

This alkaloid was isolated as a pale brown solid. The LRCIMS indicated the presence
of an MH+ peak at m/z 372. The HRCIMS indicated a molecular formula of
C21H26NO5. In the LREIMS, ions were observed at m/z 371 (M+, 100%), 355, 343, 327,
299, 296, 238, 210, 192, 162, 134, 122 and 105.

3.4.10

AO-414

This alkaloid was obtained as a pale green solid. The LRCIMS gave a peak at m/z 414
(MH+) and the HREIMS supported a molecular formula of C23H27NO6. In the LREIMS,
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ion fragments were observed at m/z 413 (M+), 385, 369, 354, 342, 310, 280, 252, 220,
212, 148, 134, 122, 105, 91, 79, 67, 57, 55, 44 (100%), 43 and 42.

3.4.11

O-466

This alkaloid was isolated as a pale green solid. The LRCIMS indicated a peak at m/z
466 for MH+. The HRCIMS supported a molecular formula of C25H40NO7. In the
LREIMS, ions were observed at m/z 465 (M+), 450, 448, 432, 422, 403, 402 (100%),
390, 374, 358, 342, 329, 300, 284, 194, 164, 148, 122, 98 and 91.
No structures could be assigned for these minor alkaloids (AO-340, 330, 372, 414 or
466) due to the very small quantities available.
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Chapter 4
Alkaloids from Corydalis gerdae Fedde

4.1

Family:

Fumariaceae

Genus:

Corydalis

Species:

gerdae

gSo-ba rig-pa name:

sTong-ril-zilpa,

Distribution:

Endemic to Himalayas

Botanical Description and Ethno-medical use

Corydalis gerdae Fedde is an annual flowering herb that grows to about 7-20 cm in
height with a long scaly rhizome and stems surrounded by persistent petiole bases of
the bipinnatisect (2-4 x 1.5-2 cm) basal leaves that have broadly ovated leaflets77,111.
The umbellate inflorescence has 3-6 horizontal flowers supported by 10-15 mm
pedicels exserting above the bracts (6-12 mm) and the petals are purple or mauve and
white with an outer pair broadly crested and lower deflexed lip petal111.
This species of Corydalis is used in Bhutanese traditional medicine in treating
malaria105, coughs and colds, and bile inflammation77. Other Corydalis species have
also been used by many cultures in folklore medicines worldwide163. The genus
Corydalis contains more than 300 species, with a vast variety of isoquinoline alkaloids
being isolated from these plants4,47,163.

4.2

Isoquinoline Alkaloids: Biosynthesis and Classifications

The isoquinoline type alkaloids are the most widely distributed alkaloids and are found
in plants of thirty two botanical families44,164. Morphine was the first isoquinoline
alkaloid to be isolated from Papaver somniferum (Papaveraceae) in 1805165. To date
about 1,200 isoquinoline alkaloids have been isolated from plants belonging to these
different types of families mentioned above44.
The classification of isoquinoline alkaloids is not clearly defined. However, based on
their structural types and biogenesis, they are commonly divided into twenty categories,
each of which is further branched into different sub-classes47. Each group presents
striking and enormously varying structural types basically derived from tyrosine, and
these types are briefly described below.
1. Simple isoquinoline derivatives, e.g Corydaldine 29.
2. Emetine group (derivatives with a monoterpenoid unit) e.g. Emetine 30.
3. Benzylisoquinolines (derived from two molecules of tyrosine), e.g. Cularine 31.
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4. Proaporphines, e.g. Orientalinone 32.
5. Aporphines (formed by phenol oxidative coupling of a benzylisoquinoline
precursor), e.g. Liriodenine 33.
6. Protoberberines (derived from benzylisoquinolines by condensation with a onecarbon unit), e.g. Ophiocarpine 34.
7. Benzophenanthridines (derived from tetrahydro-protoberberine precursors), eg.
Chelidonine 35.
8. Dibenzopyrrocoline alkaloids (derived by oxidation of a benzylisoquinoline
precursor), e.g Cryptaustoline 36.
9. Protopines (formed by oxidative ring fission of protoberberine N-metho salts),
e.g Protopine 37.
10. Rhoeadine alkaloids (derived from two tyrosine units via tetrahydroberberine
and protopine intermediates), e.g Rhoeadine 38.
11. Other categories includes Narceine and Phthalideisoquinoline alkaloids, the
Pavine/isopavine group, Spirobenzylisoquinolines166, the Protostephanine and
Hasubanonine groups, Bis-benzylisoquinoline alkaloids, the Morphine group,
and the Phenethylisoquinoline group.
Although these alkaloids are quite often typical and restricted to certain genera of the
family as in the case of rhoeadine alkaloids, which are encountered only in the Papaver
genus, more than one class of alkaloids have been observed commonly even within a
genus. The protoberberine alkaloids are distributed among the plant families
Alangiaceae, Berberidaceae, Fumariaceae, Hydrastidaceae, Lauraceae, Leguminosae,
Menispermaceae,

Papaveraceae,

Ranunculaceae,

Rutaceae

and

Annonaceae44.

However, these families also host large reservoirs of other classes of alkaloids. The
investigation of the Annona squamosa L. of the Annonaceae family resulted in the
isolation of ten alkaloids (corydine, annonaine, roemerine, norcorydine, norisocorydine,
isocorydine,

glaucine,

dienone,

aporphine

and

norlaureline)

belonging

to

protoberberine as well as aporphine alkaloids167.
The protopine group of alkaloids is distributed in a variety of genera in the
Fumariaceae (Corydalis, Dactylicapnos, Dcentra, Fumaria), Papaveraceae (Argemone,
Bocconia, Chelidonium, Eschscholtzia,
Macleaya,

Glaucium, Hunnemannia, Hylomecon,

Meconella, Meconopsis, Papaver, Roemeria, Romeya, Sanguinaria,

Stylomecon), Hypecoaceae, Berberidaceae (Berberis), Sapindaceae (Pterodophyllum),
Nandinaceae, and the Pteridophyllaceae plant families. Protopine is the principal
alkaloid of this group of families. Other groups like protoberberines and

67
benzophenanthridines were also reported from the same family along with protopine as
illustrated by the analysis of Bocconia cordata Wild.168 and Chelidonium majus
L.(Papaveraceae)169.
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The biosynthetic pathway of the protopine-type and the benzo[c]phenanthridine-type
alkaloids.

Recently, two new protopine-type alkaloids, argemexicaines-A and B along with
thirteen known alkaloids including its related alkaloid, benzo[c]phenanthridine-6acetonyldihydro-chelerythrine were isolated from the methanol extracts of Formosan
Argemone mexicana L (Papaveraceae)170. Benzo[c]phenanthridine-6-acetonyl-dihydro-
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chelerythrine exhibited a significant anti-HIV activity in lymphocytes with EC50 and TI
(Therapeutic Index) values of 1.77 µg/ml and 14.6 µg/ml respectively170. About 20
alkaloids including protopine, cryptopine, stylopine, scoulerine and sinactine171, and
minor alkaloids like fumarofine, fumaricine, fumaritine, and fumariline172, were
isolated and identified from the plant Fumaria officinalis (Fumariaceae).
These alkaloids are related biosynthetically and many biosynthetic correlations have
been studied for the isoquinolines. The biosynthetic pathways for protopine-type (e.g.
protopine) and benzo[c]phenanthridine-type (e.g. chelidonine) alkaloids from Corydalis
incisa PERS. and Chelidonium majus L. are presented. The plants are related to each
other and their biosyntheses are relevant to the alkaloids currently isolated from
Corydalis gerdae Fedde by the author.
It was suggested that the protopine-type and benzo[c]phenanthridine type alkaloids
were related biosynthetically as both were derived from the tetrahydroprotoberberine
alkaloids. Battersby et al.173 studied the biosynthetic pathway for these alkaloids using
Corydalis incisa PERS and Chelidonium majus L and established (by tracer
experiments174) the biosynthetic pathway as illustrated in Scheme 2. This pathway
showed that chelidonine and protopine were biosynthesised in plants from tyrosine 39
via (S)-reticuline 40, (S)-scoulerine 41 and (S)-stylopine 42175.
The same experiment confirmed that (S)-cheilanthifoline 47 isolated from Corydalis
incisa plants was biosynthetically converted to corynoline and protopine and was a
probable true intermediate between scoulerine and stylopine174. It has also been shown
that the protopine-type alkaloids occupy a central position biosynthetically between the
tetrahydroprotoberberine-N-metho salts and the benzophenanthridines and between the
N-quaternary tetrahydroberberines and the rhoedines168.
MeO
HO

N
H
O
CH2
O

47 (-)-(S)-cheilanthifoline
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4.3

Phytochemical and Pharmacological Investigation of Isoquinoline Alkaloids
from the genus Corydalis

Many bioactive alkaloids belonging to different classes of isoquinoline alkaloids (as
described earlier in this chapter) have been isolated from Corydalis species
(Fumariaceae). Sibiricine176 and ochrobirine177 were first isolated

from Corydalis

siberica by Manske et al. in 1936. The Dictionary of Alkaloids47 has listed 58 species
of Corydalis (including unknown species) and 119 different types of alkaloids were
reported to have been isolated from these plants. Cheilanthifoline was isolated from
Corydalis cheilanthifolia, Corydalis scouleri, Corydalis siberica and the Corydalis
gigantea178. Scoulerine and many other alkaloids were reported from Corydalis
tuberosa, Corydalis cava, and Corydalis pallida179. Examination of Corydalis
koidzumiana resulted

in

the isolation

of protopine,

α-allocryptopine,

(±)-

tetrahydropalmatine, (+)-corydaline, (+)-stylopine, (−)-scoulerine, (−)-capaurine, (−)isocorypalmine, (−)-cheilanthifoline, (+)-corybulbine, sanguinarine, oxysanguinarine,
dihydrosanguinarine, (+)-reticuline, sinoacutine and pallidine180.
Protopine was isolated from Corydalis ternata and Corydalis caseana A.Gray181.
Stylopine was also reported from a Corydalis spp47. Varieties of alkaloids were also
isolated from Corydalis bungeana Turez182 and Corydalis decumbens183 and the
isolation work is still ongoing.
Amongst different classes of alkaloids isolated from the plants, protoberberine and
protopine groups have shown a wide range of pharmacological activities. Berberine
was found to be therapeutically useful in the treatment of malaria (Plasmodium
falciparum)184. Seventeen quaternary protoberberine alkaloids related to berberine were
tested for antimalarial activity and six of them displayed more potent activity than
berberine itself185.
Protopine exhibited both anti-acetylcholinesterase and anti-amnesic properties186.
Protopine was also found to have phospholipase and thromboxane synthetase inhibitory
activity187, weak spasmolytic, weak anti-tumour activity, smooth muscle stimulant,
bactericidal activity and sedative property47. When 18 protopine derivatives were tested
for antimalarial activity, the derivatives A65, A74, A77 and A20 in which the
methylenedioxy moiety was modified by replacing a H atom with Br, NH2, I and SbCl2
respectively

exhibited

promising

antimalarial

activity188.

Stylopine

showed

antipsychotic and neuroleptic activity in mice and rats. Dehydrocorydaline, (+)corydaline and (±)-tetrahydropalmatine isolated from the Chinese Corydalis tubers
were claimed to be good pain killers and anti-ulcer medicines189. With the hope of
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finding a novel pharmacophore, we have studied one of the Corydalis plant endemic to
Himalayas.

4.4

Isolation and Identification of Alkaloids from Corydalis gerdae Fedde

The methanol extract of the air dried plant material was subjected to routine procedures
of extraction, fractionation, separation and purification (Chapter 9). Out of many
fractions, only four known alkaloids were isolated and identified by matching their
LREIMS spectra with the spectra in the Mass Spectrometer Database. NMR spectra
and physico-chemical properties of the isolated compounds were also compared to
further confirm their identification. From these analyses, it was confirmed that the
alkaloids were protopine, scoulerine, stylopine and cheilanthifoline. Other amide and
acid like compounds were also obtained in the process of alkaloid extraction.

4.4.1

Protopine

O
O

5

4

6

N

1

O

Me
8

13

O
12
11

O

37 Protopine
a. Physico-chemical properties
This alkaloid, which belongs to the protopine-type isoquinoline alkaloids, was obtained
as a white amorphous solid. It was the major alkaloid of the plant and had been isolated
before from many plants as described in the earlier part of this chapter. The alkaloid
was optically inactive and had a high melting point (203.7-207.8oC, decomposition).
An earlier literature has reported the melting point of protopine as 210-211oC190 and
207o C47.
b. Spectral Analysis
The LRCIMS indicated an MH+ peak at m/z 354. The HRCIMS and the HREIMS
supported the molecular formula as C20H19NO5 and hence a hydrogen deficiency of 12.
From the same HREIMS, the molecular ion and ion fragments were observed at m/z
353 (M+), 338, 309, 295, 281, 267, 252, 237, 224, 210, 190, 163, 149, 148 (100%), 134
and 89.
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m/z
Figure 11.

HREI MS library matching of an unknown alkaloid (top) with protopine (below).

H-2, H-3 OCH2O
N-Me
H-8

H-9, H-10 OCH2O
H-4

H-11

DMSO-d6

H-1
H-12

D M S O -d 6

C -1 2

C -1 0
C -2
C -9

C -1 4

Figure 12.

C -1 2 a

C -4 a
C 14a

C -1

C -4

C - 2 ,3 O C H 2O
C -1 1

C - 7 ( C H 3)
C -8

C -8 a

C -1 3
9 ,1 0 O C H 2O

C -5

C -6

C -3

1

H-NMR spectrum (top) and

DMSO-d6) from Corydalis gerdae.

13

C-NMR spectrum (bottom) of the major alkaloid (500 MHz,
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The molecular formula and the ion fragmentation pattern corresponded with that of
protopine. From the mass spectrometer library (in the Shimadzu QP-5000 mass
spectrometer) matching analogy, the HREIMS spectrum of the isolated alkaloid was
found to match that of protopine (Figure 11). Thus, this alkaloid was identified as
protopine.
The identification was further confirmed by comparing the 1H-NMR and
spectral values of the alkaloid with that of the 1H-NMR and

13

13

C-NMR

C-NMR spectral values

(Figure 12) reported in an earlier literature for protopine190. The 1H-NMR spectrum
(300 MHz, CDCl3) of protopine indicated the 2,3-OCH2O proton at 5.93 ppm (s), the
9,10-OCH2O at 5.91 ppm (s) and the N-CH3 protons at 1.93 ppm (s)190. These protons
were clearly observed in the 1H-NMR spectrum (500 MHz, DMSO-d6) of the unknown
major alkaloid under investigation in which the signal for the 2,3-OCH2O resonated at
5.96 ppm (s), for the 9,10-OCH2O at 5.93 ppm (s), and for the N-CH3 at 1.79 ppm (s).
The chemical shifts of the other proton signals as well as the 13C-NMR shift values of
the alkaloid corresponded to the chemical shifts of the proton and carbon signals of
protopine (Table 22) further confirming that the alkaloid was protopine.
Table 22. Comparison of 1H-NMR spectrum (500 MHz, DMSO-d6) and 13C-NMR spectrum (500 MHz, DMSO-d6) of the
major alkaloid with 1H-NMR spectrum (300 MHz, CDCl3) and 13C-NMR spectrum (75.4 MHz, CDCl3) of protopine190.
Protopine (Literature)

Alkaloid (Isolated)

δC (ppm)

δH (ppm)

1

108.0

6.89 (s)

2

145.7

145.3

3

147.8

147.3

4

110.3

4a

132.6

5

31.7

2.89 (s)

WH 18

30.5

3.15 (s)

6

57.7

2.52 (t)

5

57.4

2.38 (bs)

8

50.6

3.57 (d)

1.5

50.7

3.47 (bs)

8a

117.7

118.3

9

146.2

145.8

10

145.8

11

106.6

6.67 (d)

8.5

106.3

6.74 (d)

7.5

12

124.9

6.65 (dd)

8.5, 1.5

125.1

6.66 (d)

8.0

12a

128.8

13

46.3

14

194.8

194.8

14a

136.0

136.0

2,3-OCH2O

101.1

5.93 (s)

101.1

5.96 (s)

7-CH3

41.3

1.93 (s)

41.1

1.79 (s)

9,10-OCH2O

100.7

5.91 (s)

100.7

5.93 (s)

Carbon

J (Hz)

6.63 (s)

δC (ppm)

δH (ppm)

107.4

6.92 (s)

110.4

J (Hz)

6.77 (s)

132.7

145.4

129.6
3.79 (s)

46.1
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4.4.2

Scoulerine

MeO

5

4

6

N
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HO

H

8
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OH
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OMe
41 Scoulerine

a. Physico-chemical properties
This alkaloid was isolated as a dark brown solid compound. The alkaloid was optically
active ([α]D24 = −282, c = 0.74 in MeOH) and had a high melting point (153-157o C,
decomposition). This compound was isolated previously from many other plants as
described earlier in this chapter and had a reported melting point of 155oC and an
optical rotation of [α]D28 = −289 (c, 0.62 in MeOH)47. Thus the optical rotation and
melting point of the alkaloid closely resembled that of scoulerine.

b. Spectral analysis of Scoulerine
The LRCIMS gave an MH+ peak at m/z 328 and the HREIMS indicated the molecular
formula as C19H21NO4 which suggested an index of hydrogen deficiency of 10. In the
HREIMS, the molecular ion and ion fragments were observed at m/z 327 (100%, M+),
326, 312, 310, 207, 179, 178 (100%), 176, 162, 150, 149 and 135. The MS-library was
searched for a match and it was found that the alkaloid matched the MS spectrum of
scoulerine (Figure 13). Major fragments appeared at m/z 135, 150, 176, 178 and 326,
corresponding to the favoured cleavage of tetrahydroberberines191,192. Thus, from this
spectral matching and the close proximities of its physico-chemical properties to that of
scoulerine, the alkaloid was identified as scoulerine 41. It is also biosynthetically
plausible. Slight variations in melting point, optical rotation and peak fragments were
observed because of experimental variation and some very minor impurities.
The literature on the 1H-NMR of scoulerine191 reported the presence of two O-methyl
groups (s, τ 6.18), four aromatic protons (τ 3.1-3.5) and the absence of the N-methyl
group in the spectrum. Another publication on scoulerine193 reported the presence of
signals ascribed to the 2-OH at 5.26 ppm (2H, bs), the 2-OMe group at 3.85 ppm (6H,
s), and an AB-quartet at 3.48 ppm and 4.21 ppm with a coupling constant of 16 Hz.
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When the 1H-NMR spectrum of the isolated alkaloid was compared with the above data
reported in the literature, they corresponded well.

m/z
Figure 13. HREIMS spectrum of the alkaloid (top) and that of scoulerine (bottom).

Figure 14. 1H-NMR spectrum (300 MHz, CD3OD, TMS) of the alkaloid (identified as scoulerine)
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In the 1H-NMR spectrum (Figure 14) of the isolated alkaloid, the signal assigned to the
2-OMe group resonated at 3.24 ppm (s) and 3.21 ppm (s), the 2-OH group resonated at
5.38 ppm (s), and the ABX system resonated at 3.52 ppm (q) and 4.14 ppm (d) with a
coupling constant of 15.9 Hz. Signals for the four aromatic protons were observed
between 6.54-6.72 ppm. The slight differences observed could be due to the different
NMR solvents used in the experiments. Therefore, this comparative study further
confirmed that the alkaloid was scoulerine.

4.4.3

Cheilanthifoline
MeO

5

4

6

N

1

HO

H

8
13

O
CH2

12
11

O

47 Cheilanthifoline

a. Physico-chemical properties
This UV active alkaloid was obtained as a pale green solid and was recrystallised from
MeOH/diethyl ether. This alkaloid was also a known alkaloid. Its optical rotation
([α]D20= −262 , c = 0.60 in CDCl3) and the melting point (168-170.4oC, decomposition)
corresponded broadly to that of cheilanthifoline whose melting point was reported as
184oC and its optical rotation as [α]D20 = −311 (MeOH)47. In another report, its melting
point was reported to be 170o C (decomposition) and the optical rotation of [α]D20 =
−315193. The difference in optical rotation observed may be due to the different solvent
used.

b. Spectral analysis
In the LRCIMS, an MH+ peak was observed at m/z 326 for the alkaloid. The HREIMS
indicated its molecular formula as C19H19NO4 and hence an index of hydrogen
deficiency of 11. In the LREIMS spectrum of the alkaloid, the main ion fragments were
observed at m/z 325 (M+), 177 and 148 (100%) suggesting that the alkaloid was a
protoberberine base194. When this LREIMS spectrum of the alkaloid was searched in
the mass spectrometer library, it was found to correspond with that of
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cheilanthifoline193 (Figure 15). Based on this comparative analogy, the alkaloid was
identified as cheilanthifoline.
To further confirm the identification, the 1H-NMR spectrum (Figure 16) of the alkaloid
was obtained and its chemical shifts were compared with the 1H-NMR data of
cheilanthifoline reported in the literature193. In the 1H-NMR spectrum of the alkaloid
isolated here the methoxy group signal resonated at 3.87 ppm (s, 3H, OMe), the
methylenedioxy resonated at 5.93 ppm (d, 2H,-CH2-) and the C-8 methylene protons
resonated at 3.53 (q) and 4.09 ppm (d, J=15 Hz).

m/z
Figure 15. LREIMS of the unknown alkaloid (top) and that of cheilanthifoline (bottom)

OMe
Four aromatic protons

OH
C-8 methylene protons

Solvent peak
Methylenedioxy protons

Figure 16. 1H-NMR (500 MHz, CDCl3, TMS) of the alkaloid (cheilanthifoline).
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These chemical shifts were in agreement with the 1H-NMR values of cheilanthifoline
reported in the literature193 in which the methoxy group (s, 3H, OMe) signal resonated
at 3.85 ppm, the methylenedioxy resonated at 5.90 ppm (d, 2H, -CH2-) and the C-8
methylene resonated at 3.48 ppm (q) and 4.21 ppm (1H, d, J = 16 Hz). The 1H-NMR
spectrum of the alkaloid also indicated the presence of the hydroxy group at 1.25 ppm
and the four aromatic protons (m) between 6.59 ppm to 6.81 ppm. The DEPT
experiment of the isolated alkaloid, though not clear, distinctly showed the presence of
four methylene groups in the structure. This comparative analysis of the data on 1HNMR further confirmed that the alkaloid was cheilanthifoline 47.

4.4.4

Stylopine

O

5

4

6

O

N

1

H

8
13

O
12
11

O

42 Stylopine

a. Physico-chemical properties
This known alkaloid was isolated as a brown solid. It had a melting point of 163-165o C
(decomposition) and was optically active with [α]D24 = −304 (c, 0.56 in MeOH). The
literature47 has reported the melting point of stylopine as 2040C and an optical rotation
of [α]D23 −310. In other literature on stylopine, its melting point was reported as 220221°C175 and 194-195°C195 and no consistency was observed in the melting points of
this alkaloid. The differences in these physicochemical properties could be due to
instrumentation error. However, spectral analysis confirmed that the alkaloid was
stylopine 42.

b. Spectral analysis
The LRCIMS gave a MH+ peak at m/z 324. The HREIMS indicated a molecular
formula of C19H17NO4 for the alkaloid and hence an index of hydrogen deficiency of
12. In the LREIMS of the alkaloid, the major ion fragment peaks were observed at m/z
323 (M+), 322, 174 and 148 (100%) and this corresponded to the ion fragmentation
pattern of stylopine195. When the mass spectrometer library was searched for its match,
it was confirmed that the alkaloid was stylopine (Figure 17).
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Figure 17. LREIMS of the alkaloid (top) and that of stylopine (bottom).

4.4.5

CG-337

This UV absorbing compound was a minor alkaloid. The HREIMS indicated a
molecular formula as C19H15NO5 and hence an index of hydrogen deficiency of 13.
Since the amount of the alkaloid was very small, not enough data was obtained for
identifying the alkaloid.

4.4.6

9-Octadecenamide

O
H2N

48 9-octadecenamide
This non-alkaloid compound was isolated as white solid. The LRCIMS gave an MH+
peak at m/z 338 and HREIMS confirmed its molecular formula as C22H43NO. In the
HREIMS, ion fragments were observed at m/z 337 (M+), 319, 277, 136, 122, 97, 83, 72,
69, 59 (100%), 43, and 41.
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Figure 18. HREIMS of compound (top)and that of 9-octadecenamide (from library, bottom).

The compound was identified as 9-octadecenamide based by the MS library matching
(Figure 18). This fatty acid amide occurs naturally in plants and has been isolated
before from Vetiveria zizanioides196 and Clausena lansium197 (collected in Hainan
Island, China). 9-octadecenamide was also isolated from the freshwater green algae
Rhizoclonium hieroglyphicum growing in the Ural Mountains198 as its major
component (2.26%).
Another two non-alkaloid compounds with molecular mass 337 and 335 were also
isolated as white solids (Chapter 9).
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Chapter 5
Alkaloids from Tribulus terrestris Linn.

5.1

Family:

Zygophyllaceae

Genus:

Tribulus

Species:

terrestris

Common name:

Puncture vine or Caltrop fruit

gSo-ba Rig-pa name:

dZe-ma-ra-go-ma

Distribution:

Cosmopolitan

Botanical Description and Ethno-medical use

Tribulus terrestris is a prostrate annual herb. It is known as goathead in the USA,
“Ying-jili” in China and dZe-ma ra-go-ma in Bhutan. The genus Tribulus comprises of
approximately 20 species which grow as shrubs about 10-60 cm high199,200. It is
considered a noxious weed and is found abundantly on roadsides and vacant lots with
many reddish branches spreading radially from a central point. It has small oppositely
arranged pinnate leaves with three to seven branching green oblong leaflets (3-7 cm
long)201. It gives yellow flowers202. The fruits are light brown when mature and
measure about a centimeter in diameter. It has sharp spines (2 spines measuring 2-3
cm) accompanied by several spikes around it201. The fruits and seeds are of great
importance to traditional or natural medicines practiced worldwide (Table 23).
Table 23. Traditional medicines using Tribulus terrestris Linn
Traditional
Medicines

Ethno-medical use

Bhutanese

Kidney and its related disorders, impotence and as diuretics.

Bulgarian

Libido enhancer and treating infertility203.

Chinese

Calm liver, dizziness, headache, premature ejaculation, cardio-vascular
diseases204, acute conjunctivitis and vertigo205.

Greeks

As a diuretic, mood enhancer, headache, constipation, sexual dysfunction,
hypertension and hypercholesterolemia206,207.

Indians

As a diuretic, antiseptic and anti-inflammatory203.

Pakistanis

As a tonic and aphrodisiac.

Turkish

As a diuretic, for colic pain and hypercholesterolemia207.

However, the plant had been found to have adverse toxic effects on livestock,
especially on sheep. The ingestion of its leaf and foliage in large quantities caused the
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hepatogenous photosensitization, known as geeldikkop, tribulosis ovis or yellow
bighead in sheep and goats208,209. The outbreak of this disease has been reported in
South Africa208, Australia108,109,210, United States211, Argentina and Iran ever since
1932209.

5.2

Chemical and Pharmacological Studies of Tribulus species

Owing to ethno-medical claims and also after the tragedy of photosensitization
outbreak in sheep, the plant has been extensively investigated by a number of workers
in those countries. The presence of steroidal glycosides, steroidal saponins, flavonoids
and alkaloids in the plant have been reported107. Saponins such as glucopyranosyl,
galactopyrans, ruscogenin, hecogenin, gitogenin, titogenin, protodioscin, diosgenin and
yamogenin212,213; sterols such as sitosterol, and campesterol; flavonoids such as
kaemferol, kaempferol-3-glucoside, tribuloside and quercetin214,215; and other
constituents like fatty acids, polysaccharides, tannins, amino acids and potassium salts
have been isolated from this plant.
Alkaloids like norharman 49, harman 50, harmol 51, harmine 52, 3-hydroxymethylnorharman 53, harmalol 54, harmaline 55, tetrahydronorharman 56, tetrahydroharman
57, 2-ethyltetrahydro-norharman 58, tribulusterine 59, and amides such as
terrestriamide, terrestribisamide, N-p-coumaroyltryamine and cinnamic amide110,205,216
were also isolated from the plant. At least five such alkaloids were isolated from the
Australian Tribulus terrestris and harman and norharman were found out to be the main
alkaloids of this plant107,217. Recently, the structure of tribulusterine 59 has been revised
to that of perlolyrine with a 5-hydroxymethyl substituent in the furan ring218.
The saponins and the β-carboline alkaloids in Tribulus terrestris have been reported to
have shown a wide range of pharmacological activity219. It was suggested that steroidal
saponins, diosgenin and yamogenin caused the geeldikkop diseases220. When the
synthetic harman and norharman were administered subcutaneously to sheep at a dose
rate of 54mg/kg, it was found that both of them caused similar nervous system effects
(mainly limb paresis)110. This result suggested that the β-carboline alkaloids were
responsible for causing staggers in sheep. Tribulus terrestris also treats impotence,
increases sperm count (50%) and serves as a natural testosterone enhancer that
invigorates and boost strength, stamina, muscles growth, fat loss and libido.
Protodioscin was reported to be the main active steroidal saponin exhibiting
aphrodisiac properties221,222.
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A cream made from an extract of this plant showed very strong antibacterial, antiinflammation, anti-virus, anti-herpes effects and in some cases was found to block the
growth of cancer cells223. It was suggested that the activity of the Tribulus terrestris
extracts could be due to unknown steroidal saponins224. Tribulosin and β-sitosterol-Dglucoside from Tribulus terrestris showed anthelmintic activity with ED50 values of
76.25 and 82.50 μg/ml respectively225. Tribusponin was found to be a useful as an
antisclerotic agent226. Some β-carboline alkaloids, flavonoids, kaemferol and quercetin
are known to have antimicrobial effects227,228.
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N
H

N
R1

49 Norharman:

R1 = H, R2 =H, R3 =H

50 Harman:

R1 = CH3, R2 = H, R3 = H

51 Harmol:

R1= CH3, R2 =OH, R3= H

52 Harmine:

R1 = CH3, R2 = OCH3, R3 = H

53 3-Hydroxymethylnorharman: R1 = H, R2 =H, R3 = CH2OH
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54 Harmalol:

R = OH

55 Harmaline:

R = OCH3

56 Tetrahydronorharman:

R2 = H, R2 = H

57 Tetrahydroharman:

R1 = CH3, R2 = H
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58 2-Ethyltetrahydronorharman: R1 = H, R2 = CH2CH3

N
N
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O

59 Tribulusterine
The search for new such bioactive saponins and β-carboline alkaloids is still
proceeding. This study is directed towards the Australian sourced Tribulus terrestris
species and aimed to isolate new minor alkaloids (if any) present in the plant.
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5.3

β-Carboline Alkaloids and Classification

β-Carboline alkaloids are defined as heterocyclic amines with a 9H-pyrido[3,4-b]
indole structure and they are found in various plants including edible plants229. These
alkaloids are biosynthetically derived from the amino acid L-tryptophan. They were
first isolated from the plant Peganum harmala L and based on this, the β-carbolines are
also known as harmala alkaloids107. Since then, they have been reported in a variety of
plant families including the Leguminoseae, Malpighiaceae, Rubiaciae, Rutaceae,
Graminae, Simaroubaceae and Zygophyllaceae.
The β-carboline derivatives include C-1 unsubstituted β-carbolines (e.g 1, 2, 3, 4tetrahydro-6-methoxy-2-methyl-β-carboline), the C-1 methyl substituted harman group,
the C-1 vinyl, acyl or carboxyl substituted group, and the C-3 substituted group47.
Many groups of β-carboline alkaloids have also been isolated from marine sources.
Only recently two new β-carbolines, eudistomin-W 60 and eudistomin X 61 which
exhibited antibiotic activity toward Bacillus subtilis, Staphyloccocus aureus and
Escherichia coli and fungicidal activity against Candida albicans, were discovered in a
Micronesian ascidian Eudistoma species230.

HO

HO
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H
HO

H

60 Eudistomin W

N
H

N

(CH3)2N
61 Eudistomin X

It was suggested that the pathway for the biosynthesis of these β-carboline alkaloids
involves tryptophan, tryptamine and then 1-methyl-1,2,3,4-β-carboline-1-carboxylic
acid107. Stolle and GrÖger proposed that condensation of tryptamine with pyruvic acid
formed the β-carboline ring of harman with 1,2,3,4-tetrhydro-β-carboline-1-carboxylic
acid as an intermediate product 231.

5.4

Attempted Isolation of β-Carboline Alkaloids from Tribulus terrestris Linn.

Aerial parts of Tribulus terrestris Linn were collected in New South Wales by Dr. C.
Bourke (NSW Agriculture, Orange) and the plant material was dried before processing.
The regular process of solvent extraction, fractionation, separation (PTLC) and
purification of the plant’s crude extract unfortunately gave no alkaloid fractions. The
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extraction procedure was kept specific for alkaloids, but the major component isolated
gave an MH+ peak at m/z 209 (LRCIMS) and absorbed the UV light but didn’t give a
positive alkaloid test with Dragendorff’s reagent. HRCIMS indicated a molecular
formula of C11H13O4. The compound was identified as 3,4-Dimethoxycinnamic acid 62
based on the comparative analysis and the 1H-NMR spectral peaks of the compound
with those reported in the literature47. Extra peaks observed in the 1H-NMR of the
compound were from small impurities.

MeO

H
COOH

MeO
H

62 3,4-Dimethoxycinnamic acid

3,4-Dimethoxycinnamic acid occurs naturally and has been isolated before from plants,
Zanthoxylum acutifolium (leaf)232 and Milletia ovalifolia (seed)233, and also from
beeswax234.
Although some crude fractions also showed CI peaks at m/z 213, m/z 183 and m/z 265
corresponding to those expected for harmine, harman and perlolyrine, none of these
could be isolated for structural confirmation. TLC analysis revealed that these
compounds had similar retention factors as those of the standards: harmine, harman and
perlolyrine. Extractions of the plant material with different solvents were also
conducted but no substantial amount of crude alkaloid could be recovered. It should be
noted that the dried plant material gave only a very faintly positive Culvenor Fitzgerald
test106 for the presence of alkaloids. This confirmed that the alkaloid content of the
plant was extremely low which could have been caused by either inappropriate drying
of the plant material or its time of collection. Extreme drying and exposure to light can
cause some alkaloids to degrade. As discussed in Chapter 1, alkaloid content may also
vary from season to season and with geographical location. Alkaloid yields may be thus
improved by collecting the plant at an appropriate time. Further collections of the plant
were not conducted due to time constraints.

86

Chapter 6
Investigation of Ranunculus brotherusi Freyn for alkaloids
Family:

Ranunculaceae

Genus:

Ranunculus

Species:

brotherusi

gSo-ba Rig-pa name: lche-tsa
Distribution:
6.1

Himalayas

General Introduction

Ranunculus brotherusi is an erect plant with yellow flowers. This plant is used in the
traditional medicine of Bhutan as an antipyretic and for treating infections and wounds.
The genus is found in aquatic and terrestrial habitats. Some Ranunculus species have
been found to cause diarrhoea, drooling, licking air, teeth grinding, excessive chewing,
paddling and death in cattle235. Other studies have shown that Ranunculus species
(Ranunculus acer) contain a vesicant toxin called ranunculin that is released upon
mastication236,237.

6.2

Phytochemical and Pharmacological Studies of the genus Ranunculus

Many saponins, flavonoids and glycosides have been isolated from this plant.
Stigmasterol, hexadecanoic acid, eicosanoic acid, nonacosanol, ternatolide A and 5hydroxy-benzaldehyde were isolated from Ranunculus ternatus238. Coumarins like
aesculetin (6,7-dimethoxycoumarin) and scopoletin 63, which showed potent antiviral
and cytotoxic activity, were isolated from the Egyptian species Ranunculus asiaticus
L239. Four major quercetin triglycosides, namely quercetin 3-sophoroside-7-glucoside,
quercetin 3-sambubioside-7-glucoside and quercetin 3-diglucoside were isolated along
with other components from an Antarctic Ranunculus species240.
Alkaloids have also been found in Ranunculus species. For example, protoberberinetype quaternary alkaloids like palmatine 64, berberine 65 and columbamine 66, and the
benzylisoquinoline-type magnoflorine 67, were isolated from the rhizomes of
Ranunculus serbicus241. The leaf extract of Ranunculus sceleratus L. showed a rapid
fungicidal action, tolerance against heavy fungal inoculum, activity on a broad pH
range, broad fungicidal spectrum, and no phytotoxicity with a lethal dose of 1:40
dilution242. Phytochemical investigation of this plant species led to the isolation of the
glycoside ranunculin, its aglycone protoanemonin 68, and anemonin 69243.
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Protoanemonin was also isolated from Ranunculus oxyspermus M.B. and Ranunculus
acer244. It was suggested that protoanemonin has hepatotoxic activity245. It showed
bacteriostatic and bactericidal activity against a large number of Gram-positive and
Gram-negative bacteria as well as fungistatic activity against Saccharomyces cerevisiae
and Candida albicans246. An extract of Ranunculus japonicus showed analgesic and
anti-inflammatory effects when determined in several animal models (mice and rats)247.

6.3

Investigation of Ranunculus brotherusi Freyn for Alkaloids

The methanol extract of Ranunculus brotherusi only afforded a very small quantity of
crude alkaloid material after an acid/base separation. This separation gave many UVactive fractions, but none of them gave any positive results when tested for alkaloids
with Dragendorff’s reagent. The sequential extraction was repeated by increasing the
pH from 9 to 11 and then to 13 using aqueous sodium hydroxide. A liquid-liquid
extraction

was

then

performed

using

different

solvents

like

chloroform,

dichloromethane and ethyl acetate but still no alkaloids were obtained. The Culvenor-
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Fitzgerald test was performed for this plant before the methanol extraction was
conducted and it gave a faint positive test. No further work was done on this plant due
to time constraints.
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Chapter 7
Microbiological Bioassay
7.1

General Introduction

As discussed in Chapter one, medicinal plants offer a vast resource of interesting
bioactive lead compounds. Studies of the Structure-Activity Relationships of the leads
combined with computer-aided modelling should then result in molecules with optimal
activity, better bioavailability, fewer side effects and an acceptable therapeutic index
and consequently, good candidates for the development to new drugs248. Thus, one of
the key steps in the methodology of drug development is the bioassaying or the testing
of activities of the plant isolates. To conduct the bioassays, efficient collaborations with
pharmacologists, medical doctors, plant pathologists and biologists may sometimes be
crucial, and there are relatively few simple laboratory-based in vitro methods which
could be performed by chemists alone249.
Bioassays involve quantitation of the response which follows the application of a
stimulus to a biological system250. The bioassays are performed on crude extracts
especially in bioactivity-guided screening or on blindly purified compounds249. The
bioassays can be best divided into general screening bioassays and the specialized
screening bioassays. Antimalarial testing is one example of a specialised screening
bioassay. The general screening bioassays can be further classified to broad screening
bioassays and primary screening bioassays. Primary screening bioassays include the in
vivo animal assays (even involving human volunteers) and the in vitro microbiological
assays248.
The microbiological bioassays involve the detection of antibacterial and antifungal
activities and potencies (Minimum Inhibitory Concentration; MIC) of compounds using
different end point methods like plate assays (agar diffusion assay) and tube assays
(agar dilution streak assays and broth dilution MIC assays)250,251. Due to the
requirement of a long incubation time, the agar diffusion assay (plate assay) cannot be
used for volatile and unstable compounds and therefore, agar-overlay methods (agar
dilution methods or liquid media methods) have normally been followed.
In the agar-overlay methods, the degree of antimicrobial activity and the MIC of a
compound are greatly influenced by factors like “compound concentration, carbon
dioxide and oxygen concentration, media compatibility with the test compound,
solubility and stability of the test compound, pH of the medium, types nutrient of
media, temperature, the duration of the exposure to the compound and the types of
strains (bacterial, fungal or viral) used in the testing”54,58. For these reasons, growth
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promoting or inhibiting potencies of test samples have to be standardised and compared
with standard preparations of the test compound250. Thus, the choice of antimicrobial
bioassay method has to be selectively adapted taking the above factors into
consideration. Such methods should be sensitive enough to detect active principles, the
minimum inhibitory concentrations, and the dose response of the microorganisms
(bacteria and fungi). A comparison of the disk diffusion method, the hole-plate
diffusion method and the bioautographic TLC assay showed that the nature and amount
of substance influence to a great extent the selection of the test method252.
A number of alkaloids (about 300) have been shown to possess antimicrobial
activity253. Screening of medicinal plants used in traditional medicines has shown that
the incidence of antimicrobial activity found is much higher than for random
screening253. In conjunction with this, alkaloids isolated from some of the traditional
medicinal plants of Bhutan were analysed here for their antibacterial and antimalarial
activities.

7.2

Assays for Detecting Antibacterial Activity

To test if a sample can exert antibacterial activity, it should preferably be made up into
an aqueous solution by dissolving in water254. If it is insoluble in water,
ultrasonification should be first tried and if that too fails, water miscible organic
solvents like methanol, acetone or the use of emulsifying agents, are other
options254,255. In such cases, however, care must be taken to avoid false test positives
due to lethality of the uncontrolled final concentration of the solvent or emulsifying
agents.
The antibacterial activity assay is distinguishable into bacteriostatic activity and
bactericidal activity. Bacteriostatic activity of the compounds refers to stopping or
inhibiting bacterial growth and multiplication. Bactericidal activity is the property of an
antibacterial agent responsible for killing bacteria. Both disk diffusion assay and broth
methods can be used to examine bacteriostatic activities but the bactericidal activities
can be detected only by microscopic analysis or by the assessment of bacterial cell
recovery in fresh media58 .
Susceptibility of Mycobacterium tuberculosis to antimicrobial agents has been tested
by the bioluminescent assay (ATP) method, the Mycobacteria Growth Indicator Tube
(MGIT) method, the MIC method and the M24-T agar proportion method. It was found
that the ATP method was the most rapid and reliable method for the assessment of drug
(antibacterial) susceptibility testing256. The Fluorescein Diacetate (FDA) Assay, based
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on the enzymatic hydrolysis of fluorescein diacetate to fluorescein, is suitable for use
with a wide range of different microorganisms and was recommended for determining
the MIC of crude extracts and purified compounds257. This method is commonly used
in antibacterial testing, although problems can arise with fluorescent components in the
growth media or fluorescence of the test compound. Kamia et al. also has reported that
the turbidometric assay was rapid, reproducible and a very useful method for
quantitative estimation of antibacterial activity258.

7.2.1

Results of the Antibacterial Testing

The crude methanol extracts (AO-ME and CG-ME), crude alkaloids (AO-CEA and
CG-CEA), atisinium chloride, orochrine and protopine (CG-354) obtained from
Aconitum orochryseum Stapf. and Corydalis gerdae Fedde were sent for antibacterial
assay at the Amrad Corporation Laboratories, Melbourne using the antibacterial
screening methodology described in Chapter 9. All the samples were prepared in
DMSO (2.5%) solution. The crude plant extracts and the alkaloids were tested against
Staphylococcus aureus and all these samples showed very weak activity against this
bacterium with MIC values greater than 125 µg/ml. Atisinium chloride and orochrine
were tested against vancomycin-resistant and vancomycin sensitive Enterococcus
faecium. These alkaloids were also found to be essentially inactive against this
bacterium with similar MIC values (>125 µg/ml).
Antibacterial tests could not be conducted on the other alkaloids isolated in this project
since they were available in very small quantities. However, from the results obtained,
antibacterially active components did not appear to be present in Aconitum
orochryseum or Corydalis gerdae, at least for Gram-positive bacteria.
7.3

Assays for Detecting Antimalarial Activity

Different types of antimalarial test methods like biochemical and molecular techniques,
colorimetric enzyme assays, flow cytometry, and micro-dilution assays, have been
developed over the past years259. The colorimetric enzyme assay which was described
by Basco et al. is based on the measurement (using spectrophotometry)260 of the
activity of the enzyme lactate dehydrogenase in living Plasmodium falciparum and
Plasmodium ovale. A semi-automated micro-dilution assay261 involves the inhibition of
uptake of a nucleic acid precursor, 3[H]-hypoxanthine, in to the malarial protozoa. A
modified form of this method was used in this study.
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A simple and reproducible method has also been described by Pandey et al and
modified micro-dilution assay methods has been routinely used in the identification of
potential antimalarial compounds54.

7.3.1

Results of Antimalarial Testing

The pharmacopeia of Bhutanese Traditional Medicine (gSo-ba rig-pa) had indicated
Corydalis gerdae for the treatment of malaria and Aconitum orochryseum for treating
infections, snake bites and high fever arising from blood poisoning, cold and flu, bile
inflammation and malaria105. Based on this ethno-medical information, in vitro
antimalarial activity testing against Plasmodium falciparum, for both an antifolate
sensitive strain (TM4) and an antifolate resistant strain (K1) was performed on the
crude methanol plant extracts, crude alkaloids and the major alkaloids of these two
plants.
The methanol extracts, crude alkaloids and the major alkaloids (protopine and atisinium
chloride) of these two plants were found to be active against both strains of
Plasmodium falciparum. Comparably, Corydalis gerdae was found to possess active
antimalarial compounds. The methanol extract (CG-ME) of this plant (Corydalis
gerdae) inhibited the TM4 strain with an IC50 value of 1.00 µg/ml and the K1 strain
with an IC50 value of 2.56 µg/ml. The inhibitory activity of the crude alkaloid (CGCEA) of the same plant increased significantly with IC50 values of 0.33 µg/ml for the
TM4 strain and 0.63 µg/ml for the K1 strain. However, decreased antimalarial activities
of the alkaloids, protopine and cheilanthifoline, were observed. Protopine inhibited the
TM4 strain with an IC50 value of 4.25 µM (1.50 µg/ml) and the K1 strain with an IC50
value of 4.29 µM (1.51 µg/ml). Cheilanthifoline inhibited the TM4 strain and the K1
strain with IC50 values of 2.78 µM (0.90 µg/ml) and 3.76 µM (1.22 µg/ml) respectively.
This suggested perhaps that a minor alkaloid was responsible for the high activity
exhibited by the crude alkaloid extract. The high activity of this extract could also be
due to the synergistic effects of the total range of alkaloids present.
The methanol extract of Aconitum orochryseum inhibited the TM4 strain with an IC50
value of >10 µg/ml and the K1 strain with an IC50 value of >10 µg/ml. The crude
alkaloid extract showed increased antimalarial levels and inhibited the TM4 strain with
an IC50 value of 20.4 µg/ml and the K1 strain with an IC50 value of 19.2 µg/ml. The
antimalarial activity very significantly increased for the pure alkaloid atisinium
chloride (the major alkaloid of the plant). This alkaloid inhibited the K1 Strain with an
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IC50 value of 3.59 µM (1.35 µg/ml) and the TM4 Strain with an IC50 value of 4.02 µM
(1.51 µg/ml). Though atisinium chloride was reported previously, no antimalarial
testing has been done before on this alkaloid. Thus, from the above antimalarial assay
results, it was evident that these two plants, Aconitum orochryseum and Corydalis
gerdae contain bioactive alkaloids which are potential antimalarial drug leads.
The antimalarial assay was not done for the rest of the alkaloids isolated from these two
plants since their quantities were too small. It would be worthwhile to synthesise the
new alkaloids and test them for malaria along with the known alkaloids isolated from
Corydalis gerdae. The high activity of the crude alkaloid of Corydalis gerdae could be
either due to scoulerine or stylopine, which was not tested. It was also possible that
some minor alkaloids were responsible for the high activity of this crude alkaloid
mixture or all the alkaloids present in the mixture might have acted synergistically to
bring in that high activity against K1 and TM4 strains. Alkaloids from Aconitum
orochryseum could also possibly have antiviral activities since the plant was indicated
ethno-medically for treating cold and flu.
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Chapter 8
Conclusions and Future Directions
8.1

Conclusions

Infectious diseases like HIV-AIDS, tuberculosis, malaria and other viral and bacterial
infections are claiming millions of lives every year. These diseases will continue to be
leading causes of death unless researchers find a concrete arsenal of drugs to combat
them. One approach is to search for such new drugs from natural sources. Bhutan is one
of the countries that is rich in biodiversity as well as being rich in traditional medical
knowledge. It thus has the potential to contribute towards discovering natural productbased drugs.
Systematic natural product screening should be based on appropriate search strategies
for efficient drug discovery. Since Bhutan has a reservoir of ethno-medical knowledge,
the “ethno-directed biorational approach” provided such a strategy in combination with
a chemo-directed approach based on alkaloids. The author has successfully engaged
this joint strategy for this study in which plant selection was directed by the traditional
medicine of Bhutan used for antibacterial or antimalarial treatments (ethno-directed
biorational approach) and the presence of alkaloids in these plants (chemo-directed
approach).
The alkaloids from six selected plants were investigated. From Aconitum orochryseum
Stapf., eleven alkaloids were isolated. Three of these were identified as new diterpenoid
alkaloids and were named as orochrine, 2-O-acetylorochrine and lingshinaline. The
crude methanol extract (AO-ME), crude alkaloid mixture (AO-CA), and the alkaloids
atisinium chloride (AO-344, major alkaloid) and orochrine (AO-342) were inactive
against the Gram-positive human pathogenic bacteria Staphylococcus aureus and
Enterococcus faecium. However, in vitro activity was seen against the malarial
protozoan Plasmodium falciparum (strains TM4 and K1, see Table 24 for the
summarized results). Atisinium chloride gave the highest antimalarial activity among
the analytes obtained from this plant. Although this alkaloid had been isolated
previously from other species in the genus Aconitum, it had not been tested against
malaria. Atisinium chloride thus provides a new anti-malarial drug lead. The other
alkaloids (orochrine, 2-O-acetylorochrine, lingshinaline, virescenine and unidentified
alkaloids) isolated from Aconitum orochryseum could also have similar activity, but
due to the small quantities obtained, it was not possible to conduct an antibacterial
assay and antimalarial assay on these alkaloids.
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Table 24. The summary of the results of alkaloid investigation of the plants

Plants

Alkaloids

Antibacterial activity

Antimalarial activity

(IC50 in µM)

(IC50 in µM or µg/ml)

Staph.

VRE

TM4 strain

K1 strain

Aconitum

Methanol extract (AO-ME)

>125

N/T

>10 µg/ml

>10 µg/ml

orochryseum

Crude alkaloid (AO-CA)

>125

N/T

20.4 µg/ml

19.2 µg/ml

Stapf.

Atisinium chloride

>125

>125

4.02 µM

3.59 µM

1.51 µg/ml

1.35 µg/ml

Orochrine

>125

>125

N/T

N/T

2-O-acetylorochrine

N/T

N/T

N/T

N/T

Lingshinaline

N/T

N/T

N/T

N/T

Virescenine

N/T

N/T

N/T

N/T

AO-330

N/T

N/T

N/T

N/T

AO-340

N/T

N/T

N/T

N/T

AO-358

N/T

N/T

N/T

N/T

AO-372

N/T

N/T

N/T

N/T

AO-414

N/T

N/T

N/T

N/T

AO-465

N/T

N/T

N/T

N/T

Corydalis

Methanol extract (CG-ME)

>125

N/T

1.00 µg/ml

2.56 µg/ml

gerdae

Crude alkaloid (CG-CA)

>125

N/T

0.33 µg/ml

0.63 µg/ml

Fedde.

Protopine

>125

>125

4.25 µM

4.29 µM

1.50 µg/ml

1.51 µg/ml

2.78 µM

3.76 µM

0.90 µg/ml

1.22 µg/ml

Cheilanthifoline

N/T

N/T

Scoulerine

N/T

N/T

N/T

N/T

Stylopine

N/T

N/T

N/T

N/T

CG-337

N/T

N/T

N/T

N/T

Staph. = Staphylococcus aureus, VRE = Vancomycin Resistant Enterococcus faecium, Red = new
alkaloid, Green = known alkaloids, Blue = unidentified, N/T = not tested

From the plant Corydalis gerdae Fedde four known alkaloids, namely protopine (major
alkaloid), scoulerine, cheilanthifoline and stylopine were obtained, together with one
unidentified alkaloid. The crude methanol extract (CG-ME), crude alkaloid mixture
(CG-CA) and the alkaloids protopine and cheilanthifoline were analysed for in vitro
antimalarial activity. These analytes gave interesting and promising antimalarial
activity results as summarised in Table 24. The inhibitory activity was highest in the
case of the crude alkaloid mixture (CG-CA), possibly due to a highly active minor
alkaloid. It could be also due to synergistic effects amongst the alkaloids present in the
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mixture. The protopine (major alkaloid) and cheilanthifoline also showed significant
activity in this assay.
The extracts and isolates of Corydalis gerdae showed better antimalarial activity than
those of Aconitum orochryseum. These results substantiated for the first time at the
molecular level the ethno-medical use of these plants in anti-malarial treatment.
Ranunculus brotherusi failed to yield any alkaloids although a preliminary test on the
plant gave a positive test for alkaloids. Similarly, Tribulus terrestris also failed to yield
any alkaloids. Ranunculus brotherusi had not been studied previously. Many βcarboline alkaloids like harman, harmine, norharman and harmaline had been isolated
from Tribulus terrestris in past work. Thus, it was concluded that these plant materials
were either collected at the wrong time or their alkaloids could have been lost on
drying.

8.2

Future directions

Since the extracts and the alkaloids of Aconitum orochryseum and Corydalis gerdae
were found potentially active against Plasmodium falciparum strains, the immediate
follow up work should be focused on doing antimicrobial assays with the other minor
alkaloids present in these plants. In doing so, large scale extraction would be needed to
get a reasonable amount of the minor alkaloids, especially from Corydalis gerdae
because the crude alkaloid of this plant showed highest inhibitory activity (Table 24).
Since the high activity of this crude alkaloid (Corydalis gerdae) could also be due to
synergistic effects of total alkaloids (protopine, scoulerine, cheilanthifoline and
stylopine) present in the crude extract, the antimalarial testing should be done on
various mixtures of commercially available alkaloids (protopine, scoulerine,
cheilanthifoline and stylopine) so as to find out if the activity of the crude alkaloid was
because of synergistic effects.
The six unidentified alkaloids of Aconitum orochryseum require further study and
further bulk extraction of the plant material will be needed in order to obtain sufficient
quantities for their structure elucidation and the evaluation of antimicrobial activities.
Modifying the structures of the new alkaloids as well as of the known alkaloids
(atisinium chloride, virescenine, protopine, scoulerine, cheilanthifoline and stylopine)
which were active against Plasmodium falciparum could improve their antimalarial
activities. This could lead ultimately to the development of candidates for new
antimalarial drugs.
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Since Aconitum orochryseum is traditionally used against colds, influenza and other
microbial infections, it would also be worthwhile undertaking antifungal and antiviral
(like SARS and HIV) testing on the alkaloids from this plant. The non-alkaloidal
components of the plants studied here may be bioactive or at least could also be acting
synergistically with the alkaloids. They should thus also be purified, identified and
tested for bioactivity in the future.
The results obtained in this study indicate that the combined ethno-medical-alkaloid
search strategy is an efficient and direct one for locating potential new drug leads. The
application of the strategy to other medicinal plants in Bhutan should thus be
investigated. The chemical and pharmacological investigation of traditional Bhutanese
drugs should be pursued in the long term. Such steps would mean a way forward in
meeting the WHO standards for such drugs and, most significantly, in providing
patients with better herbal medicines.
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Chapter 9
Experimental Section
9.1
9.1.1.

Equipment and Chemical Specifications
Equipment

Preparative thin layer chromatography plates were made using Merck Kieselgel 60
PF254 on glass plates (0.3 mm thickness, 20 × 20 cm). Pre-made silica plates with
aluminium backing (0.2 mm thickness) supplied by Merck were used for separating
smaller quantities of isolates. Visualization of the separated bands on preparative TLC
plates was done using short and long wave UV light. Normal pH paper was used for
determining the pH of the extracts and the solutions. Extracting funnels were used for
the liquid-liquid separations and sintered glass funnels were used for filtration. A Büchi
Rotary Evaporator with a high vacuum pump was used for evaporation of solvents
under reduced pressure at 40oC. Nitrogen gas was used for evaporation of smaller
quantities of solvents.
Chemical ionisation mass spectra (LRCIMS) were obtained on a Shimadzu QP-5000
(isobutane as the carrier gas) spectrometer by the direct insertion technique. Electron
impact mass spectra (at 70 eV) were also obtained on a Shimadzu QP-5000
spectrometer. HRCIMS were run on a Fison/VG Autospec oa-TOF Mass Spectrometer
(methane as the carrier gas). Electrospray (ES) mass spectroscopy was performed on a
Micro-mass Q-Tof-2TM with acetonitrile as solvent. Gas Chromatographic Mass
Spectrometric (GCMS) analysis was conducted using a QP-5000 Shimadzu
Spectrometer and VG Autospec (Fisons Instrument) Spectrometer. For the NMR
spectra, one dimensional experiments like 1H-NMR, gCOSY,

13

C-NMR (at 75.42

MHz), DEPT and NOESY and two dimensional experiments like gHSQC, gHMBC and
TOCSY were obtained using a Nanoprobe on a Varian Unity Inova-500 MHz NMR
Spectrometer unless otherwise stated.
The melting points were determined using a Reichert hot stage apparatus and were
corrected. Melting points were corrected using the 2-benzoylbenzoic acid (m.p.126129oC) as a standard. The Optical Rotations were measured with a Jasco Dip-370
Digital Polarimeter with a sodium lamp. The specific rotation was calculated by using
the equation: [α] D = α/l.c. where, α = observed rotation at temperature to Celsius, l =
t

length of polarimeter cell (dm), and c = concentration of sample (g/100ml). An average
of ten optical rotation readings was taken for the rotation α-value.
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9.1.2.

Chemicals and solvents

All the solvents were AR (analytical reagent) grade or distilled. DCM, chloroform and
methanol were the main solvents used in carrying out the experiments. Deuterated
chloroform, methanol, acetone, and acetonitrile were used as NMR solvents. Ethanol,
diethyl ether, ethyl acetate, acetone and butanol were used for crystallizations unless
otherwise stated. Methanol (10% v/v) in dichloromethane was used as the solvent for
dissolving, loading and recovering extracts or compounds from the silica on preparative
TLC plates. Sodium sulfate was used for drying traces of water in the separated organic
solvents. Sodium carbonate (20% w/v) and potassium hydroxide (10% w/v) were used
for the basification of the aqueous plant extracts to a pH of 8-11. Sulfuric acid (0.1 M
to 1 M) was used for acidification. To improve separation and overcome tailing of
alkaloids on TLC, concentrated aqueous ammonia (28%, 6 drops and 1 ml) was added
in the TLC solvent system.

9.2

Detection Methods and Spray Reagent

Dragendorff’s reagent and Mayer’s reagent were used for the detection of alkaloids in
the plant extracts. Mayer’s reagent was prepared by dissolving mercuric chloride (1.4
g) and potassium iodide (5 g) in water (100 ml).
Dragendorff’s reagent (Munier and Mache-boeuf)262 was prepared as follows:
a. Bismuth subnitrate (2.5 g) was dissolved in a solution of
water (20 ml) and glacial acetic acid (5 ml).
b. Potassium iodide (4 g) was dissolved in water (10 ml).
Solution a and b were then mixed together and stored as the stock solution. The spray
reagent was prepared by mixing the stock solution (5 ml) with glacial acetic acid
(10ml) and water (85 ml). On TLC plates, alkaloids gave an orange-red colouration
with this spray reagent.

9.3

Collection of Plant Material

Six medicinal plants: Aconitum orochryseum (Ranunculaceae), Aletris pauciflora
(Liliaceae), Codonopsis bhutanica (Campanulaceae), Corydalis gerdae (Fumariaceae),
Ranunculus brotherusi (Ranunculaceae) and Tribulus terrestris (Zygophyllaceae) were
selected for the study. The first five medicinal plants were collected from Lingshi
Dungkhag (Bhutan) in June and August 2002 (see Chapter 2, Table 8). They were airdried at room temperature in the drying unit at Lingshi and were then transported to the
Pharmaceutical and Research Unit (Bhutan). The herbarium was maintained and stored
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in the Research Unit with appropriate labelling including herbarium numbers (see
Chapter 2, Table 8).
The preliminary test for alkaloids was done in the Pharmaceutical and Research
laboratory in Bhutan following the Culvenor and Fitzgerald method106. A mortar and
pestle was used for grounding plant material (10 g) with acid-washed sand.
Dichloromethane (15 ml) and concentrated aqueous ammonia (5 drops) was then added
to the ground material and stirred for 5 minutes. The mixture was filtered. The filtrate
was acidified with 1 Molar H2SO4 (1 ml), shaken thoroughly and then allowed to stand
for 30 minutes to effect good phase separation. A portion of the aqueous layer (5 drops)
was transferred into a small petri dish. When the Mayer’s reagent (K2HgI4) was added,
the solution turned milky with the alkaloid salt precipitate. The turbidity varied from
plant to plant depending on the percentage of alkaloid content in that plant.
Since two of the plant extracts from Codonopsis bhutanica and Aletris pauciflora were
damaged on transportation to Australia and a Ranunculus brotherusi didn’t give any
alkaloids, a locally available plant Tribulus terrestris, which caused neurotoxicity in
sheep, was selected for the study. This plant is also used in Bhutanese traditional
medicine. The air-dried (room temperature) plant material (stem, leaves, flowers and
fruits, approx. 8 kg) which has been coarse chopped following drying using a petrol
driven plant mulching machine, was supplied by Dr. C.Bourke, NSW Agriculture,
Orange, NSW. It was collected near Wellington (Central West, NSW) in February 2002
(Chapter 2, Table 8).

9.4

General Procedure for Extraction and Isolation of Alkaloids.

The alcoholic extraction method was applied to all the selected plants. The plant
material (1 kg) was chopped into small pieces. The material was then soaked overnight
in methanol (Analytical Grade). The methanol extract was filtered and the process was
repeated four times (over 4 days) to ensure no alkaloids were remained in the residues.
All the extracts obtained in each set were combined. The methanol was then removed
by rotary evaporation. The dried methanol extracts obtained from each plant were then
packed in glass bottles (250 ml) and then brought to Australia. The residues from the
methanol extracts were air dried and stored with proper labelling for future reference.
The extracts were kept refrigerated and away from light (wrapping with aluminium
foil) prior to further processing.
Sequential extractions and isolations were done following the schematic procedures
outlined in Scheme 3. The solvents in the filtrates were evaporated under reduced
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pressure and the crude alkaloids were obtained. The crude alkaloids were then
separated using Preparative Thin Layer Chromatography on silica gel.

Chopped plant material (1 kg)
 Soaked in Methanol (4× 17 hrs)
 Filtered

Filtrate (MeOH extract)
 Evaporated MeOH at 40o C

Residues
 Dried and stored

 Acidified with 0.1M H2SO4
 Extracted with CHCl3 (3 × 60 ml)

Organic phase I
 Neutral and acidic
materials (stored)

Tested for
alkaloids with
Mayer’s reagent

Aqueous phase I

 Basified with 20% Na2CO3 to pH 9/10
 Extracted with CHCl3 (3 × 60ml)

Organic phase II
 Washed with H2O
 Dried with Na2SO4
 CHCl3 evaporated at 40o C
Crude alkaloids

Aqueous phase II
 Water soluble
materials

 Tested for alkaloids with
Dragendorff’s reagent

 Separated and purified using PTLC
 NMR and identification of alkaloids
Pure alkaloids

Antimicrobial assays (Antibacterial and Antimalarial testing)

Scheme 3. Outline of the alkaloid separation procedure carried out for the selected medicinal
plants of Bhutan and the sources of materials used in the antimicrobial assays.
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The alkaloids were recovered from the silica gel as soon as the preparative plate TLC
separation was complete to prevent decomposition. The alkaloids were also kept for
minimal time in solution in order to avoid reaction and formation of artefacts. The
appropriate developing solvent system was determined by manipulating the ratios of
the mixture of different solvents, mainly dichloromethane, chloroform and methanol.
The TLC separation yielded different fractions of compounds with different polarities.
Each fraction was tested for purity using TLC, MS and 1H-NMR analysis. The process
of TLC separation and purification was repeated for each fraction till pure compounds
were isolated. Concentrated aqueous ammonia solution (28%, 6 drops to 1 ml) was
used to prevent tailing in the TLC separation. However, the merging of bands on silica
plates occurred when compounds with closer Rf values were present together.

9.5

Purification and Structure Elucidation of Alkaloids from Aconitum
orochryseum Stapf.

A methanol extract (101.65 g) was obtained from the dried plant material (1 kg) and a
reference sample (26.21 g of this extract) was kept refrigerated. A portion of this
reference material (20 mg) was used for antimicrobial testing (Scheme 3). The
remaining crude methanol extract was extracted for alkaloids using the general
schematic isolation and extraction procedure (Scheme 3). Crude alkaloid (0.561 g) was
obtained. Again this crude alkaloid (51 mg) was tested for antimicrobial activity. The
LRCIMS of the crude alkaloid revealed ion peaks at m/z 344, 342, 384, 400, 358, 424,
440, 406, 314, 448/466 and 298. The ion peak at m/z 344 was the major component.
Focussing on these individual peaks, preparative plate separations were conducted.
All the crude alkaloid (494.0 mg) was dissolved in MeOH (10%): DCM (90%) solvent
and was loaded on PTLC plates (65 g × 8 plates). An appropriate mobile phase was
developed using DCM (89%): MeOH (10%): Ammonia solution (28%, 1 ml). Eleven
fractions/bands were obtained and each band was monitored using the LRCIMS peaks
(Table 25). Each band contained a mixture of compounds. All the fractions/bands
containing similar mass peaks and with the same Rf values were grouped together as in
Table 25 and were further purified by development in an appropriate solvent system
and the process was repeated until pure compounds were obtained.
Group 1 was purified by PTLC on silica gel in DCM (85%): MeOH (14%) : Ammonia
solution (28%, 1 ml). This gave two fractions. Fraction one (AO-gr-1-1) contained a
LRCIMS peak at m/z 344 (MH+), and gave crystals when it was recovered from the
silica. It was recrystallized from methanol/diethyl ether and fine needle-like crystals
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(16.9 mg) were obtained. A crystal was sent for X-ray crystallography and was
identified as atisinium chloride.

Table 25. Bands separated from the crude alkaloid of Aconitum orochryseum
Bands

Net wt.

Peaks present (LRMS-CI, m/z)

(in mg)

Major peaks in

Inferences

the fractions (m/z)

1

61.7

326, 344, 342, 424, 358, 400

326, 344, 342

Band 1, 2, 3 and 4

2

24.1

400, 342, 456, 384

400, 342

formed group 1

3

20.2

384, 342, 400, 440

384, 342

4

16.3

400, 406, 424, 342, 456, 384

400, 424

5

21.8

384, 406, 424, 358, 448, 466, 390

384

Band

6

20.3

384, 448, 466, 358

384

formed group 2

7

31.9

358, 374, 448, 466, 179

358

Band 7, 8, 9, 10

8

26.7

432, 358, 450, 374

432, 358

and

9

38.1

358

358

group 3

10

18.6

358, 303

358

11

16.9

358, 257, 303

358, 257, 303

5

11

and

6

formed

The second fraction (Ao-gr-1-2) still contained a mixture of compounds. Further
separation by PTLC on silica gel using DCM (89%): MeOH (10%): Ammonia solution
(28%, 1 ml) resulted in the isolation of three compounds: orochrine (LRCIMS peak at
m/z 342), Ao-372 (LRCIMS peak at m/z 372), 2-O-acetylorochrine (LRCIMS peak at
m/z 384) and lingshinaline (LRCIMS peak at m/z 400). Recrystallization from several
solvents was attempted on each of these fractions. However, only orochrine gave fine
small crystals (14.9 mg) from acetone/diethyl ether but the crystals were not big
enough to determine the structure by X-ray crystallography. This was then sent for
synchrotron X-ray crystallography in the USA. Unfortunately, no results were available
at the time of completing this thesis. Crystallization was also attempted on the Group 2
and Group 3 fractions using acetone/diethyl ether but they failed to crystallise.
Group 2 was then purified by PTLC on silica gel with MeOH (8%): CHCl3 (91%):
Ammonia solution (28%, 1 ml) as the developing solvent. This resulted in the isolation
of another alkaloid, virescenine (LRCIMS peak at m/z 424).
Group 3 was also subjected to PTLC on silica gel in DCM (95%): MeOH (5%):
Ammonia solution (28%, 10 drops). This group yielded the minor alkaloids designated
as AO-358, AO-414, AO-372, AO-466, AO-340, and AO-330 (Table 26). The final
NMR spectra were obtained using a Nanoprobe for all of the five major alkaloids. Due
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to very small quantities of sample, it was impossible to obtain useful NMR data for the
minor alkaloids like AO-330, AO-358, AO-372, AO-372, AO-414 and AO-466.

Table 26. Alkaloids isolated from each fractions using discrete solvent system.
No.

Alkaloid

MW

Molecular

Wt.

formula

(mg)

PTLC solvent system

1

Orochrine

341

C21H27NO3

14.9

10% MeOH:89% DCM:1% NH3

2

Atisinium chloride

343

C22H33NO2

16.9

85% DCM:14% MeOH:1% NH3

3

2-O-acetylorochrine

383

C23H29NO4

5.2

8% MeOH: 91% CHCl3:1% NH3

4

Lingshinaline

399

C 23H29NO5

8.1

10% MeOH: 89%DCM: 1%NH3

5

Virescenine

423

C23H37NO6

4.6

6% MeOH: 93% DCM:1% NH3

6

AO-330

329

C20H27NO3

1.8

10% MeOH:89% DCM:1% NH3

7

AO-340

339

C21H25NO3

1.9

10% MeOH:89% DCM:1% NH3

8

AO-358

357

C22H31NO3

2.9

97% DCM:2% MeOH:1% NH3

9

AO-372

371

C21H25NO5

2.1

10% MeOH:89% DCM:1% NH3

10

AO-414

413

C23H27NO6

2.2

6% MeOH:93% DCM:1% NH3

11

AO-466

465

C25H39NO7

3.6

10% MeOH:89% DCM:1% NH3
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22 Orochrine
Orochrine 22: Colourless crystals (needles); m.p. 210.1-213.6oC; [α]D23 = ─ 65 (c, 0.62
in MeOH); 1H-NMR (CD3OD, 500 MHz, Nanoprobe), δ 2.90 (s, 3H, N-Me), δ 5.04
and δ 4.94 (bs, 1H each, H-17 exocyclic methylene), δ 4.14 (bs, 1H, H-2β), δ 1.48 (s,
3H, H-18 methyl), δ 1.59 (d, 1H, H-1, J = 15 Hz), δ 1.75 (d, 1H, H-1, J =15 Hz), δ 1.60
(d, 1H, H-3, J =15 Hz), δ 1.93 (t, 1H, H-3, J =15 Hz), δ 2.15 (s, 1H, H-5), δ 2.23 (d,
1H, H-7, J =12.5 Hz), δ 2.31 (d, 1H, H-7, J =15 Hz), δ 2.20 (s, 1H, H-9), δ 1.86 (d, 1H,
H-11, J =14 Hz), δ 2.03 (d, 1H, H-11, J =14.5 Hz), δ 2.97 (bs, 1H, H-12), δ 2.98 (bs,
1H, H-14), δ 2.52 (d, 1H, H-15, J =17.5 Hz), δ 2.69 (d, 1H, H-15, J =17 Hz), δ 3.35 (d,
1H, H-19, J =11.5 Hz), δ 4.30 (d, 1H, H-19, J =11.5 Hz) and δ 4.27 (s, 1H, H-20).
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C-NMR (CD3OD, 500 MHz, Nanoprobe), δ 34.5 (C-1), δ 65.5 (α-OH, C-2), δ 41.4

(C-3), δ 36.6 (C-4), δ 59.1 (C-5), δ 106.2 (C-6), δ 38.2 (C-7), δ 43.9 (C-8), δ 49.4 (C9), δ 47.4 (C-10), δ 23.3 (C-11), δ 53.5 (C-12), δ 208.7 (C-13), δ 56.3 (C-14), δ 32.6
(C-15), δ 142.6 (C-16), δ 112.3 (Exocyclic methylene, C-17), δ 30.3 (Me, C-18), δ 70.5
(C-19), δ 75.1 (C-20), δ 37.3 (N-Me, C-21).
gHSQC

(CD3OD, 500 MHz, Nanoprobe), δ 1.59 (d) & δ 1.75 (d)/ δ 34.5 (C-1), δ 4.14

(bs, H-2β)/δ 65.5 (C-2), δ 1.60 (d) & δ 1.93 (t)/ δ 41.4 (C-3), δ 2.15 (s)/ δ 59.1 (C-5), δ
2.23 (d) & δ 2.31 (d)/ δ 38.2 (C-7), δ 2.20 (s)/ δ 49.4 (C-9), δ 1.86 (d) & δ 2.03 (d)/ δ
23.3 (C-11), δ 2.97 (bs)/ δ 53.5 (C-12), δ 2.98 (bs)/ δ 56.3 (C-14), δ 2.52 (d) & δ 2.69
(d)/ δ 32.6 (C-15), δ 5.04 (bs) & δ 4.94 (bs)/ δ 112.3 (C-17), δ 1.43 (s)/ δ 30.3 (C-18),
δ 3.35 (d) & δ 4.30 (d)/ δ 70.5 (C-19), δ 4.27 (s)/ δ 75.1 (C-20), δ 2.90 (s)/ δ 37.3 (C21).
gHMBC

(CD3OD, 500MHz, Nanoprobe), δC to δH, C-1/H-20; C-2/H-1, H-3; C-3/H-

1, H-18, H19; C-4/H-3, H-18, H-19; C-5/H-1, H-3, H-7, H-15, H-20; C-6/H-7, H-9, H19, H-20, H-21; C-8/H-7, H-11, H-15, H-20; C-9/H-5, H-7, H-15, H-20; C-10/ H-1, H3, H-11, H-12, H-14, H-20; C-12/H-9, H-11, H-15, H-17; C-13/H-11, H-12, H-14, H20; C-14/H-7, H-12, H-15, H-19, H-20; C-15/H-12, H-14, H-17; C-16/H-11, H-12, H14, H-15; C-17/H-12, H-15; C-18/H-3, H-5, H-19; C-19/H-3, H-5, H-18, H-20, H-21;
C-20/H-1, H-2, H-5, H-9, H-12, H-14, H-19, H-21; C-21 (N-Me)/H-19.
δH to δC, H-1/C-2, C-3, C-4, C-5, C-10, C-20; H-2/C-20; H-3/C-1, C-2, C-4, C-5, C10, C-18; H-5/C-9, C-18, C-19, C-20; H-7/C-5, C-6, C-8, C-9, C-11, C-14, C-15, C-20;
H-9/C-5, C-6, C-8, C-10, C-11, C-12, C-14, C-20; H-11/C-8, C-9, C-10, C-12, C-13,
C-16; H-12/C-13, C-14, C-15, C-16, C-17; H-14/C-9, C-13, C-15, C-16, C-20; H15/C-7, C-8, C-9, C-12, C-14, C-16, C-17; H-17/C-12, C-15, C-16 (w); H-18/C-3, C-4,
C-5, C-19; H-19/C-3, C-4 (w), C-5 (w), C-6, C-14, C-18, C-20, C-21; H-20/C-1, C-4
(w), C-6, C-8, C-9, C-10 (w), C-13, C-14, C-19; H-21/C-6, C-19, C-20.
LRCIMS, m/z 342 (MH+); LREIMS, m/z 341 (M+), 326, 313, 298, 282, 254, 192, 173,
157, 136, 122, 105, 91, 84, 55 and 44 (100%); HREIMS, C21H27NO3 (M+, measured
341.1974, calc.341.1990).
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25 2-O-acetylorochrine

2-O-Acetylorochrine 25: Amorphous solid; m.p. 148.3-150.1o C; [α]D22 = ─82.47 (c,
0.82 in CHCl3). 1H-NMR (CD3OD, 500 MHz, Nanoprobe), δ 2.91 (s, 3H, N-Me), δ
4.86 and δ 4.95 (bs, 1H each, H-17 exocyclic methylene), δ 5.11 (bs, 1H, H-2β), δ 1.43
(s, 3H, H-18 methyl), δ 1.65 (d, 2H, H-1, J =17.5 Hz), δ 1.66 (d, 1H, H-3, J =15.5 Hz),
δ 1.92 (d, 1H, H-3, J =16 Hz), δ 2.17 (s, 1H, H-5), δ 2.23 (d, 1H, H-7, J =14.5 Hz), δ
2.27 (d, 1H, H-7, J =14.5 Hz), δ 2.17 (s, 1H, H-9), δ 1.84 (m, 2H, H-11, J =3.5 Hz), δ
2.89 (d, 1H, H-12, J = 3.5 Hz), δ 2.97 (d, 1H, H-14, J = 2Hz), δ 2.47 (d, 1H, H-15, J
=17 Hz), δ 2.62 (d, 1H, H-15, J =17.5 Hz), δ 3.37 (d, 1H, H-19, J = 12 Hz), δ 3.79 (d,
1H, H-19, J =12 Hz), δ 3.76 (s, 1H, H-20), δ 2.06 (s, 3H, H-23/CH3COO).
13

C-NMR (CD3OD, 500MHz, Nanoprobe), δ 31.6 (C-1), δ 69.0 (α-acetyl, C-2), δ 38.5

(C-3), δ 36.5 (C-4), δ 58.5 (C-5), δ 106.6 (C-6), δ 38.0 (C-7), δ 44.2 (C-8), δ 49.3 (C9), δ 47.4 (C-10), δ 23.3 (C-11), δ 53.3 (C-12), δ 208.7 (C-13), δ 56.2 (C-14), δ 32.4
(C-15), δ 142.3 (C-16), δ 112.4 (Exocyclic methylene, C-17), δ 30.1 (Me, C-18), δ 70.5
(C-19), δ 75.1 (C-20), δ 37.3 (N-Me, C-21), δ 171.3 (C-22, COOCH3), δ 21.3 (C-23,
COOCH3).
gHSQC

(CD3OD, 500 MHz, Nanoprobe), δ 1.65 (d)/ δ 31.6 (C-1), δ 5.11 (bs, H-2β)/δ

69.0 (C-2), δ 1.66 (d) & δ 1.92 (d)/ δ 38.5 (C-3), δ 2.17 (s)/ δ 58.5 (C-5), δ 2.23 (d) & δ
2.27 (d)/ δ 38.0 (C-7), δ 2.17 (s)/ δ 49.3 (C-9), δ 1.84 (m)/ δ 23.3 (C-11), δ 2.89 (d)/ δ
53.3 (C-12), δ 2.97 (d)/ δ 56.2 (C-14), δ 2.47 (d) & δ 2.62 (d)/ δ 32.4 (C-15), δ 4.86
(bs) & δ 4.95 (bs)/ δ 112.4 (C-17), δ 1.43 (s)/ δ 30.1 (C-18), δ 3.37 (d) & δ 3.79 (d)/ δ
70.5 (C-19), δ 3.76(s)/ δ 75.1 (C-20), δ 2.90 (s)/ δ 37.3 (C-21), δ 2.06(s)/ δ 21.3 (C-23,
CH3COO).
gHMBC

(CD3OD, 500 MHz, Nanoprobe), δC to δH, C-1/H-3, H-11(w), H-20; C-2/H-

1, H-3, H-18(w); C-3/H-1, H-19; C-4/H-1, H-3, H-18, H-19; C-5/H-1, H-3, H-7, H-9,
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H-18; C-6/H-5, H-7, H-19, H-20, H-21; C-7/H-9(w), H-15; C-8/H-7, H-9, H-11, H-15;
C-9/H-5, H-7, H-11, H-12, H-14, H-15, H-20; C-10/H-1, H-3, H-9 (w), H-11, H-14; C12/H-9, H-11, H-15, H-17; C-13/H-11, H-12, H-14, H-20; C-14/H-7, H-9, H-15, H-19
(w), H-20, H-21(w); C-15/H-7, H-12, H-17; C-16/H-11, H-15; C-17/H-12 (w), H-15;
C-18/H-1, H-3, H-5, H-19; C-19/H-3, H-5, H-18, H-20, H-21; C-20/H-1, H-5, H-14,
H-19, H-21; C-22/H-2, H-23 (CH3COO).
δH to δC, H-1/C-2, C-3, C-4, C-5, C-10, C-20; H-2/C-22; H-3/C-1, C-2, C-4, C-5, C10, C-18, C-19; H-5/C-7 (w), C-9 (w), C-14, C-18, C-19, C-20; H-7/C-5, C-6, C-8, C-9
(w), C-14, C-15 (w); H-9/C-5 (w), C-7 (w), C-12, C-14, C-20; H-11/C-1 (w), C-8(w),
C-9, C-10, C-12, C-13, C-16; H-12/C-9, C-13, C-14, C-15; H-14/C-9, C-10, C-13, C20; H-15/C-7 (w), C-8, C-9, C-12, C-14, C-16, C-17; H-17/C-12, C-15; H-18/C-3, C-4,
C-5, C-19; H-19/C-4, C-5, C-14(w), C-18, C-20; H-20/C-1, C-6, C-8, C-9 (w), C-13,
C-14 (w), C-19; H-21/C-6, C-19, C-20, H-23(CH3COO)/C-22.
LRCIMS, 384 (MH+); LREIMS, m/z 383 (M+), 368, 355, 340, 324, 296, 282, 268,
254, 226, 176, 174, 173, 148, 134, 122, 105, 91, 84, 70, 55, 44, 43; HREIMS,
C23H29NO4 (M+, measured 383.2085, calc.383.2096).
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26 Lingshinaline

Lingshinaline 26: Pale green solid; m.p. 110-112o C; [α]D25 = ─31.76 (c, 0.34 in
MeOH); 1H-NMR (500 MHz, Nanoprobe, CD3OD), δ 3.12 (s, 3H, N-Me), δ 4.92 and δ
5.00 (bs, 1H each, H-17 exocyclic methylene), δ 5.21 (s, 1H, H-2β), δ 1.52 (s, 3H, H18 methyl), δ 1.65 (d, 1H, H-1, J = 16.5 Hz), δ 1.74 (d, 1H, H-1, J =15.5 Hz), δ 1.65 (d,
1H, H-3, J =17 Hz), δ 1.93 (d, 1H, H-3, J =16.5 Hz), δ 2.15 (s, 1H, H-5), δ 4.35 (s, 1H,
H-7β), δ 2.20 (d, 1H, H-9, J = 7.5 Hz), δ 1.86 (d, 2H, H-11, J =6.5 Hz), δ 2.95 (d, 1H,
H-12), δ 3.00 (d, 1H, H-14), δ 2.48 (d, 1H, H-15, J =17.5 Hz), δ 2.96 (d, 1H, H-15, J
=17.5 Hz), δ 3.42 (d, 1H, H-19, J = 11.5 Hz), δ 3.61 (d, 1H, H-19, J =10 Hz), δ 3.63
(s, 1H, H-20), δ 2.01 (s, 3H, H-23, CH3COO).
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C-NMR (CD3OD, 500 MHz, Nanoprobe), δ 31.2 (C-1), δ 66.9 (α-acetyl, C-2), δ 37.9

(C-3), δ 35.9 (C-4), δ 55.8 (C-5), δ 105.7 (C-6), δ 71.7 (C-7), δ 45.3 (C-8), δ 46.7 (C9), δ 47.7 (C-10), δ 22.1 (C-11), δ 51.6 (C-12), δ 206.7 (C-13), δ 52.5 (C-14), δ 28.2
(C-15), δ 139.1 (C-16), δ 113.1 (exocyclic methylene, C-17), δ 29.7 (Me, C-18), δ 70.4
(C-19), δ 73.5 (C-20), δ 40.4 (N-Me, C-21), δ 169.1 (C-22, COOCH3), δ 21.4 (C-23,
CH3COO).
gHSQC

(CD3OD, 500 MHz, Nanoprobe), δ 1.65 (d) & δ 1.74 (d) /δ 31.6 (C-1), δ 5.21

(s, H-2β)/δ 66.9 (C-2), δ 1.65 (d) & δ 1.93 (d)/ δ 37.9 (C-3), δ 2.12 (s)/ δ 55.8 (C-5), δ
4.35(s)/ δ 71.7 (C-7), δ 2.20 (d)/ δ 46.7 (C-9), δ 1.86 (d)/ δ 22.1 (C-11), δ 2.95 (s)/ δ
51.6 (C-12), δ 3.00 (s)/ δ 52.5 (C-14), δ 2.48 (d) & δ 2.96 (d)/ δ 28.2 (C-15), δ 4.92
(bs) & δ 5 .00(bs)/ δ 113.1 (C-17), δ 1.52(s)/ δ 29.7 (C-18), δ 3.42 (d) & δ 3.61 (d)/ δ
70.4 (C-19), δ 3.63(s)/ δ 73.5 (C-20), δ 3.12 (s)/ δ 40.4 (C-21), δ 2.01(s)/ δ 21.4 (C-23,
CH3COO).
gHMBC

(CD3OD, 500 MHz, Nanoprobe), δC to δH, C-1/H-3, H-20; C-2/H-1, H-3, H-

18 (w), H-23 (-COOCH3, vw); C-3/H-1 (w), H-18, H-19; C-4/H-3, H-18, H-19; C5/H-1, H-3, H-18; C-6/H-20, H-21; C-7/H-21 (w), H-5 (w); C-8/H-1 (w), H-11, H-14;
C-9/H-5, H-11, H-12, H-14, H-15; C-10/H-7, H-20; C-12/ H-11, H-15 (w), H-17; C13/H-11, H-12, H-14, H-20; C-14/H-7, H-15; C-15/ H-7 (w), H-17; C-16/H-11, H-12,
H-15; C-17/H-12, H-15; C-18/H-5, H-19; C-19/H-5, H-18, H-20, H-21; C-20/H-5, H14, H-19, H-21, C-22(COOCH3)/H-23 (CH3COO).
δH to δC, H-1/C-2, C-3 (w), C-4, C-5, C-8 (w); H-3/C-1, C-2, C-4 (w), C-5; H-5/C-7,
C-9, C-18, C-19, C-20; H-7/C-10, C-14; H-11/C-8, C-9 (w), C-12 (w), C-13, C-16; H12/C-9, C-16, C-17; H-14/C-8, C-9, C-13, C-20; H-15/ C-9, C-14, C-16, C-17; H17/C-12, C-15; H-18/C-2, C-3, C-4, C-5, C-19 ; H-19/C-3, C-4, C-5, C-18, C-20, C-21
(N-Me, w); H-20/C-1, C-6, C-10, C-13, C-19 (w); H-21/C-6, C-7, C-19, C-20, H-23
(CH3COO)/C-22 (COOCH3), C-2(w).
LRCIMS, m/z 400 (MH+); LREIMS: m/z 399 (M+), 382, 370, 356, 340, 315, 312, 270
176, 174, 173, 148, 134, 122, 105, 91, 84, 55, 44, 43. HREIMS, C23H29NO5 (M+,
measured 399.2155, calc.399.2045).
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OH
OH
N

Et

OH
H

OH

MeO
27 Virescenine
Virescenine 27: Colourless crystals (needles); m.p. 76.7-79.8oC; [α]D26 = + 14.07 (c,
0.8 in MeOH); 1H-NMR (500 MHz, Nanoprobe, CDCl3), δ3.67 (s, 1H, H-1β), δ 1.45
and δ1.57 (q, 1H each, H-2), δ1.63 and δ1.82 (dd, 1H each, J = 5Hz, 6Hz, H-3), δ1.71
(t, 1H, J = 7 Hz, H-5), 1.54 and δ 2.26 (d, 1H each, H-6), δ2.15 (t, 1H, J=5.5, H-9),
δ1.76 (q, 1H, H-10), δ1.55 and δ1.97 (t, 1H each, H-12), δ 2.27 (m, 1H, H-13),δ4.17 (t,
1H, J=4.5 Hz, H-14β), δ1.73 and 2.89 (d, 2H, J=9.5Hz, H-15), δ3.37 (q, 1H, H-16),
δ2.83 (s, 1H, H-17), δ3.01 and δ3.16 (d, 1H each, J=9 Hz, H-18), δ2.49 and δ2.72 (d,
1H each, J=11Hz, H-19), δ2.95 and δ3.06 (q, 1H each, N-CH2-), δ1.08 (t, 3H, J=7.5
Hz, N-CH2CH3), δ3.28 (s, 3H, C-18OCH3), δ3.31 (s, 3H, C-16OCH3).
13

C-NMR (500 MHz, Nanoprobe, CDCl3), δ72.0 (C-1), δ28.7 (C-2), δ26.6 (C-3), δ37.6

(C-4), δ41.7 (C-5), δ33.3 (C-6), δ85.7 (C-7), δ76.0 (C-8), δ47.7 (C-9), δ43.3 (C-10) ,
δ49.3 (C-11), δ28.2 (C-12), δ39.4 (C13), δ75.3 (C-14), δ35.8 (C-15), δ81.5 (C-16),
δ65.2 (C-17), δ78.4 (C-18), δ55.7 (C-19), δ50.7 (NCH2-), δ13.4 (NCH2CH3), δ59.3 (C18OCH3), δ56.3 (C-16OCH3).
gHSQC (500 MHz, Nanoprobe, CDCl3), δ3.67 (s, 1H, H-1β)/δ72.0 (C-1), δ 1.45 and
δ1.57 (q, 1H each, H-2)/ δ28.7 (C-2), δ1.63 and δ1.82 (dd, 1H each, J = 5Hz, 6Hz, H3)/ δ26.6 (C-3), δ1.71 (t, 1H, J = 7 Hz, H-5)/ δ41.7 (C-5), δ1.54 and δ 2.26 (d, 1H each,
H-6)/ δ33.3 (C-6), δ2.15 (t, 1H, J=5.5, H-9)/ δ47.7 (C-9), δ1.76 (q, 1H, H-10)/ δ43.3
(C-10), δ1.55 and δ1.97 (t, 1H each, H-12)/δ28.2 (C-12), δ 2.27 (m, 1H, H-13)/ δ39.4
(C-13), δ4.17 (t, 1H, J=4.5 Hz, H-14β)/δ75.3 (C-14), δ1.73 and 2.89 (d, 2H, J=9.5Hz,
H-15)/ δ35.8 (C-15), δ3.37 (q, 1H, H-16)/ δ81.5 (C-16), δ2.83 (s, 1H, H-17)/ δ65.2 (C17), δ3.01 and δ3.16 (d, 1H each, J=9 Hz, H-18)/ δ78.4 (C-18), δ2.49 and δ2.72 (d, 1H
each, J=11Hz, H-19)/ δ55.7 (C-19), δ2.95 and δ3.06 (q, 1H each, N-CH2-)/δ50.7 (C20), δ1.08 (t, 3H, J=7.5 Hz, N-CH2CH3)/ δ13.4 (C-21), δ3.28 (s, 3H, C-18OCH3)/
δ59.3 (C-22), δ3.31 (s, 3H, C-16OCH3)/ δ56.3 (C-23).
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gHMBC (500 MHz, Nanoprobe, CDCl3), δC to δH, C1/H-3, H-5; C-2/H-3 (w); C3/H-1, H-18, H-19; C-4/H-3, H-5, H-6, H-18, H-19; C-5/H-6, H-10, H-17, H-18, H-19;
C-6/H-17; C-7/H-5, H-6, H-15; C-8/H-5, H-6, H-9, H-10, H-14, H-15, H-17; C-9/H10, H-13, H-15; C-10/H-1, H-2, H-5, H-9, H-13, H-12, H-15, H-17; C-11/H-12, H-10,
H-17; C-12/H-9, H-10, H-16 (w); C-13/H-9, H-12, H-15; C-14/H-12, H-16; C-15/H-9,
H-13; C-16/H-12, H-14, H-15, H-23; C-17/H-5, H-6, H-10, H-19, H-20 (w); C-18/H-3,
H-5, H-19, H-22; C-19/H-3, H-5, H-17, H-18, H-20; C-20/H-17 (w), H-19, H-21; C21/H-20; C-22/H-18; C-23/H-16.
δH to δC, H-1/C-3, C-5; H-2/C-4,C-5,C-11; H-3/C-1,C-4, C-18, C-19; H-5/C-4, C-7,
C-10, C-11, C-17, C-18, C-19; H-6/C-4,C-5,C-7,C-11,C-17; H-9/C-8,C-10,C-12,C13,C-15; H-10/C-1(w),C-2,C-8,C-5, C-9, C-11, C-12, C-17; H-12/C-5, C-10, C-11, C13, C-14, C-16; H-13/C-9, C-10, C-15, C-16; H-14/C-8, C-16; H-15/C-6, C-7, C-8, C9, C-13, C-16; H-16/C-12 (w), C-14, C-23; H-17/C-5, C-6, C-8, C-10, C-11, C-19, C20; H-18/C-3, C-4, C-5, C-19, C-22; H-19/C-3, C-4, C-5, C-17, C-18, C-20; H-20/C17, C-19, C-21; H-21/C-20; H-22/C18; H-23/C-16.
LRCIMS, m/z 424; HREIMS, C23H37NO6 (M+, measured 423.2619, calc. 423.2620).
LREIMS, m/z 423 (M+), 408, 407, 406, 390, 374, 365, 352, 336, 98, 85, 71, 58
(100%).
CH2

S

HO

Cl

N

20

S

+

R
S
R

H

OH

S

H

6
R

H
CH3
28 Atisinium chloride

Atisinium chloride 28: Crystals (needle shaped); [α]D25 = +31.27 (c, 0.94 in MeOH);
m.p. 230.7-233.6oC (decomposition); LREIMS, m/z 343 (M+), 342, 328, 314, 300,
284, 257, 241, 186, 171, 159, 143, 131, 105, 91, 79, 72, 55, 44. HRESMS (electrospray), C23H33NO2 (measured 344.2572, calculated 344.2590). The structure was
determined and confirmed by single crystal X-ray crystallography (Figure 10).
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Figure 10. The X-ray structure of Atisinium chloride.

o

o

27

AO- 358: white solid; m.p. 122.6 -124.2 C, [α]D

= +86.6 (c, 0.09 in MeOH);

LRCIMS, m/z 358 (MH+); HREIMS, m/z 357 (M+), 344, 342, 329, 328 (100%), 327,
326, 312, 300, 286,284,250, 234, 148,122, 105, 91, 77, 71, 60. HRCIMS, C22H32NO3
(MH+, measured 358.2399, calculated 358.2382). Another alkaloid with same LRCIMS
peak at m/z 358 (MH+) was obtained. It had a lower RF than the one described above.
HRCIMS, C15H5NO10 (MH+, measured 358.9901, calculated 358.9913).
AO-466: pale green solid, LRCIMS, m/z 466 (MH+); LREIMS, m/z 465 (M+), 450,
448, 432, 422, 403, 402 (100%), 390, 374, 358, 342, 329, 300, 284, 194, 164, 148, 122,
98, 91; HRCIMS, C25H40NO7 (MH+, measured 466.2785, calculated 466.2804).
AO-340: white solid; LREIMS, m/z 339 (M+), 322, 310, 297, 283, 245, 179, 159, 128,
124 (100%), 108, 94, 79, 65, 55 and 42. HRCIMS, C21H26NO3 (MH+, measured
340.1912, calculated 340.1912).
AO-372: pale brown solid; LREIMS, m/z 371 (M+, 100%), 355, 343, 327, 299, 296,
238, 210, 192, 162, 134, 122 and 105; HRCIMS, C21H26NO5 (MH+, measured
372.1816, calc. 372.1811).
AO-414: pale green solid; LREIMS, m/z 413 (M+), 385, 369, 354, 342, 310, 280, 252,
220, 212, 148, 134, 122, 105, 91, 79, 67, 57, 55, 44 (100%), 43, 42; HREIMS,
C23H27NO6 (M+, measured 413.1822, calculated 413.1838).
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AO-330: white solid; HRCIMS, C20H28NO3 (MH+, measured 330.2066, calculated
330.2069).

9.6

Purification and Structure Elucidation of Alkaloids from Corydalis gerdae
Fedde.

A methanol extract (58.22 g) was obtained from dried plant material (1 kg). Part of the
methanol extract (15.22 g) was kept refrigerated as reference material. Antimicrobial
testing was done on a portion of this reference material. The remaining MeOH extract
(43 g) was extracted for alkaloids using the general schematic isolation and extraction
procedure (Scheme 3). This yielded crude alkaloids (303.8 mg) and antimicrobial
testing was conducted on a portion of this alkaloid mixture (40 mg). The mass spectral
analyses (CIMS) on the crude alkaloids revealed ion peaks at m/z 354, 338, 326, 324,
and 224. The ion peak at m/z 354 was the major component. Focussing on these ion
peaks, the isolation and purification was conducted using preparative TLC.
The crude alkaloids (about 260 mg) was dissolved in MeOH (10%):DCM (90%)
solvent and then applied to PTLC silica gel plates (65 g × 4 plates). A mixture of DCM
(95%): MeOH (4%): Concentrated aqueous NH3 solution (28%, 1 ml) was found to be
the best solvent system for separating this crude extract. The solvent was allowed to
saturate the tank for 1 hour and the PTLC separation was then performed. Ten bands
were obtained and each of them contained different compounds with CIMS ion peaks
(MH+) as tabulated below (Table 27).
Table 27. Bands separated from the crude alkaloid of Corydalis gerdae
Bands

Net wt.

Peaks present

Suitable

solvent

system

used

(mg)

LRCIMS (m/z)

purifying respective bands (PTLC)

for

Compound
isolated
(m/z)

1+2

24.6

237, 257, 308,354

DCM (83ml):MeOH (17ml):NH3 (1ml)

354

3+4

21.9

328,354,410

DCM (93ml):MeOH (7ml):NH3 (1ml)

328

5

28.8

282, 312, 328, 354

DCM(94ml):MeOH (5ml):NH3 (1ml)

328

6

66.5

354,410

DCM (94ml):MeOH (5ml):NH3 (1ml)

354

7+8

57.8

257, 312, 326, 354

DCM (98.5 ml) : MeOH (1ml):NH3 (0.5ml)

326, 338

9

28.0

257, 324

DCM (99ml): MeOH (0.5 ml):NH3 (0.5 ml)

324

10

12.6

257, 338, 354,371

DCM (99ml): MeOH (0.5 ml):NH3 (0.5 ml)

282, 338

The bands/fractions were initially not pure and contained mixtures of compounds. They
were separated again by PTLC on silica gel by developing in different solvent systems
and each of these first bands gave two or more bands with different mass peaks
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(LRCIMS). The fractions with the same Rf values and same LRCIMS peaks were
combined and were again purified by developing appropriate solvent system and the
purification was repeated till pure compounds were obtained (Table 28).
Crystallization was attempted for all fractions using single solvent and a two different
solvents system. In a crystallization which involved two solvent systems
(chloroform/ethanol, MeOH/acetone, ethanol/acetronitrile and MeOH/diethyl-ether),
the compound was first dissolved in the more powerful solvent, and the second, more
volatile and less powerful solvent allowed it to diffuse into it, which facilitated steady
growth of large crystals. However, only cheilanthifoline gave small crystals from
methanol/diethyl-ether. The crystals were washed with diethyl-ether and was collected
and sent for synchrotron X-ray crystallography to USA. This result will further confirm
its structure but its result was not available at the time of completion of this thesis.
Finally four alkaloids were isolated from this plant.
Table 28. Alkaloids isolated from Corydalis gerdae
Alkaloids

Mol.Wt.

Molecular formula

Wt. obtained

Protopine

353

C20H19NO5

23.1

Scoulerine

327

C19H21NO4

9.2

Cheilanthifoline

325

C19H19NO4

6.5

Stylopine

323

C19H17NO4

5.9

Unidentified

337

C19H15NO5

1.6

O
N

O

Me

O
O
O

37 Protopine

Protopine 37: white amorphous solid; m.p. 203.7-207.8oC (decomposition; optically
inactive; LRCIMS, m/z 354 (MH+); HREIMS, C20H19NO5 (MH+, measured 354.1342,
calc.354.1341); HREIMS m/z 353 (M+), 281, 267, 252, 190, 163, 149, 148 (100%)
134 and 89. 1H-NMR (500 MHz, Nanoprobe, DMSO-d6), δ6.92 (s, H-1), δ6.77 (s, H3), δ3.15 (s, H-5), δ2.38 (bs, H-6), δ3.47 (bs, H-8), δ6.74 (d, J=7.5 Hz, H-11), δ6.66 (d,
J=8.0 Hz, H-12), δ5.96 (s, 2,3-OCH2O), δ5.93 (s, 9,10-OCH2O), δ1.79 (s, 7-CH3). 13CNMR (500 MHz, Nanoprobe, DMSO-d6), δ107.4 (C-1), δ145.3 (C-2), δ147.3 (C-3),
δ110.4 (C-4), δ132.7 (C-4a), δ30.5 (C-5), δ57.4 (C-6), δ50.7 (C-8), δ118.3 (C-8a),
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δ145.8 (C-9), δ145.4 (C-10), δ106.3 (C-11), δ125.1 (C-12), δ129.6 (C-12a), δ46.1 (C13), δ194.8 (C-14), δ136.0 (C-14a), δ101.1 (2,3-OCH2O), δ41.1 (7-CH3), δ100.7 (9,10OCH2O).

MeO
N

HO

H

OH
OMe

41 Scoulerine
Scoulerine 41: reddish brown solid; m.p. 153-157oC (decomposition); [α]D24 = ─282
(c, 0.74 in MeOH); 1H-NMR (CD3OD, 300 MHz): δ 3.21 (s, OMe), δ 3.24 (s, OMe), δ
5.38 (s, OH), δ 3.52 and δ 4.14 (AB-quartet, J = 15.9 Hz). HREIMS, C19H21NO4
(measured 327. 1461, calc.327.1471); HREIMS: m/z 327 (100%, M+), 326, 312, 310,
207, 179, 178 (100%), 176, 162, 150, 149 and 135.

MeO
HO

N
H
O
CH2
O

47 (-)-(S)-cheilanthifoline

Cheilanthifoline 47: pale green solid; m.p. 168-170.4oC (decomposition);

[α]D20 =

─262 (c, 0.60 in CDCl3); LRCIMS, m/z 326 (MH+); LREIMS, m/z 325 (M+, 100%),
310, 176, 162 and 148 (100%); HREIMS, C19H19NO4 (measured 325.1304,
calc.325.1314); 1H-NMR (CDCl3, 500 MHz): δ 3.87 (s, 3H, OMe), δ 5.93 (d, 2H,
methylenedioxy), δ 3.53(q) and δ 4.09(d) (C-8 methylene, J = 15 Hz), δ 1.25 (bs, -OH),
δ 6.59 to δ 6.81 (4 H, aromatic).
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42 Stylopine

Stylopine 42: pale green solid; m.p. 163-165o C; [α]D24 = ─304 (c, 0.56 in MeOH);
LRCIMS: m/z 324 (MH+); LREIMS: m/z 323 (M+), 207, 174, 148 (100%) and 89.
HREIMS: C19H17NO4; (measured 323.1145, calc.323.1157).

O
H2N

48 9-octadecenamide
9-Octadecenamide 48: white solid; blue fluorescence under UV; LRCIMS, m/z 338
(MH+); HREIMS, C22H43NO (measured 337.3382, calc.337.3344); HREIMS, m/z 337
(M+), 277, 136, 122, 97, 83, 72, 69, 59 (100%), 43 and 41.
CG-338: white solid; LRCIMS, m/z 338 (MH+); HREIMS, C19H15NO5 (measured
337.0940, calc.337.0936).
CG-336: white solid; LRCIMS, m/z 336 (MH+); LREIMS, m/z 335 (M+, 100%), 320,
306, 292, 248, 190, 167, 153, 139, 124, 95, 82, 75 and 63. HREIMS, C15H29NO7
(measured 335.1939, calc.335.1944).

9.7

Attempted Extraction and Isolation of Alkaloids from Tribulus terrestris L

9.7.1

Attempt-I.

A methanol extract (127.74 g) was obtained from air dried plant material (1.2 kg).
Antimicrobial testing was performed on a part (15 mg) of this extract. The remaining
methanol extract was extracted for alkaloids using the general schematic isolation and
extraction procedure (Scheme 3) and yielded a crude alkaloid fraction (540 mg).
However, when the crude fraction was tested with Dragendorff’s reagent, it gave a
negative test. A portion of this crude extract (25.6 mg) was kept as reference material.
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The mass spectral analysis (LRCIMS) on this crude extract revealed ions at m/z 144,
163, 175 (major component), 191, 193, 209, 225 and 265.
The crude alkaloid extract was dissolved in MeOH (10%) /DCM (90%) solvent and
was loaded on to silica PTLC plates (65 g × 8 plates). After trying different ratios, a
mixture of DCM (94%): MeOH (6%): concentrated aqueous NH3 solution (28%, 3
drops) was selected as the best solvent system for separating this crude extract. The
solvent system was left to saturate the tank for 1 hour and the PTLC separation was
then performed. Ten bands were separated and each band was tested for alkaloids.
None gave a positive test with Dragendorff’s reagent. One band yielded 3,4dimethoxycinnamic acid, as the major component isolated.

MeO

H
COOH

MeO
H

62 3,4-Dimethoxycinnamic acid
3,4-Dimethoxycinnamic acid 62: pale green solid; absorbed UV light; 1H-NMR
(CDCl3, 300 MHz), δ 7.70 (d, 1H, J = 15.9 Hz), δ 7.07 to δ 7.13 (3H, aromatic
protons), δ 6.92 (d, 1 H, J = 8.4 Hz), δ 3.80 (s, 3H, OMe) and δ 3.93 (s,3H,OMe);
LRCIMS,

m/z 209 (MH+); HRCIMS,

C11H13NO4 (MH+,

measured 209.0817,

calc.209.0813).

9.7.2

Attempt-II

To recheck the result obtained in the first attempt to isolate alkaloids from Tribulus
terrestris, the extraction and the isolation of alkaloids from this plant was attempted for
a second time using a slightly modified procedure. In this method, the air dried plant
material (1.5 kg) was ground using a Grinder (mixer) and was then extracted with
analytical grade methanol for 5 days. The separated methanol extract was evaporated
and the residue was acidified (to pH 1) with 1 M H2SO4 (15 ml). The acidic solution
was washed with chloroform and petroleum ether (4 × 60 ml). The aqueous layer was
then basified (to pH 10) with Na2CO3 solution (20% w/v) and then extracted with
chloroform (4 × 60 ml). This chloroform extract was evaporated and the residue tested
for alkaloids. The crude extract failed to give any test for alkaloids when tested with the
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Dragendorff’s reagent and with Mayer’s reagent. This confirmed that this batch of
Tribulus terrestris contained no alkaloids.

9.8

Attempted Isolation of Alkaloid from Ranunculus brotherusi Freyn

A methanol extract (85.01 g) was obtained from air dried plant material (1 kg) and a
small portion of this extract (15.90 g) was kept as a reference sample. The remaining
methanol extract was extracted for alkaloids using the general schematic isolation and
extraction procedure (Scheme 3) and yielded a crude alkaloid fraction (72.8 mg). This
crude extract gave a negative test for alkaloids with Dragendorff’s reagent. The
LRCIMS of the crude alkaloid extract gave ions at m/z 225, 209, 207, 197, 195 (major
peak), 193, 191, 175, 163, 145, 127 and 86.
All the crude basic extract was separated using PTLC plates (36 g × 2 plates) and the
solvent system: DCM (90%):MeOH (10%):Concentrated aqueous NH3 solutions(28%,
1 ml). The solvent was allowed to saturate the tank for 1 hour and PTLC separation was
then performed. Eleven bands were separated and each band contained a mixture of
different compounds (on the basis of LRCIMS analyses). None of the fractions gave a
positive test with Dragendorff’s reagent. No further work was done on this plant
extract.

9.9

Antibacterial assay

9.9.1

Sample Preparation

The methanol extract (AO-ME, 10 mg), crude alkaloid (AO-CEA, 10 mg) and
atisinium chloride isolated from Aconitum orochryseum were packed in small vials.
Similarly, the methanol extract (CG-ME, 10 mg), crude alkaloid (CG-CEA, 10 mg) and
protopine isolated from Corydalis gerdae were packed in small vials. These samples
were then sent for antibacterial assays to the Amrad Corporation, Melbourne. All
assays used the Staphylococcus aureus strain ATCC 6538P, or VRE strains 243, 449,
820 and 987. It should be noted however that two strains, VRE 243 and 987 were in
fact sensitive to vancomycin.

9.9.2

Antibacterial Testing Methodology263

The Mueller-Hinton Broth (MHB) Medium culture media was prepared with final
concentrations of 1 µg/mL MgCl2 and 2 µg/mL CaCl2 and was pre-warmed for 2-3
hour at 37oC before use. Mueller-Hinton Agar (MHA) Medium culture media was
prepared with final concentrations of 1.5% Agar (Merck Agar 1.01614). S.aureus was
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streaked onto MHA and the plate was incubated overnight at 37oC. From this plate, 10
cryovial were prepared by looping several colonies into 0.5 mL of 20% glycerol
solution and were immediately stored at −140oC. A cryovial was removed from −140oC
storage and thawed at room temperature. The MHA plate was streaked with a loopful
of bacterial suspension and incubated overnight at 37oC to create a parent plate (P1).
The parent plate was stored at 4oC. A daughter plate (D1) was incubated overnight at
37oC and its loop of colony was used to inoculate a 125 mL flask containing 20 mL of
MHB containing 25 µg/mL CaCl2.2H2O) and 12. 5 µg/mL MgCl2.6H2O. The flask was
shaken at 260 rpm for 18 hour at 37oC on an orbital incubator shaker. The parent plates
1 and 2 were each used twice to generate two daughter plates (D1 and D2) before being
discarded.
The standardised inocula for assays was prepared as 1/10 dilution of seed cultures by
adding 250 µL of the cultures to 2,250 µL of MHB in a disposable cuvette and the
required dilution factor was calculated by dividing the observed OD650. Sufficient
volumes of the final inoculum cultures were prepared in pre-warmed MHB (37oC) by
diluting the standardised cultures to the required final concentration (108 dilution).

9.9.3

Assay Procedure for 96-well Microtitre Plates

To each well of the 96-well microtitre plate was added 50 µL of liquid medium and 50
µL of peptoid test solution which was prepared by dissolving in 2.5 % DMSO was
added in triplicate to the top of the microtitre plate. A vancomycin control set
(triplicate) and a compound negative control set (triplicate) were also set up on each
plate. The inoculated culture medium was incubated at 37oC for 30 min shaking it at
130 rpm and using the multichannel pipette and multistepper pipette the adding,
transferring and mixing of the inoculum were performed on the wells of the plates. The
plates were incubated at 37oC for 18 hrs shaking at 100 rpm in an environment with
90% relative humidity and the results were recorded as the highest dilution of test
compound that prevented bacterial growth (MIC). The MIC was also determined for
DMSO (2.5%) as a control measure.

9.9.4

Results of Antibacterial Testing

When the methanol extracts, crude alkaloids and the major alkaloids (protopine and
atisinium chloride) of the plants were tested, the following results (Table 29) were
obtained.
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Table 29. Antibacterial activities of the plant extracts and alkaloids on Staphylococcus aureus and
Vancomycin resistant Enterococcus faecium
Compound

Culture

MIC (µg/ml)

AO-ME

Staph

>125

AO-CEA

Staph

>125

Orochrine

Staph

>125

VRE # 243, VRE # 449,

Atisinium chloride

VRE # 820 and VRE # 987

>125

Staph

>125

VRE # 243, VRE # 449,
VRE # 820 and VRE # 987

>125

CG-ME

Staph

>125

CG-CEA

Staph

>125

Protopine

Staph

>125

Vancomycin

Staph

2.5

(Standard)

VRE # 243, VRE # 449,

1.95 (< 0.98), 62.5, 125 and 1.95

VRE # 820 and VRE # 987

respectively

Note: VRE = Vancomycin resistant Enterococcus; Staph = Staphylococcus aureus; Vanc = Vancomycin,
MIC = Minimum Inhibitory Concentration.

9.10
9.10.1

Antimalarial assay
Sample Preparation

The methanol extract (AO-ME, 20 mg), crude alkaloid (AO-CEA, 20 mg) and
atisinium chloride isolated from Aconitum orochryseum were packed in small vials.
Similarly, the methanol extract (CG-ME, 20 mg), crude alkaloid (CG-CEA, 20 mg),
protopine and cheilanthifoline, isolated from Corydalis gerdae, were packed in small
vials. These samples were then sent for antimalarial testing at the Protein-Ligand
Engineering and Antimalarial Screening Laboratories, National Centre for Genetic
Engineering and Biotechnology, National Science and Technology Development
Agency

in

Bangkok,

Thailand.

The

tests

were

done

by

Dr.

Sumalee

Kamchonwongpaisan and by Miss Roonglawan Rattanajak using a Microdilution
Radioisotopes Technique.

9.10.2

Antimalarial Assay Method

Samples were made up in DMSO solution. Using the Microdilution Radioisotope
Technique, the in vitro antimalarial activity of the alkaloids was tested against
Plasmodium falciparum, TM4 and K1 Strains. The first strain is an anti-folate sensitive
one while the second is an antifolate resistant strain.
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The sample (25 µl, in the culture medium) was placed in triplicate in a 96-well plate.
Red blood cells (200 µl) infected with Plasmodium falciparum with a cell suspension
(1.5%) of parasitemia (0.5-1%) were added to the wells. The range of the final
concentrations of the samples varied from 1 x 10-5 to 1 x 10-8 g/ml with 0.1% of the
organic solvent. The plates were cultured under standard conditions for 24 hours and
the 3H-hyphoxanthine (25 µl, 0.5 mCi) was added. The culture was incubated for 18-20
hours. The parasites’ DNA was then harvested from the culture onto glass fibre filters.
A radiation counter determined the amount of 3H-hypoxanthine. The inhibitory
concentration of the sample was determined from its dose-response curves or by
calculation.
The Trager and Jensen method264 was used to culture Plasmodium falciparum K1
strain. The parasites were maintained in human red blood cells in a culture medium.
RPMI 1640 was supplemented with 25 mM HEPES, 0.2% sodium bicarbonate, and 8%
human serum, at 37oC in a CO2 incubator54.

9.10.3

Results of the Antimalarial Assay

The following in vitro antimalarial test results (Table 30) were obtained for the
methanol extracts (AO-ME and CG-ME), crude alkaloid mixtures (AO-CEA and CGCEA), atisinium chloride, protopine and cheilanthifoline.

Table 30. Antimalarial activities of extracts and alkaloids isolated from Aconitum orochryseum and
Corydalis gerdae (IC50 value against Plasmodium falciparum; TM4 and K1 strains).
IC50
Plants

Sample

TM4

K1

Aconitum orochryseum

AO-ME

>10 µg/ml

>10 µg/ml

AO-CEA

20.4 ± 1.74 µg/ml

19.2 ± 3.84 µg/ml

Atisinium chloride

4.02 ± 0.69 µ M

3.59 ± 1.24 µ M

(1.51 µg/ml)

(1.35 µg/ml)

CG-ME

1.00 ± 0.34 µg/ml

2.56± 0.46 µg/ml

CG-CEA

0.33 ± 0.03 µg/ml

0.63 ± 0.14 µg/ml

Protopine

4.25 ± 0.69 µ M

4.29 ± 1.24 µ M

(1.50 µg/ml)

(1.51 µg/ml)

2.78 ± 0.39 µ M

3.76 ± 1.00 µ M

(0.90 µg/ml)

(1.22 µg/ml)

Corydalis gerdae

Cheilanthifoline

An antibacterial and antimalarial testing were not done for Ranunculus brotherusi and
Tribulus terrestris extracts.

121
References
(1)

Hulse, H. J. Ethical issues in biotechnologies and international trade. J. Chem.
Technol. and Biotechnol. 2002, 77, 607-615.

(2)

Dax, S. L. Antibacterial chemotherapeutic agents; First ed.; Blackie Academic
& Professional, Chapman & Hall: London, UK, 1997.

(3)

Miller, C. J.; Shattock, R. J. Target cells in vaginal HIV transmission. Microbes
Infect. 2003, 5, 59-67.

(4)

Microsoft Encarta Premium Suite; 12.0.0.0.0602 ed.; Microsoft Corporation;
Website:http://www.microsoft.com/mswish.: Raymond, USA.

(5)

A Global Strategy for Malaria Control; World Health Organization: Geneva,
1993.

(6)

Rouhi, A. M. Tuberculosis: A tough adversary. In Chem. Eng. News, 1999; pp
52-70.

(7)

Rodriguez, A. D.; Ramirez, C.; Rodriguez, I. I.; Gonzalez, E. Novel
antimycobacterial benzoxazole alkaloids, from the West Indian Sea Whip
Pseudopterogorgia elisabethae. Org. Lett. 1999, 1, 527-530.

(8)

Walsh, W. Molecular mechanisms that confer antibacterial drug resistance.
Nature 2000, 406, 775-781.

(9)

Hanno, H. Types, characteristics, and break points of antibacterial drugs.
Kagaku Ryohono Ryoiki 1997, 13, 1365-1372.

(10)

Williams, R. A. D.; Lambert, P. A.; Singleton, P. Antimicrobial drug action;
Bios Scientific Publishers Ltd,: UK,, 1996.

(11)

Levy, S. B. The challenge of antibiotic resistance. Sci. Am. 1998, 278, 46-53.

122
(12)

Mitscher, L. A.; Pillai, S. P.; Gentry, E. J.; Shankel, D. M. Multiple drug
resistance. Med. Res. Rev. 1999, 19, 477-496.

(13)

Lipsitch, M. The rise and fall of antimicrobial resistance. Trends in Microbiol.
Review 2001, 9, 438-444.

(14)

Dever, L. A.; Dermody, T. S. Mechanisms of bacterial resistance to antibiotics.
Arch. Int. Med. 1991, 151, 886-895.

(15)

Claude, C.; Raul, I. Narrow versus broad spectrum antibacterials: factors in the
selection of pneumococcal resistance to beta-lactams. Drugs 2002, 62, 12891294.

(16)

Pradipsinh, K. R.; McErlean, T.; Lee, P. C. Variations in frequencies of drug
resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci, USA 1997, 94,
9389-9393.

(17)

Hardwicke, C. J. The World Health Organization and the Pharmaceutical
Industry. Common areas of interest and differing views. Adverse Drug React.
and Toxicol. Rev. 2002, 21, 51-99.

(18)

Phillipson, J. D. Phytochemistry and medicinal plants. Phytochemistry 2001, 56,
237-243.

(19)

Phillipson, J. D. Radioligand-receptor binding assays in the search for bioactive
principles from plants. J. Pharm. Pharmacol. 1999b, 51, 493-503.

(20)

Hyde, J. E. Mechanisms of resistance of Plasmodium falciparum to antimalarial
drugs. Microbes Infect. 2002, 4, 165-174.

(21)

Kondrashin, A. V.; Rooney, W. Overview: Epidemiology of malaria and its
control in countries of the WHO South-East Asia region. South East Asian J.
Trop. Med. Pub. Health 1992, 23, 13-22.

123
(22)

Van Agtmael, M. A.; Eggelte, T. A.; Van Boxtel, C. J. Artemisinin drugs in the
treatment of malaria: from medicinal herb to registered medication. TiPs 1999,
20, 199-206.

(23)

Zhang, H. J.; Tamez, P. A.; Hoang, V. D.; Tan, G. T.; van Hung, N. et al.
Antimalarial compounds from Rhaphidophora decursiva. J. Nat. Prod. 2001,
64, 772-777.

(24)

Federici, E.; Palazzino, G.; Galeffi, C.; Nicoletti, M. Antiplasmodial activity of
the alkaloids of Peschiera fuchsiaefolia. Planta Med. 2000, 66, 93-95.

(25)

Valsaraj, R.; Pushpangadan, P.; Smitt, U. W.; Adesersen, A.; Christensen, B. S.
et al. New anti-HIV-1, antimalarial, and antifungal compounds from Terminalia
bellerica. J. Nat. Prod. 1997, 60, 739-742.

(26)

Nosten, F.; Brasseur, P. Combination therapy for Malaria, the way forward?
Drugs 2002, 62, 1315-1329.

(27)

Foote, S. J.; Kyle, D. E.; Martin, R. K., et al. Several alleles of the multidrug
resistance gene are closely linked to chloroquine resistance in Plasmodium
falciparum. Nature 1990, 345, 255-258.

(28)

Austin, D. J.; Kristinsson, K. G.; Anderson, R. M. The relationship between the
volume of antimicrobial consumption in human community and the frequency
of resistance. Proc. Natl. Acad. Sci, USA 1999, 96, 1152-1156.

(29)

Sepala, H. The effect of changes in the consumption of macrolide antibiotics on
erythromycin resistance in group A streptococci in Finland. New Engl. J. Med.
1997, 337, 441-446.

(30)

Guillemot, D.; Carbon, C.; Balkau, B. Low dosage and long treatment duration
of β−lactam.Risk factors for carriage of penicillin-resistant Streptococcus
pneumoniae. JAMA 1998, 279, 365-370.

124
(31)

Patrick, G. Medicinal Chemistry-Instant Notes; First ed.; Bios Scientific
Publishers Limited, UK: Leeds, UK, 2001; 77-83.

(32)

Gyllenhaal, C. Intellectual property rights, naturally derived bioactive
compounds, and resource conservation. Meeting report. J. Nat. Prod. 1996, 59,
334-337.

(33)

Harvey, A. L. Medicines from nature: are natural products still relevant to drug
discovery? In TiPS, 1999; pp 196-198.

(34)

Verpoorte, R. Chemodiversity and the biological role of secondary metabolites,
some thoughts for selecting plant material for drug development. Bioassay
Methods in Natural Product Research and Drug Development; Kluwer
Academic Publishers: The Netherlands, 1999; pp 11-23.

(35)

Bremner, J. B. Lecture/Tutorial course outline-natural products in drug
discovery; Department of Chemistry, University of Wollongong: Wollongong,
2002.

(36)

James, A. A.; Robert, W. B.; Wayne, M. B.; Lindsay, T. B.; Jack, R. C.; Steven,
M. C.; Anthony, R. G.; Neville, G. M.; Neil, R.; Melvyn, V. S.; Colette, G. S.;
Zdzislaw, E. S.; Robert, D. T. Constituents of Conospermum brachyphyllum.
Improved methods for the isolation and synthesis of (+)-Conocurvone and the
structure of (+)-Brachyphyllone. Aust. J. Chem. 1999, 52, 57-62.

(37)

Hostettmann, K.; Marston, A.; Wolfender, J. L. Strategy in the search for new
biologically active plant constituents. Phytochemistry of Plants Used in
Traditional Medicine; Oxford University Press Inc. New York:
Laussane,Switzerland, 1993; pp 17-45.

(38)

Cragg, G.; Newman, D. Chemists' toolkit, Nature's bounty. Chem. Brit. 2001,
22-26.

125
(39)

Merrilyn, A. K. Complementary Therapies for Health Care Providers;
Lippincott williams and Wilkins: Baltimore, 1999.

(40)

Kinghorn, A. D.; Balandrin, M. F. Human Medicinal agents from plants; ACS
Symposium Series 534, Washington, DC., 1993.

(41)

Elmqvist, T. Plant biodiversity-evolutionary and ecological perspectives.
Bioassay Methods in Natural Product Research and drug Development; Kluwer
Academic Publishers: Biomedical Centres of Uppsala University, Sweden,
1997; pp 1-9.

(42)

Heywood, V. H. Global biodiversity assessment,; UNEP, Cambridge University
press, 1995; pp 174-185.

(43)

Wilkinson, J. A.; Wahlqvist, M. L.; Clark, J. New food and pharmaceutical
products from agriculture . Rural Industries Research and Development
Corporation: Australia, 2002; pp 1-30.

(44)

Hesse, M. Alkaloids, nature's curse or blessing?; Verlag Helvetica Chimica
Acta and Wiley-VCH: Zurich, 2002; 293.

(45)

Fusetani, N. Introduction. Drugs from the Sea; Karger: Tokyo, Japan, 2000; pp
1-5.

(46)

Roberts, M. F.; Wink., M. Introduction. Alkaloids: Biochemistry, Ecology, and
Medicinal Application; Plenum press: New York, 1998; pp 1-7.

(47)

Southon, I. W.; Buckingham, J. Dictionary of Alkaloids; Chapman and Hall:
London, 1989.

(48)

Pelletier, S. W. Introduction. Chemistry of the alkaloids; Van Nostrand
Reinhold Company: New York, 1970; pp 1-10.

126
(49)

Cordell, G. A.; Quinn-Beattie, M. L.; Farnsworth, N. R. The potential of
alkaloids in drug discovery. Phytother. R. 2001, 15, 183-205.

(50)

Yunusov, S. Y. Dynamics of accumulation, formation of alkaloids, and their
role in plants. Akad. Nauk Uz. SSR 1966, 2, 104-106.

(51)

Polonovski, M. The method of formation and the role of alkaloids in plants.
Bull. Soc. Chim. 1926, 35, 1365-1398.

(52)

Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and
computational approaches to estimate solubility and permeability in drug
discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.

(53)

King, S. R.; Tempesta, M. S. From shaman to human clinical trials: the role of
industry in ethnobotany, conservation and community reciprocity. CIBA
Foundation Symposium; Shaman Pharmaceutical Inc.: South San Francisco,
1994; pp 197-213.

(54)

Hadi, S. Bioactive alkaloids from medicinal plants of Lombok (PhD Thesis).
PhD Thesis; University of Wollongong: Wollongong, 2002

(55)

Cowan, M. M. Plant products as antimicrobial agents. Clin. Microbiol. Rev.
1999, 12, 564-582.

(56)

Daly, J. W.; Garaffo, H. M.; Spande, T. F.; Decker, M. W.; Sullivan, J. P. et al.
Alkaloids from frog skin: the discovery of epibatidine and the potential for
developing novel non-opiod analgesics. Nat. Prod. Rep. 2000, 17, 131-135.

(57)

Jensen, P. R.; Fenical, W. Marine microorganisms and drug discovery: Current
status and future potential. Drugs from the Sea; Karger: Tokyo, 2000.

(58)

Benkendorf, K. Bioactive molluscan resources and their conservation:
biological and chemical studies on egg masses of marine molluscs (PhD
Thesis). PhD; University of Wollongong: Wollongong, 1999

127
(59)

Wink, M. A short history of alkaloids. Alkaloids-Biochemistry, Ecology, and
Medicinal Applications; Plenum Press: New York, 1998; pp 11-44.

(60)

Neuwinger, H. D. Alkaloids in Arrow Poisons. Alkaloids; Biochemistry,
Ecology and Medicinal Applications; Plenum Press: New York, 1998; pp 45-84.

(61)

Smanla, A. T. A brief introduction to traditional Tibetan medicine in Ladakh
(online); Website:http://home.t-online.de/home/5200972789940001/yuthog/engl/med.html; Neugebauer, A., 1998.

(62)

Wangchuk, P. Natural product-based drug discovery: Recent development
(literature review); University of Wollongong., 2002.

(63)

Mann, J. Murder, Magic and Medicine; Oxford University Press: London, 1992.

(64)

Tokar, E. Tibetan medicine (online); Website: http://www.tibetanmedicine.com;
Eliot Tokar, 1998.

(65)

Dompnier, R. The Art of Healing. In Tashi Delek, Druk air's in-flight magazine,
1998.

(66)

Dorji, P.; Morisco, P. An Introduction to Traditional Medicine in Bhutan;
National Institutes for Traditional Medicines, Ministry of Health and Education:
Thimphu, 1989.

(67)

Bright, M. A. Paradigm shifts. Holistic Health and Healing; F.A. Davis
Company: Philadelphia, USA, 2002; pp 3-30.

(68)

Kimura, M. The molecular patho-pharmacological studies for novel drug design
by a principle of drug action in Japanese traditional Sino-medicine system.
Yakugaku Zasshi 1997, 117, 133-154.

128
(69)

Ligumsky, M.; Sallon, S.; Shapiro, H.; Ben-Ari, E.; Davidson, R. et al.
Treatment of irritable bowel syndromme (IBS) with Tibetan herbal
multicompound, PADMA-179: A controlled, double-blind study.
Gastroenterology 1999, 116, G4473.

(70)

Drabaek, H.; Mehlsen, J.; Himmelstrup, H.; Winther, K. A botanical compound,
PADMA-28, increases walking distance in stable intermittent claudation.
Angiology-The Journal of Vascular Diseases 1993, 44,11, 863-867.

(71)

Winther, K.; Kharazmi, A.; Himmelstrup, H.; Drabaek, H.; Mehlsen, J.
PADMA-28, A botanical compound, decreases the oxidative burst response of
monocytes and improves fibrinolysis in patients with stable intermittent
claudation. Fibrinolysis 1994, 8, Suppl.2, 47-49.

(72)

Suter, M.; Richter, C. On the effect of PADMA-28: Antioxidative mechanisms
at a molecular Level; Institut fur Biochemie, Eidgenossische Technische
Hoschschule ETH Zurich: Switzerland, 2000; pp 17-22.

(73)

Bagozzi, D. Traditional and Alternative medicine, Fact Sheet Nο 297; World
Health organization; Website: http://www.who.int/, 2002.

(74)

Karki, M. Medicinal and Aromatic Plants Program in Asia (MPPA); IDRC
/CRDI, 2001.

(75)

Prance, G. T.; Chadwick, D. J.; Marsh, J. Ethnobotany and the search for new
drug discovery. Ethnobotany and the search for new drugs; John Wiley and
Sons: England, 1994.

(76)

Soejarto, D. D.; Pezzuto, J. M.; Fong, H. H. S.; Tan, G. T.; Zhang, H. J. et al.
An international collaborative program to discover new drugs from tropical
biodiversuty of Vietnam and Laos. Nat. Prod. Sci. 2002, 8, 1-15.

129
(77)

Ugyen. Sustainability: An assessment of medicinal plants in Bhutan; University
of Kent at Canterbury, Durrel Institute of Conservation, The Royal Botanic
Gardens: Kew, UK, 1999.

(78)

Men-tsee-khang (Homepage); Tibetan Medical and astrologyl Institute, Mentsee-khang, India (online); Website:http://www.mentseekhang.org, 2002.

(79)

Tibetan medicine-an alternative and complementary medicine resource guide;
Alternative medicine foundation, Inc., Bethesda, Maryland; Website:
http://www.amfoundation.org/tibetanmedicine.htm, 2000.

(80)

Dagthon, J. G. An introduction to Tibetan astronomical science; The Office of
Tibet, London; Website: http://www.tibet.com/Med_Astro/astro.html, 2003.

(81)

Meyer, F. The world of Tibetan Medicine. Oriental medicine-an illustrated
guide to Asian arts of healing; Serindia Publications: London, 1995; pp 107143.

(82)

Angele, E. Notes on history of Tibetan medicine. Tibetan medicine; Library of
Tibetan Works and Archives: New Delhi, 1984; pp 1-14.

(83)

Report of research laboratory; National Institute of Traditional Medicine:
Thimphu, 1995.

(84)

Norbu, K. Fundamentals of Tibetan medical practice; D.L.Tashigangpa:
Ladakh, 1974.

(85)

NITM Database: National Essential Traditional Medicine List; Institute for
Traditional Medicine Services: Thimphu, 2001; 1-8.

(86)

Bhutan to unveil herbal secrets (online); London, Europe world,
Website:http://www.europaworld.org/issue15/bhutantounveilherbalsecrets2912
00.htm, 2003.

130
(87)

Kingdom of Bhutan poised to offer west their ancient medicinal heritage thanks
to funding by the European Commission (online); Oxford Natural Products,
UK.; Website:http://www.oxfordnaturalproducts.com/site/onp/oooo6, 2000.

(88)

Karan, P. P.; Jenkins, W. M. J. Bhutan: A physical and cultural geography;
University of Kentucky Press: Lexington, 1967.

(89)

The biodiversity of Bhutan; Bhutan Trust Fund for Environmental Conservation
(online); Website:http://www.bhutantrustfund.org/biodiversity.htm, 2003.

(90)

Grierson, A. J. C.; Long, D. G. Flora of Bhutan: Including a record of plants
from Sikkim; Royal Botanic Garden: Edinburgh, 1994.

(91)

Introduction to Bhutan; Lhayul Tours and Treks (online);
Website:http://www.lhayul.com/bhutanintro.htm, 2002.

(92)

Bohlin, L.; Bruhn, J. G. Bioassay methods in natural product research and drug
development. Proceedings of the Phytochemical Society of Europe; Kluwer
academic publishers, The Netherlands,. 1999.

(93)

Bhutan (online); Indianvisit tours, 2002.
Website:http://www.indianvisit.com/ivnew/destinationguides/neighboursofindia
/bhutan.htm.

(94)

Giri, S. Country Programme Strategy-Second Operational Phase (1999-2001)
1999, 1-17.

(95)

Introduction to Bhutan; Lhayul Tours and Treks.
Website:http://www.lhayul.com/bhutanintro.htm.

(96)

Mainka, S. A. The use of animal ingredients in Bhutanese traditional medicine;
RGoB and Commision of European Communities: Thimphu, 1996; pp 4-53.

131
(97)

NITM Database: List of Ingredients of Traditional Medicine; NITM: Thimphu,
2001; pp 1-10.

(98)

Chhetri, B. B. Vegetable oil and ornamental plants. Non-wood forest products
of Bhutan; RAP Publications-FAO United Nations: Bangkok, Thailand, 1996;
pp 1-16.

(99)

Ngawang, R. Medicinal plants. Non-wood forest products of Bhutan; RAP
Publications-FAO United Nations: Bangkok, Thailand, 1996.

(100) Mulliken, T. Implementing CITES for Himalayan Medicinal Plants
Nardostachys grandiflora and Picrorhiza kurrooa. In Traffic Bulletin, 2000; pp
1-16.

(101) Emmett, S. Mountain medicines; New agriculturist; Website: http://www.newagri.co.uk/03-1/focuson/focuson5.html, 2003.

(102) Norbu, P. W. Basic information on Bhutan's Himalayan yew (Taxus baccata).
Non-wood Forest Products of Bhutan; RAP Publications/FAO, UN.: Bangkok,
Thailand, 1996; pp 1-3.

(103) Winter, H.; Seawright, A. A.; Noltie, H. J.; Mattocks, A. R.; Jukes, R. et al.
Pyrrolizidine alkaloid poisoning of yaks: identification of the plants involved.
Vet. Rec. 1994, 134, 135-139.

(104) Klatzel, F.; Kirby, K. E. S.; Wangdi, K. The Natural World of Bhutan; Royal
Society for Protection of Nature-World Wildlife Fund: Thimphu, 1999; 4-24.

(105) Medicinal Flora of Bhutan; NITM, KMT Printing Works: Thimphu, Bhutan,
1999.

(106) Culvenor, C. C. J.; Fitzgerald, J. S. A. A field method for alkaloid screening of
plants. J. Pharm. Sci. 1963, 52, 303-304.

132
(107) Sengpracha, W. Synthesis of tribulusterine, a potent toxic alkaloid from
Tribulus terrestris, M.Sc. Thesis;University of Wollongong, Wollongong, 2001;
pp 78

(108) Bourke, C. A. Hepatopathy in sheep associated with Tribulus terrestris. Aust.
Vet. J. 1983, 60, 189.

(109) Bourke, C. A. Staggers in sheep associated with the ingestion of Tribulus
terrestris. Aust. Vet. J. 1984, 61, 360-363.

(110) Bourke, C. A.; Stevens, G. R.; Carrigan, M. J. Locomotor effects in sheep of
alkaloids identified in Australian Tribulus terrestris. Aust. Vet. J. 1992, 69, 163165.

(111) Grierson, A. J. C.; Long, D. G. Flora of Bhutan; Royal Botanic Garden:
Edinburg, 1984.

(112) Baillie, L. C.; Batsanov, A.; Bearder, J. R.; Whiting, D. A. Synthesis of the
A/E/F sections of conaconitine, napelline and related diterpenoid alakloids of
the aconitine group. J. Chem. Soc. Perkin Trans.1 1998, 3471-3478.

(113) Chopra, R. N.; Chopra, I. C.; Handa, K. L.; Kapur, L. D. Chopra's indigenous
drugs of India.; U.N.Dhur and sons Private Ltd.: Calcutta, 1958; 54-57.

(114) Pelletier, S. W.; Aneja, R.; Gopinath, K. W. The alkaloids of Aconitum
heterophyllum Wall.: Isolation and characterization. Phytochem. 1968, 7, 625635.

(115) Yue, J.; Xu, J.; Zhao, Q.; Sun, H. Diterpenoid alkaloids from Aconitum
leucostomum. J. Nat. Prod. 1996, 59, 277-279.

(116) Flora Reipublicae Popularis Sinicae; Institute of Botany, Chinese Academy of
Sciences & Institute of Materia Medica, Chinese Academy of Medical
Sciences.Science Press: Beijing, 1979; 235-236.

133
(117) Mesia, L. R.; Madinaveitia, A.; Reina, M.; Rodriguez, M. L.; Fuente, G. d. l. et
al. Four new alkaloids from Consolida glandulosa. J. Nat. Prod. 2002, 65, 496499.

(118) Pelletier, S. W.; Joshi, B. S. Alkaloids: Chemical and Biological Perspectives;
Springer: New York, 1991; pp 297-565.

(119) Benn, M. H.; Jacyno, J. M. Alkaloids: Chemical and biological perspectives;
John Wiley & Sons.: New York, 1983; 153-210.

(120) Grandez, M.; Madinaveitia, A.; Gavin, J. A.; Alva, A.; Fuente, G. d. l.
Alkaloids from Consolida oliveriana. J. Nat. Prod. 2002, 65, 513-516.

(121) Dalton, D. R. The Alkaloids: The fundamental chemistry. A biogenetic
approach; Marcel Dekker, Inc.: New York, 1979; 1-789.

(122) Bessonova, I. A.; Saidkhodzhaeva, S. A. Hetisane-type diterpenoid alkaloids.
Chem. Nat. Compd. 2000, 36, 419-477.

(123) Pelletier, S. W.; Mody, N. V.; Joshi, B. S.; Schramm, L. C. Alkaloids: Chemical
and Biological Perspectivess; Wiley-Interscience: New York, 1984; pp 205.

(124) Diaz, J. G.; Ruiz, J. G.; Fuente, G. d. l. Alkaloids from Delphinium
staphisagria. J. Nat. Prod. 2000, 63, 1136-1139.

(125) Pelletier, S. W.; Keith, L. H. The diterpene alkaloids. Chemistry of the
Alkaloids; van Nostrand Reinhold Company: New York, 1970; pp 503-590.

(126) Boronova, Z. S.; Sultankhodzhaev, M. N. Alkaloids of Aconitum tuberosum.
Structure of tuberaconitine and tubermesaconitine. Chem. Nat. Compd. 2001,
37, 269-271.

134
(127) Zhou, X. L.; Chen, Q. H.; Chen, D. L.; Wang, F. P. Hemsleyatine, a novel C19diterpenoid alkaloids with 8-amino group from Aconitum hemsleyanum. Chem.
Pharm. Bull. 2003, 51, 592-594.

(128) Shen, X. L.; Zhou, X. L.; Chen, Q. H.; Chen, D. L.; Wang, F. P. New C19diterpenoid alkaloids from the roots of Delphinium potaninii
var.jiufengshanense. Chem. Pharm. Bull. 2002, 50, 1265-1267.

(129) Pelletier, S. W. The diterpene alkaloids:The structure of Atidine. J. Am. Chem.
Soc. 1965, 87, 799-802.

(130) Pelletier, S. W.; Mody, N. V. The conformational analysis of the E and F rings
of Atisine, Veatchine, and related alkaloids. The existence of C-20 Epimers. J.
Am. Chem. Soc. 1977, 99, 284-286.

(131) Pelletier, S. W.; Mody, N. V.; Moore, J. F.; Desai, H. K. The structure and
absolute configuration of heterophylloidine. Tetrahedron Lett. 1981, 22, 313314.

(132) Cookson, R. C.; Trevett.M.E. Aconitum and Delphinium alkaloids. Part II.
Interrelation of the functional groups of delpheline. J. Chem. Soc. 1956, 3121.

(133) Hanson, J. R. The tetracyclic diterpenes; First ed.; Pergamon Press Ltd.:
London, 1968; 1-127.

(134) Rahman, A. Handbook of natural products data, diterpenoid and steroidal
alkaloids; Elsevier Science Publishers: Amsterdam, 1990.

(135) Rahman, A.-u.; Nasreen, A.; Akhtar, F.; Shekhani, M. S.; Clardy, J. et al.
Antifungal diterpenoid alkaloids from Delphinium denudatum. J. Nat. Prod.
1997, 60, 472-474.

135
(136) Grina, J. A.; Schroeder, D. R.; Wydallis, E. T.; Stermitz, F. R. Alkaloids from
Delphenium geyeri. Three new C20-diterpenoid alkaloids. J. Org. Chem. 1986,
51, 390-394.

(137) Pelletier, S. W.; Parthasarathy, P. C. The diterpene alkaloids. Further studies of
atisine chemistry. J. Am. Chem. Soc. 1965, 87, 777-798.

(138) Pelletier, S. W.; Oeltmann, T. N. NMR studies of diterpene alkaloids.
Tetrahedron 1968, 24, 2019-2038.

(139) Pelletier, S. W.; Locke, D. M. The diterpene alkaloids.Correlation of the atisine
and Garrya series of alkaloids. J. Am. Chem. Soc. 1965, 87, 761-776.

(140) Rahman, A. U. Handbook of natural products data: Diterpenoid and Steroidal
alkaloids.; Elsevier Science Publishers B.V., 1990; 1-962.

(141) Saidkhodzhaeva, S. A.; Bessonova, I. A.; Abdullaev, N. D. Arcutinine, a new
alkaloid from Aconitum arcuatum. Chem. Nat. Compd. 2001, 37, 466-469.

(142) Sultankhodzhaev, M. N.; Tashkhodzhaev, B.; Averkiev, B. B.; Antipin, M. Y.
Secokaraconitine, a new diterpenoid alkaloid from Aconitum karacolicum.
Chem. Nat. Compd. 2002, 38, 78-82.

(143) Ichinohe, Y.; Yamaguchi, M.; Katsui, N.; Kakimoto, S. On the structure of
miyaconitine. Tetrahedron Lett. 1970, 2323.

(144) Benn, M.; Richardson, F. Hetisine 13-O-acetate, a new diterpenoid alkaloid
from Delphinium nutallianum Pritz. Heterocycles 1986, 24, 1605-1607.

(145) Takayama, H.; Okazaki, T.; Yamaguchi, K.; Aimi, N.; Haginiwa, J. et al.
Structure of two new diterpene alkaloids, 3-epi-ignavinol and 2,3dehydrodelcosine. Chem. Pharm. Bull. 1988, 36, 3210.

136
(146) Schemeller, T.; Wink, M. Utilization of alkaloids in modern medicine.
Alkaloids: Biochemistry, Ecology and Medicinal Applications; Plenum Press:
New York, 1998; pp 435-459.

(147) Dzhakhangirov, F. N.; Bessonova, I. A. Alkaloids of Aconitum coreanum. X.
Curare-like activity-structure relationship. Chem. Nat. Compd. 2002, 38, 74-77.

(148) Shakhidoyatova, N. K.; Dzhakhangirov, F. N.; Sultankhodzhaev, M. N.
Medicinal plants: Antiarrhythmic acitivity of diterpenoid alkaloids of the
napelline-type and their acylated derivatives. Pharm. Chem. J. 2001, 35, 266267.

(149) Venkateswarlu, V.; Srivastava, S. K.; Joshi, B. S.; Desai, H. K.; Pelletier, S. W.
13-O-Acetylvakhmatine, a new diterpenoid alkaloid from the seeds of
Consolida ambigua. J. Nat. Prod. 1995, 58, 1527.

(150) Sakai, S.; Yamaguchi, Y.; Takayama, H.; Yamamoto, I.; Okamoto, T. The
structure of a new diterpene alkaloid: Sanyonamine. Chem. Pharm. Bull. 1982,
30, 4576.

(151) Jiang, Q.; Pelletier, S. W. Two new diterpenoid alkaloids from Aconitum
palmatum. J. Nat. Prod. 1991, 54, 525-531.

(152) Bai, Y.; Sun, F.; Benn, M.; Majak, W. Diterpenoid and norditerpenoid alkaloids
from Delphinium nuttallianum. Phytochemistry 1994, 37, 1717.

(153) Konno, C.; Shirasaka, M.; Hikino, H. Structure of senbusine A, B and C,
diterpenic alkaloids of Aconitum carmichaeli roots from China. J. Nat. Prod.
1982, 45, 128-133.

(154) Pelletier, S. W.; Mody, N. V.; Venkov, A. P.; Jones, J. S. B. Alkaloids of
Delphinium virescens Nutt. Virescenine and 14-acetylvirescenine. Heterocycles
1979, 12, 779.

137
(155) Bando, H.; Wada, K.; Amyiya, T.; Kobayashi, K.; Fujimoto, Y. et al. Studies on
the Aconitum species. V. Constituents of Aconitum yesoense var.
Macroyesoense (Nakai) Tamura. Heterocycles 1987, 26, 2623.

(156) Aiyar, V. N.; Kulanthaivel, P.; Benn, M. The C19-diterpenoid alkaloids of
Aconitum delphinifolium. Phytochemistry 1986, 25, 973.

(157) Chen, S. Y.; Li, S. H.; Hao, H. J. The diterpenoid alkaloids of Aconitum
nagarum var. Lasiandrum W.T.Wang and its chemotaxonomic significance.
Acta Botanica Sinica. 1986, 28, 86.

(158) Chen, Y.; Koelliker, S.; Oehme, M.; Katz, A. Isolation of diterpenoid alkaloids
from herb and flowers of Aconitum napellus ssp.vulgare and electrospray ion
trap multiple MS study of these alkaloids. J. Nat. Prod. 1999, 62, 701-704.

(159) Joshi, B. S.; Glinski, J. A.; Chokshi, H. P.; Chen, S.; Srivastava, S. K. et al.
Deltasine, a new C19-Diterpenoid Alkaloid from Delphinium tatsienense
Franch. Heterocycles 1984, 22, 2037-2042.

(160) Joshi, B. S.; Puar, M. S.; Bai, Y.; Panu, A. M.; Pelletier, S. W. The structure of
andersonbine, a new diterpenoid alkaloid from Delphinium andersonii Gray.
Tetrahedron 1994, 50, 12283.

(161) Han, Y.; Liu, J.; Wang, M. Chemical constituents of Korean monkshood
(Aconitum coreanum). Zhongcaoyao 1994, 25, 619-621, 624.

(162) Pelletier, S. W.; De Camp, W. H.; Mody, N. V. Epimerization and
isomerization in C20-diterpenoid alkaloids. Crystal and molecular structures of
Atisinium chloride, Dihydroatisine, and Veatchine. J. Am. Chem. Soc. 1978,
100, 7976-7987.

(163) Caius, J. F. The medicinal and poisonous plants of India; Scientific Publishers:
Jodhpur, India, 1986.

138
(164) Vennerstrom, L. J.; Klayman, D. L. Protoberberine alkaloids as antimalarials. J.
Med. Chem. 1988, 31, 1084-1087.

(165) Kametani, T. The chemistry of the isoquinoline alkaloids; Hirokawa Publishing
Company, Inc.: Tokyo, 1969; 266.

(166) Hughes, D. W.; Nalliah, B. C.; Holland, H. L.; MacLean, D. B. 13C nuclear
magnetic resonance spectra of the benzylisoquinoline alkaloids and related
model compounds. Can. J. Chem. 1977, 55.

(167) Bhakuni, D. S.; Tewari, S.; Dhar, M. M. Aporphine alkaloids of Annona
squamosa. Phytochemistry 1972, 11, 1819-1822.

(168) Iwasa, K.; Okada, M.; Takao, N. Protopine-N-oxide, an alkaloid from Bocconia
cordata. Phytochemistry 1983, 22, 627-628.

(169) Han, L.-F.; Nowicky, W.; BGutmann, V. Reversed-phase high-performance
liquid chromatographic separation of tertiary and quaternary alkaloids from
Chelidonium majus L. J. Chromat. 1991, 543, 123-128.

(170) Yuh-chwen, C.; Pei-Wen, H.; Fang-Rong, C.; Ru-rong, W.; Chih-Chuang, L. et
al. Two new protopines argemexicaines A and B and the anti-HIV alkaloid, 6acetonyldihydrochelerythrine from formosan Argemone mexicana. Planta Med.
2003, 69, 148-152.

(171) Yu, C. K.; Sauders, J. K.; MacLean, D. B. The structure of fumarofine. Can. J.
Chem. 1971, 49.

(172) MacLean, D. B.; Bell, R. A.; Sauders, J. K.; Chen, C. Y. Structures of three
monor alkaloids of Fumaria officinalis L. Can. J. Chem. 1969, 47.

(173) Battersby, A. R.; Staunton, J.; Wiltshire, H. R.; Francis, R. J.; Southgate, R.
Biosynthesis. Part XXII.1,2. The origin of chelidonine and of other alkaloids

139
derived from the tetrahydroprotobererine skeleton. J. Chem. Soc. Perkin I.
1975, 1147-1156.

(174) Takao, N.; Iwasa, K.; Kamigauchi, M.; Sugiura, M. Studies on the alkaloids of
papaveraceous plants. XXV. Biosynthesis of alkaloids of Corydalis incisa Pers
and Chelidonium majus L. Incorporations of tetrahydroprotoberberines, Nmethosalts of tetrahydroprotoberberines, and protopine. Chem. Pharm. Bull.
1976, 24, 2859-2868.

(175) Battersby, A. R.; Francis, R. J.; Hirst, M.; Ruveda, E. A.; Staunton, J.
Biosynthesis.Part XXI.1,2 Investigations on the biosynthesis of stylopine in
Chelidonium majus. J. Chem. Soc. Perkin I 1975, 1140-1147.

(176) Manske, R. H. F.; Rodrigo, R.; MacLean, D. B.; Gracey, D. E. F.; Sauders, J. K.
Structure of sibiricine, an alkaloid of Corydalis sibirica. Can. J. Chem. 1969,
47.

(177) Manske, R. H. F.; Rodrigo, R.; MacLean, D. B.; Gracey, D. E. F.; Sauders, J. K.
The structure of ochrobirine. Can. J. Chem. 1969, 47.

(178) Margvelashvili, N. N.; Prisyazhnyuk, N. P.; Kislov, L. D.; Tolkachev, O. N.
Alkaloids from Corydalis gigantea. Khimiya Prirodnykh Soedinenii 1976, 832.

(179) Kaneko, H.; Naruto, S. Constituents of Corydalis species.VII.Constituents of
Corydalis pallida var.tenuis. Yakugaku Zasshi. 1971, 91, 101-108.

(180) Tani, C.; Nagakura, N.; Hattori, S.; kao, M. T. Alkaloids of papaveraceae
plants.XIX. Alkaloids of Corydalis koidzumiana. Yakugaku Zasshi. 1976, 94,
844-851.

(181) Manske, R. H. F.; Miller, M. R. The alkaloids of fumaraiceous plants.
XVII.Corydalis caseana A.Gray. Can. J. Res. 1938, 16, 153-157.

140
(182) Xu, X. Y.; Li, B. M.; He, L. Y.; Sagara, K.; Ohshima, T. et al. Determination of
isoquinoline alkaloids in Corydalis bungeana Turez by reversed-phase ion-pair
high-performance liquid chromatography. Yaoxue Xuebao. 1994, 29, 785-789.

(183) Wu, C. Z.; Kadota, S.; Li, J. X.; Basnet, P.; Namba, T. A comparative study of
alkaloidal constituents in Corydalis decumbens tubers by high-performance
liquid chromatography. Shoyakugaku Zasshi 1993, 47, 440-445.

(184) Vennerstrom, J. L.; Klayman, D. L. Protoberberine Alkaloids as Antimalarials.
J. Med. Chem. 1988, 31, 1084-1087.

(185) Iwasa, K.; Nishiyama, Y.; Ichimaru, M.; Moriyasu, M.; Kim, H.-S. et al.
Structure-activity relationships of quaternary protoberberine alakloids having an
antimalarial activity. Eur. J. Med. Chem. 1999, 34, 1077-1083.

(186) Kim, S. R.; Hwang, S. Y.; Jang, Y. P.; Park, M. J.; Markelonis, G. J. et al.
Protopine from Corydalis ternata has anticholinesterase and antiamnesic
activities. Planta Med. 1999, 65, 218-221.

(187) Shiomoto, H.; Matsuda, H.; Kubo, M. Effects of protopine on blood platelet
aggregation.III. Effect of protopine on the metabolic system of arachidonic acid
in platelets. Chem. Pharm. Bull. 1991, 39, 474-477.

(188) Zhao, Y.; Zheng, J.; Huang, S.; Li, X.; Lin, Q. et al. Experimental studies on the
antimalarial effect of protopine derivatives. Yaoxue Tongbao 1981, 16, 7-10.

(189) Nagai, Y.; Matsukura, H.; Naruta, S.; Nanba, K. Analysis of alkaloidal
components in Corydalis tubers. Pharm. Tech. Japan 1988, 4, 37-43.

(190) Takahashi, H.; Iguchi, M.; Onda, M. Utilization of protopine and related
alkaloids.XVII. Spectroscopic studies on the ten-membered ring conformations
of protopine and α-allocryptopine. Chem. Pharm. Bull. 1985, 33, 4775-4782.

141
(191) Brochmann-Hanssen, E.; Nielsen, B. The Isolations of (-)-Scoulerine from
Opium. Tetrahedron Lett. 1966, 20, 2261-2263.

(192) Budzikiewicz, H.; Djerassi, C.; Williams, D. H. Structure elucidation of natural
products by Mass Spectrometry. Alkaloids; Holden-Day Inc.: San Francisco,
1964; pp 181.

(193) Furuya, T.; Nakano, M.; Yoshikawa, T. Biotransformation of (RS)-reticuline
and morphinan alkaloids by cell cultures Papaver somniferum. Phytochem.
1978, 17, 891-893.

(194) Ohashi, M.; Wilson, J. M.; Budzikiewicz, H.; Shamma, M.; Slusarchyk, W. A.
et al. Mass Spectrometry in structural and stereochemical problems. XXXI.
Aporphines and related alkaloids. J. Am. Chem. Soc. 1963, 85, 2807.

(195) Narasimhan, N. S.; Mali, R. S.; Kulkarni, B. K. Synthetic application of
lithiation reactions-XVI. Syntheses of (+/−)stylopine and (+/−) sinactine.
Tetrahedron 1983, 39, 1975-1982.

(196) Huang, J.; Li, H.; Yang, J.; Chen, Y.; Liu, Y. et al. Chemical components of
Vetiveria zizanoides volatiles. Yingyong Shengtai Xuebao 2004, 15, 170-172.

(197) Zhao, J.; Nan, P.; Zhong, Y. Chemical composition of the essential oils of
Clausena lansium from Hainan Island. J. Biosci. 2004, 59, 153-156.

(198) Dembitsky, V. M.; shkrob, I.; Rozentsvet, O. A. Fatty acid amides from
freshwater green alga Rhizoclonium hieroglyphicum. Phytochemistry 2000, 54,
965-967.

(199) Bedir, E.; Khan, I. K. New steroidal glycosides from the fruits of Tribulus
terrestris. J. Nat. Prod. 2000, 63, 1699-1701.

(200) Yan, W.; Ohtani, K.; Kassai, R.; Yamasaki, K. Steroidal saponins from fruits of
Tribulus terrestris. Phytochemistry 1996, 42, 1417-1422.

142
(201) Terra, E. A Simpler Way: Tribulus terrestris; A Simpler Way; Website:
http://www.asimplerway.com/archives/000008.html, 2002.

(202) Ganzera, M.; Bedir, E.; Khan, I. A. Determination of steroidal saponins in
Tribulus terrestris by reversed-phased high-performance liquid chromatography
and evaporative light scattering detection. J. Pharm. Sci. 2001, 90, 1752-1758.

(203) Higher power Tribulus terrestris (online); Website:
http://www.bodybuilding.com/store/trib.htmlBody; Body Building.Com, 2003.

(204) Tribulus terrestris facts, information, and research (online);
Website:http://www.bodybuildingforyou.com/pro-hormones/tribulus-terrestrisfacts.h; Body Building for You.Com, 2003.

(205) Wu, T. S.; Shi, L. S.; Kuo, S. C. Alkaloids and other constituents from Tribulus
terrestris. Phytochemistry 1999, 50, 1411-1415.

(206) Sahelian, R. Tribulus terrestris: underrated roadside sex weed that works; Ray
Sahelian; Website: http://www.raysahelian.com/tribulus.html, 2003.

(207) Arcasoy, H. B.; Erenmemisoglu, A.; Tekol, Y.; Kurucu, S.; Kartal, M. Effect of
Tribulus terrestris L.saponin mixture on some smooth muscle preparations: a
preliminary study. 1998, 2003.

(208) Henning, M. W. Virus and deficiency diseases, plant poisonings. Animal
diseases in South Africa: South Africa, 1932; pp 855-867.

(209) Aslani, M. R.; Movassaghi, A. R.; Mohri, M.; Pedram, M.; Abavisani, A.
Experimental Tribulus terrestris poisoning in sheep: Clinical, laboratory and
pathological findings. Vet. Res. Commun.; Kluwer Academic Publishers:
Netherland, 2003; pp 53-62.

143
(210) Glastonbury, J. R.; Doughty, F. R.; Whitaker, S. J.; Sergeant, E. A syndrome of
hepatogenous photosensitisation, resembling geeldikkop, in sheep grazing
Tribulus terrestris. Aust. Vet. J. 1984, 61, 314-316.

(211) McDonough, S. P.; Woodbury, A. H.; Galey, F. D.; Wilson, D. W.; East, N. et
al. Hepatogenous photosensitization of sheep in California associated with
ingestion of Tribulus terrestris (puncture vine). J. Vet. Diagn. Invest. 1994, 6,
392-395.

(212) Xu, Y.; Xie, S.; Zhao, H.; Han, D.; Xu, T. et al. Studies on chemical
constituents of Tribulus terrestris. Yaoxue Xuebao 2001, 36, 750-753.

(213) Xu, Y.; Chen, H. S.; Liang, H. Q.; Gu, Z. B.; Liu, W. Y. et al. Three new
saponins from Tribulus terrestris. Planta Med. 2000, 66, 545-550.

(214) Zafar, R.; Nasa, A. K. Quercetin and kaempferol from the fruits and stem of
Tribulus terresris. Indian J. Nat. Prod. 1987, 3, 17-18.

(215) Bhutani, S. P.; Chibber, S. S.; Seshadri, T. R. Flavonoids of the fruits and leaves
of Tribulus terrestris: Constitution of tribuloside. Phytochem. 1969, 8, 299-303.

(216) Wu.;, T.-S.; Shi.;, L.-S.; Kuo., S.-c. Alkaloids and other constituents from
Tribulus terrestris. Phytochemistry 1999, 50, 1411-1415.

(217) Zafar, R.; Nasa, A. K. Quercetin and kaempferol from the fruits and stem of
Tribulus terrestris Linn. Indian J. Nat. Prod. 1987, 3, 17-18.

(218) Bremner, J. B.; Sengpracha, W.; Southwell, I.; Bourke, C.; Slkelton, B. W.;
White, A. H. A revised structure for the alkaloid, tribulusterine, from Tribulus
terrestris L. Aust. J. Chem. 2004, 57, 273-276.

(219) Reinehart, K. L. J.; Kobayashi, J.; Harbour, G. C.; Gilmore, J.; Mascal, M. et al.
Eudistomins A-Q, β−carbolines from the antiviral Caribbean Tunicate
Eudistoma olivaceum. J. Am. Chem. Soc. 1987, 109, 3378-3387.

144
(220) Miles, C. O.; Wilkins, A. L.; Erasmus, G. L.; Kellerman, T. S. Photosensitivity
in South Africa.VIII.Ovine metabolism of Tribulus terrestris saponins during
experimentally induced geeldikkop. Onderstepoort J. Vet. Res. 1994, 61, 351359.

(221) Gauthaman, K.; Adaikan, P. G.; Prasad, R. N. V. Aphrodisiac properties of
Tribulus terrestris extract (protodioscin) in normal and castrated rats. Life Sci.
2002, 71, 1385-1396.

(222) Adimoeja, A. Phytochemicals and the breakthrough of traditional herbs in the
management of sexual dysfunctions. Int. J. Androl. 2000, 23, 82-84.

(223) Alexis, B. Natural antibacterial, anti-inflamation,anti-virus, anti-herpes cream
containing Tribulus extract. PCT Int. Appl. 2001, 21.

(224) Tribulus terrestris (online); Chinese Herbs &Co.; Website: http://www.chineseherbs.org/tribulus-terrestris/, 2002.

(225) Deepak, M.; Dipankar, G.; Prashanti, D.; Asha, M. K.; Amit, A. et al.
Tribulosin and β-sitosterol-D-glucoside, the anthelmintic principles of Tribulus
terrestris. Phytomedicine 2002, 9, 753-756.

(226) Kemertelidze, E. P.; Pkheidze, T. A.; Kachukhashvili, T. N.; Turova, A. D.;
Sokolova, L. N. et al. Tribusponin-an antisclerotic agent; All-Union ScientificResearch Institute of Medicinal and Aromatic Plants: U.S.S.R, 1977.

(227) El Gammal, A. A.; Mansour, R. M. A. Antimicrobial activities of some
flavonoid compounds. Zentralblatt fuer Mikrobiologie 1986, 141, 561-565.

(228) Ahmad, A.; Khan, K. A.; Sultana, S.; Siddiqui, B. S.; Begum, S. et al. Study of
the invitro antimicrobial activity of harmine, harmaline and their derivatives. J.
Ethnopharmacol. 1992, 35, 289-294.

145
(229) Allen, J. R. F.; Holmstedt, B. R. The simple β-carboline alkaloids.
Phytochemistry 1980, 19, 1573-1582.

(230) Schupp, P.; Poehner, T.; Edrada, R.; Ebel, R.; Berg, A. et al. Eudistomins W
and X, Two new β-carbolines from the Micronesian tunicate Eudistoma sp. J.
Nat. Prod. 2003, 66, 272-275.

(231) Stolle, K.; Gröger, D. Studies on the biosynthesis of harmine. Arch. pharm.
1968, 301, 561.

(232) Arruda, M. S. P.; Fernandes, J. B.; Da Silva, M. F. d. G. F.; Vieira, P. C.; Pirani,
J. R. Quinolone alkaloids from Zanthoxylum acutifolium. Phytochemistry 1992,
31, 3617-3619.

(233) Krishnamurti, M.; Islam, A. Isolation of isolonchocarpin, 3,4dimethoxycinnamic acid, and heptacosanol from Milletia ovalifolia seeds. J.
Bangladesh Acad. Sci. 1987, 11, 133-135.

(234) He, Z.; Pan, w.; Lu, Y.; Zhang, C.; Yuan, M. Study on organic acids in beeswax
of Guizhou. Zhongcaoyao 2002, 33, 405-406.

(235) Davis, U. C. Lab notes; CVDLS, 1999.

(236) Murphy, J. E.; Beckmen, K., B.; Johnson, J. K.; Cope, R. B.; Lawmaster, T. et
al. Toxic and feeding deterrent effects of native aquatic Macrophytes on exotic
grass carp(Ctenopharyngodon idella). Ecotoxicology 2002, 11, 243-254.

(237) Schumacher, E.; Hulftegger, E. The action of Ranunulus acer on the PH and
fermentation in the rumen and on the surviving rumen wall of cattle. Schweiz.
Arch. Tierheilk. 1958, 100, 415-427.

146
(238) Li, H.; Du, S.; Hou, F.; Wang, D.; Liu, G. et al. Study of chemical constituents
of Ranunculus ternatus Thumb. Shenyang Yaoke Daxue Xuebao 1999, 16, 2427.

(239) Addel-Kader, M. S.; EI-Lakany, A. M.; EI-Fiky, F. K. Coumarins with antiviral
and cytotoxic activity from Egyptian Ranunculus asiaticus L. J.Pharm.Sci.
1996, 10, 5-7.

(240) Gluchoff-Fiasson, K.; Fiasson, J. L.; Favre-Bonvin, J. Quercetin glycosides
from antarctic Ranunculus species. Phytochemistry 1994, 37, 1629-1633.

(241) Bonora, A.; Tosi, B.; Dall'Olio, G.; Bruni, A. Quaternary alkaloids in rhizomes
of Ranunculus serbicus. Phytocheistry 1990, 29, 2389-2390.

(242) Misra, S. B.; Dixit, S. N. Antifungal properties of leaf extract of Ranunculus
sceleratus L. Experientia 1978, 34, 1442-1443.

(243) Saber, A. H.; Mahran, G. H.; EI-Alfy, T. Phytochemical investigation of
Ranunculus sceleratus L. Planta Med. 1968, 16, 231-238.

(244) Zechner, L.; Wolhlmuth, H. Anemonin and protoanemonin.I. New method of
isolation of anemonin from Ranunculus acer. Scientia Pharm. 1954, 22, 74-89.

(245) Kelch, W. J.; Kerr, L.; Adair, H. S.; Boyd, G. D. Suspected buttercup
(Ranunculus bulbosus) toxicosis with secondary photosensitization in a
Charolais heifer. Vet. Hum. Toxicol. 1992, 34, 238-239.

(246) Tocan, V.; Baron, O. Antibiotic activity of protoanemonine from Ranunculus
oxyspermus M.B. Boll. Chim. Farm. 1969, 108, 789-791.

(247) Cao, B. J.; Meng, Q. Y.; Ji, N. Analgesic and anti-inflamatory effects of
Ranunculus japonicus extract. Planta Med. 1992, 58, 496-498.

147
(248) Vlietinck, A. J. Screeening methods for detection and evaluation of biological
activities of plant preparations. Bioassay Methods in Natural Product Research
and Drug Development; Kluwer Academic Publishers: The Netherlands, 1999;
pp 37-52.

(249) Marston, A.; Hostettmann, K. Biological and chemical evaluation of plant
extracts and subsequent isolation strategy. Bioassay Methods in Natural
Product Research and Drug Development; Kluwer Academic Publishers: The
Netherlands, 1999; pp 67-80.

(250) Hawcroft, D.; Hector, T.; Rowell, F. Quantitative bioassay, analytical
chemistry by open learning; John Wiley& Sons: London, 1987; 1-300.

(251) Venturini, M. E.; Blanco, D.; Oria, R. In vitro antifungal activity of several
antimicrobial compounds against Penicillium expansum. J. Food Protect. 2002,
65, 834-839.

(252) Brantner, A.; Pfeiffer, K. P.; Brantner, H. Applicability of diffusion methods
required by the pharmacopoeas for testing antibacterial activity of natural
compounds. Pharmazie 1994, 49, 512-516.

(253) Verpoorte, R. Antimicrobially active alkaloids. Alkaloids: Biochemistry,
Ecology, and Medicinal Applications; Plenum Press: New York, 1998; pp 397434.

(254) Spooner, D. F.; Skyes, G. Laboratory assesment of antimicrobial activity.
Methods in Microbiology 7B; Academic Press Inc.: London, 1972.

(255) Janssen, A. M.; Scheffer, J. J. C.; Baerheim, S. A. Antimicrobial activity of
essential oils: A 1976-1986 literature review. Aspects of the test methods.
Planta Med. 1987, 395-398.

(256) Toshio, Y.; Naoki, S.; Kenya, Y.; Yutaka, O.; Hajime, A. et al. Reliability of
bioluminescent assay (ATP method) for testing antimicrobial susceptibility of

Family:
148
l

Mycobacterium tuberculosis. Rinsho Byori (Japanese Journal of Clinical
Pathology) 2003, 51, 194-200.

(257) Chand, S.; Lusunzi, I.; Veal, D. A.; Williams, L. R.; Karuso, P. Rapid screening
of the antimicrobial activity of extracts and natural products. J. Antibiot. 1994,
47, 1295-1304.

(258) Kamiya, H.; Muramoto, K.; Ogata, K. Antibacterial activity in the egg mass of a
sea hare. Experientia 1984, 40, 947.

(259) Croft, S. L.; Weiss, C. R. Natural products with antiprotozoal activity. Bioassay
Methods in Natural Product Research and Drug Development; Kluwer
Academic Publishers: Dordrecht, 1999; pp 81-100.

(260) Basco, L. K.; Marquet, F.; Makler, M. M.; Le Bras, J. Plasmodium falciparum
and Plasmodium vivax-lactate dehydrogenase activity and its application for in
vitro drug susceptibility assay. Exp. Parasitol. 1995, 80.

(261) Desjardins, R. E.; Canfield, C. J.; Haynes, J. D.; Chulay, J. D. Quantitative
assessment of antimalarial activity in vitro by a semiautimated Microdilution
technique. Antimicrob. Agents Chemother., 1979; pp 710-718.

(262) Svendsen, A. B.; Verpoorte, R. Chromatography of alkaloids. Journal of
Chromatography Library, 1983; pp 502.

(263) Witchard, H. The development of novel carbazole-based peptoid antibacterials
to challenge the deadly superbugs (PhD Thesis, Appendix). PhD; University of
Wollongong: Wollongong, 2002; pp 367

(264) Trager, W.; Jensen, J. B. Human malaria parasites in continuous culture.
Science 1976, 20, 673-675.

